RECOMBINANT INFECTIOUS LARYNGOTRACHEITIS VIRUS AND USES THEREOF

Abstract: The present invention provides recombinant infectious laryngotracheitis virus (ILTV) which are useful as vaccines to protect chickens or other poultry from infectious laryngotracheitis virus. The present invention further provides methods for distinguishing an animal vaccinated with a vaccine of the present invention from an animal infected with a naturally-occurring infectious laryngotracheitis virus.

Description: RECOMBINA INFECTIOUS LARYNGOTRACHEITIS VIRUS AND USES THEREOF ithin this application several publications are referenced by arabic numerals within parentheses. Full citations for these publications may be found at the end of the specification immediately preceding the claims. The disclosures of these publications are hereby incorporated by reference into this application in order to more fully describe the state of the art to which this invention pertains. Field, of the Invention The present invention involves recombinant infectious laryngotracheitis (ILT) viruses useful in vaccines to protect poultry from naturally-occurring infectious laryngotracheitis virus and other poultry diseases. Eac σround of the Invention The ability to isolate viral DNA and clone this isolated DNA into bacterial plasmids has greatly expanded the approaches available to make viral vaccines. The methods used to make the present invention involve modifying cloned viral DNA sequences by insertions, deletions and single or multiple base changes. The modified DNA is then reinserted into the viral genome to render the virus non-pathogenic. The resulting live virus may then be used in a vaccine to elicit an immune response in a host animal and to protect the animal against a disease. One group of animal viruses, the herpesviruses or Herpetoviridae, is an example of a class of viruses amenable to this approach. These viruses contain 100,000 to 200,000 base pairs of DNA as their genetic material. Importantly, several regions of the genome have been identified that are nonessential for the replication of virus in vitro in cell culture. Modifications in these regions of the DNA may lower the pathogenicity of the virus, i.e., attenuate the virus. For example, inactivation of the thymidine kinase gene renders human herpes simplex virus non-pathogenic (1) , and pseudorabies virus of swine non-pathogenic (2) . Removal of part of the repeat region renders human herpes simplex virus non-pathogenic (3, 4). A repeat region has been identified in Marek's disease virus that is associated with viral oncogenicity (5) . A region in herpesvirus saimiri has similarly been correlated with oncogenicity (6) . Removal of part of the repeat region renders pseudorabies virus non-pathogenic (U.S. Patent No. 4,877,737, issued October 31, 1989). A region in pseudorabies virus has been shown to be deleted in naturally-occurring vaccine strains (7, 8) and it has been shown that these deletions are at least partly responsible for the lack of pathogenicity of these strains. It is generally agreed that herpesviruses contain non¬ essential regions of DNA in various parts of the genome. Some of these regions are associated with virulence of the virus, and modification of them leads to a less- pathogenic virus, from which a vaccine may be derived. Infectious laryngotracheitis virus (ILTV) , an alpha herpesvirus (9) , is an important pathogen of poultry in the USA, Europe, and Australia, responsible for egg production losses and death (10) . It causes an acute disease of chickens which is characterized by respiratory depression, gasping and expectoration of bloody exudate. Viral replication is limited to cells of the respiratory tract wherein infection of the trachea gives rise to tissue erosion and hemorrhage. In chickens, no drug has been effective in reducing the 5 degree of lesion formation or in decreasing clinical signs. Vaccination of birds with various modified forms of the ILT virus derived by cell passage and/or tedious regimes of administration have been used to confer acceptable protection in susceptible chickens. Due to 10 the limited degree of attenuation of current ILTV vaccines care must be taken to assure that the correct level of virus is maintained; enough to provide protection, but not enough to cause disease in the flock (11-21) . Furthermore, these viruses may revert back to 15 virulence, causing disease rather than providing protection against it. ILTV has been analyzed at the molecular level. Restriction maps of the ILTV genome have been reported 20 (22-26) . The DNA sequence of several genes have been identified, i.e., thymidine kinase (27, 28), glycoprotein gB (27, 29, 30), ribonucleotide reductase (27, 31), capsid p40 (31, 32) . 25 Furthermore, Shepard, et al. (53) disclosed that several genes located in the unique long region of the infectious laryngotracheitis virus genomic DNA are non-essential for viral replication. 30 Applicants have unexpectedly found that the unique short region of the ILT virus genomic DNA contains genes that * are associated with ILTV virulence and that a deletion in those genes leads to an attenuated ILTV. Particularly, ' it was found that a deletion in the glycoprotein gG gene 35 of the ILT virus results in an attenuated virus, which is useful as a vaccine against subsequent attack by a virulent ILTV strains. Applicants also found that a deletion in the glycoprotein gl gene of the unique short region also attenuates the ILTV. Furthermore, it is contemplated that a deletion in the US2 gene, the UL-47 like gene, and the glycoprotein g60 gene of the unique short region will also attenuate the ILTV. ILTV can become latent in healthy animals which makes them potential carriers of the virus. For this reason, it is clearly advantageous to be able to distinguish animals vaccinated with non-virulent virus from animals infected with disease-causing wild-type or naturally- occurring virus. The development of differential vaccines and companion diagnostic tests has proven valuable in the management of pseudorabies disease (55) . A similar differential marker vaccine would be of great value in the management of ILTV caused disease. The construction of differential diagnostics has focused on the deletion of glycoproteins. Theoretically, the glycoprotein chosen to be the diagnostic marker should have the following characteristics: (1) the glycoprotein and its gene should be non-essential for the production of infectious virus in tissue culture; (2) the glycoprotein should elicit a major serological response in the animal; and (3) the glycoprotein should not be one that makes a significant contribution to the protective immunity. The ILT virus has been shown to specify at least four major glycoproteins as identified by monoclonal antibodies (M r - 205K, 115K, 90K and 60K) . Three glycoproteins seem to be antigenically related (M r = 205K, 115K, and 90K) (34-36). Three major ILT virus glycoproteins, gB (29, 30), gC (27, 51), and g60 (34, 53) have been described in the literature. These three genes have been sequenced and two of the ILTV genes have been shown to be homologous to the HSV glycoproteins gB, and gC. Of these, it is known that the ILTV gB gene is an 5 essential gene and would not be appropriate as deletion marker genes. Furthermore, the gC gene of herpesviruses has been shown to make a significant contribution to protective immunity as a target of neutralizing antibody (56) and as a target of cell-mediated immunity (57) . 10 Therefore, the gC gene is not desirable as a deletion marker gene. As to other glycoprotein encoding genes cited above, it is not known whether or not they would be suitable 15 candidates for deletion in order to construct a recombinant ILT virus which can be used as a diagnostic vaccine. Applicants have unexpectedly found that there are two 20 glycoprotein encoding genes located within the unique short region of the ILT viral genome which could be safely deleted in order to construct a recombinant ILT virus that can be used as a diagnostic vaccine. These are the glycoprotein gG gene and the glycoprotein gl 25 gene. By genetically engineering an ILT virus with a deletion in the glycoprotein gG gene or the glycoprotein gl gene, a ILT virus is produced which does not express any glycoprotein gG or glycoprotein gl. None of the prior arts teach or suggest that these two genes in the 30 unique short region of the virus are appropriate candidates for deletion in order to create a diagnostic 6 ILT virus vaccine. * Although several of the herpesviruses have been 35 genetically engineered, no examples of recombinant ILTV have been reported. The ability to engineer DNA viruses with large genomes, such as vaccinia virus and the herpesviruses, has led to the finding that these recombinant viruses can be used as vectors to deliver vaccine antigens and therapeutic agents for animals. The herpesviruses are attractive candidates for development as vectors because their host range is primarily limited to a single target species (37) and they have the capacity for establishing latent infection (38) that could provide for stable in vivo expression of a foreign gene. Although several herpesvirus species have been engineered to express foreign gene products, recombinant infectious laryngotracheitis viruses expressing foreign gene products have not been constructed. The infectious laryngotracheitis viruses described above may be used as vectors for the delivery of vaccine antigens from microorganisms causing important poultry diseases. Other viral antigens which may be included in a multivalent vaccine with an ILTV vector include infectious bronchitis virus (IBV) , Newcastle disease virus (NDV) , infectious bursal disease virus (IBDV) , and Marek 1 s disease virus (MDV) . Such multivalent recombinant viruses would protect against ILT disease as well as other diseases. Similarly the infectious laryngotracheitis viruses may be used as vectors for the delivery of therapeutic agents. The therapeutic agent that is delivered by a viral vector of the present invention must be a biological molecule that is a by-product of ILTV replication. This limits the therapeutic agent in the first analysis to either DNA, RNA or protein. There are examples of therapeutic agents from each of these classes of compounds in the form of anti-sense DNA, anti-sense RNA (39) , ribozymes (40) , suppressor tRNAs (41) , interferon-inducing double stranded RNA and numerous examples of protein therapeutics, from hormones, e.g., insulin, to lymphokines, e.g., interferons and interleukins, to natural opiates. The discovery of these therapeutic agents and the elucidation of their structure and function does not necessarily allow one to use them in a viral vector delivery system, however, because of the experimentation necessary to determine whether an ≠ 5 appropriate insertion site exists. * Summary of the Invention The present invention provides a recombinant, attenuated 10 infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. 15 The present invention also provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion or other alteration in the glycoprotein gG 20 gene so that upon replication, the recombinant virus produces no glycoprotein gG. The present invention also provides a method for distinguishing chickens or other poultry vaccinated with 25 a recombinant infectious laryngotracheitis virus which produces no glycoprotein gG from those infected with a naturally-occurring infectious laryngotracheitis virus. The present invention also provides a recombinant, 30 attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the US2 gene, UL47-like gene, ORF4 gene or glycoprotein g60 gene. 5 The present invention also discloses four non-essential regions of the infectious laryngotracheitis viral genome : human cytomegalovirus immediately early (HCMV IE) promoter, pseudorabies virus glycoprotein gX (PRV gX) promoter, and infectious bovine herpesvirus virus 1.1 VP8 (BHV-1.1 VP8) . These regions may be used as insertion sites for a foreign gene in constructing a recombinant infectious laryngotracheitis virus vector. Brief Description Of The Figures Figure 1. The nucleotide sequence of 13,473 base pairs Λ of contiguous DNA from the unique short 5 region of the ILT virus. This sequence * contains the entire 13,098 base pair unique short region as well as 273 base pairs of repeat region at one end and 102 base pairs of repeat region at the other end. The 10 nucleotide sequences of Figure 1 begin with the internal repeat sequence and end within the terminal repeat sequence. The unique short region begins at base pair 274 of this Figure. 15 Figure 2. Asp718 I restriction enzyme map of the infectious laryngotracheitis virus (ILTV) USDA 83-2 genome. The upper diagram identifies the unique long (U L ) , internal 20 repeat (IR) , unique short (U s ) , and terminal repeat (TR) sections found in the ILTV genome. A map of the Asp718 I restriction endonuclease sites in the ILTV genome is shown below. Letters A through O identify 25 Asp718 I restriction endonuclease fragments » with "A" representing the largest fragment. Fragment "L" is the 2.5 kb Asp718 I fragment, fragment "H" is the 5164 bp Asp718 I fragment, and fragment "G" is the 8.0 kb .Asp718 I fragment. The fragments marked with asterisks contain a hypervariable region of approximately 900 bp that is repeated from one to 12 times. Since no one size predominates, these fragments appear in submolar amounts that are not well resolved on an ethidium bromide stained gel. The position of these repeats is indicated in the figure by the crooked dashed lines. Figure 3. Open reading frames within the unique short region of infectious laryngotracheitis virus (ILTV) USDA 83-2. The 13,473 base pairs of the short region of ILTV contains the entire 13,098 base pair unique short region as well as 273 base pairs of repeat region at one end and 102 base pairs of repeat region at the other end. The unique short region contains 13 methionine initiated open reading frames (ORF) of greater than or equal to 110 amino acids (excluding smaller nested ORFs) . All 13 ORFs were aligned to the Entrez release 6.0 virus division of the Genbank DNA database utilizing the IBI MacVector Protein to DNA alignment option (default settings) . Eight of the ORFs exhibited significant homology to one or more other virus genes: unique short (US2) , protein kinase (PK) , unique long 47-like (UL47-like) , and glycoproteins gG, g60, gD, gl, and gE. Figure 4. Detailed description of the DNA insertion in Homology Vector 472-73.27. Diagram showing the orientation of DNA fragments assembled in plas id 472-73.27. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 20, 21, 22 and 23). The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, infectious laryngotracheitis virus (ILTV) , human cytomegalovirus immediate early (HCMV IE) , pseudorabies virus (PRV) , lactose operon Z gene (lacZ) , ∑scherichia coli (E. coli) , polyadenylation signal (poly A) , and base pairs (BP) . Figure 5. Detailed description of the DNA insertion in Homology Vector 501-94. Diagram showing the orientation of DNA fragments assembled in plas id 501-94. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 24, 25, 26, and 27) . The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, infectious laryngotracheitis virus (ILTV) , human cytomegalovirus immediate early (HCMV IE) , pseudorabies virus (PRV) , lactose operon Z gene (lacZ) , Escherichia coli (E. coli) , polyadenylation signal (poly A) , thymidine kinase (TK) , and base pairs (BP) . Figure 6. Detailed description of the DNA insertion in Homology Vector 544-55.12. Diagram showing the orientation of DNA fragments assembled in plasmid 544-55.12. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 28, 29, 30, and 31). The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, infectious laryngotracheitis virus (ILTV) , herpes simplex virus type 1 (HSV-1) , pseudorabies virus (PRV) , ,9-glucuronidase gene (uidA) , Escherichia coli (E. coli) , polyadenylation signal (poly A) , and base pairs (BP) . Figure 7. Detailed description of the DNA insertion in Homology Vector 562-61.IF. Diagram showing the orientation of DNA fragments assembled in plasmid 562-61.IF. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 32, 33, 34 35, 36 and 37). The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, infectious laryngotracheitis virus (ILTV) , herpes simplex virus type 1 (HSV-1) , pseudorabies virus (PRV) , ,9-glucuronidase gene (uidA) , Escherichia coli (E. coli) , polyadenylation signal (poly A) , and base pairs (BP) . Figure 8. Detailed description of the DNA insertion in Homology Vector 560-52.Fl. Diagram showing the orientation of DNA fragments assembled in plasmid 560-52.Fl. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 38, 39, 40, 41, and 42). The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, infectious laryngotracheitis virus (ILTV) , herpes simplex virus type 1 (HSV-1) , pseudorabies virus (PRV) , ,9-glucuronidase gene (uidA) , Escherichia coll (E. coli) , polyadenylation signal (poly A) , unique long 47 (UL47-like) , open reading frame 4 (ORF4) , glycoprotein G (gG) , and base pairs (BP) . Figure 9. Detailed description of the DNA insertion in Homology Vector 579-14.G2. Diagram showing the orientation of DNA fragments assembled in plasmid 579-14.G2. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 43, 44, 45, and 46). The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, infectious laryngotracheitis . virus (ILTV) , herpes simplex virus type 1 (HSV-1) , pseudorabies virus (PRV) , ,9-glucuronidase gene (uidA) , Escherichia coli (E. coli) , polyadenylation signal (poly A) , and base pairs (BP) . Figure 10. Detailed description of the DNA insertion in Plas id Vector 544-39.13. Diagram showing the orientation of DNA fragments assembled in plasmid 544-39.13. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 47, 48, 49, and 50). The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, pseudorabies virus (PRV) , ,6-glucuronidase gene (uidA) , Escherichia coli (E. coli) , herpes simplex virus type 1 (HSV- 1) , polyadenylation signal (poly A) , and base pairs (BP) . Figure 11. Detailed description of the DNA insertion in Plasmid Vector 388-65.2. Diagram showing the orientation of DNA fragments assembled in plasmid 388-65.2. The origin of each fragment is indicated in the table. The sequences located at each of the junctions between fragments are also shown (SEQ ID NO's: 51, 52, 53, and 54). The restriction sites used to generate each fragment as well as the synthetic linker sequences which were used to join the fragments are described for each junction. The synthetic linker sequences are underlined by a heavy bar. The location of several gene coding regions and regulatory elements is also given. Restriction sites in brackets [] indicate the remnants of sites which were destroyed during construction. The following abbreviations are used, human cytomegalovirus immediate early (HCMV IE) , lactose operon Z gene (lacZ), Escherichia coli (E. coli), pseudorabies virus (PRV) , polyadenylation signal (poly A) , and base pairs (BP) . Detailed Description Of The Invention The present invention provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in the glycoprotein gG gene. Said deletion attenuates the virus, rendering it suitable for use as a vaccine against infectious laryngotracheitis virus. A preferred embodiment of this invention is a recombinant infectious laryngotracheitis designated S- ILT-014 (ATCC Accession No. XXXX. The S-ILT-014 virus has been deposited pursuant to the Budapest Treaty on the International Deposit of Microorganisms for the Purposes of Patent Procedure with the Patent Culture Depository of the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852 U.S.A. on September 22, 1993 under ATCC Accession No. ) . Another preferred embodiment of this invention is a recombinant infectious laryngotracheitis virus designated S-ILT-002. For purposes of this invention, "a recombinant infectious laryngotracheitis virus" is a live infectious laryngotracheitis virus which has been generated by the recombinant methods well known to those of skill in the art, e.g., the methods set forth in HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT ILTV in Materials and Methods, and the virus has not had genetic material essential for the replication of the infectious laryngotracheitis virus deleted. The present invention further provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene and a deletion in the US2 gene. One preferred embodiment of this invention is a recombinant infectious laryngotracheitis virus designated S-ILT-009. The present invention further provides a recombinant laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene and a deletion in the ORF4 gene. The present invention further provides a recombinant infectious laryngotracheitis virus which comprises the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene and a deletion in the UL47-like gene. The present invention further provides a recombinant infectious laryngotracheitis virus which comprises the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene, a deletion in the ORF4 gene, and a deletion in the UL47-like gene. A preferred embodiment of this invention is a recombinant infectious laryngotracheitis virus designated S-ILT-015. The present invention further provides a recombinant infectious laryngotracheitis virus which comprises the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene and a deletion in the glycoprotein g60 gene. A preferred embodiment of this invention is a recombinant infectious laryngotracheitis virus designated S-ILT-017. The present invention further provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene and a deletion in the glycoprotein gl gene. The present invention further provides a recombinant infectious laryngotracheitis virus which comprises the infectious laryngotracheitis viral genome containing a deletion in the glycoprotein gG gene and a deletion in the thymidine kinase (TK) gene. The present invention further provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis virus genome which contains a deletion in the unique short region of the viral genome, wherein the deletion in the glycoprotein gG gene, and which also contains an insertion of a foreign gene. The foreign gene is inserted into a non-essential site of the infectious laryngotracheitis viral genome in such a way that it is capable of being expressed in a recombinant infectious laryngotracheitis infected host cell. For purposes of this invention, "a non-essential site" of the infectious laryngotracheitis viral genome is a region of the viral genome which is not necessary for viral infection and replication. The following non-essential sites of the infectious laryngotracheitis viral genome are preferred sites for inserting a foreign gene into the virus : the thymidine kinase (TK) gene, the US2 gene, the UL47-like gene, the 0RF4 gene, the glycoprotein gG gene, the glycoprotein g60 gene, and the glycoprotein gl gene. The foreign gene, which is inserted into a non-essential site in the infectious laryngotracheitis viral genome, may encode a screenable marker, such as E. coll B- galactosidase or E. coli B-glucuronidasβ. The foreign gene which is inserted into a non-essential site in the infectious laryngotracheitis viral genome. may encode an antigenic polypeptide which, when introduced into the host cell, induces production of protective antibodies against an avian disease causing agent from which the antigen is derived or derivable. Such antigenic polypeptide may be derived or derivable from infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus. Such antigenic polypeptide may also be derived or derivable from avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia agent. Salmonella spp,, E. coll ., Paste rella spp., Bordetella spp. Eimeria spp. Histomonas spp., Trichomonas spp. , poultry nematodes, cestodes, trematodes, poultry mites/lice, poultry protozoa. The foreign gene may be put under control of an endogenous upstream infectious laryngotracheitis virus promoter, or it may be put under control of a heterologous upstream promoter. The heterologous upstream promoter may be derived from the HCMV IE promoter, the PRV gX promoter, and BHV-1.1 VP8 promoter. The present invention further provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion or other alteration in the unique short region of the viral genome, wherein the deletion or alteration is in the glycoprotein gG gene, so that upon replication, the recombinant virus produces no glycoprotein gG. The following recombinant viruses are preferred embodiments of this invention: A recombinant infectious laryngotracheitis virus designated S-ILT-002, S-ILT-014, S-ILT-009, S-ILT-015, and S-ILT-017. The present invention further provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion or other alteration in the unique short region of the viral genome, wherein the deletion or alteration is in the glycoprotein gl gene, so that upon replication, the recombinant virus produces no glycoprotein gl. The present invention further provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion or other alteration in the unique short region of the viral genome, wherein the deletion or alteration is in the glycoprotein gG gene and in the glycoprotein gl gene, so that upon replication, the recombinant virus produces no glycoprotein gG and no glycoprotein gl. The present invention further provides a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in the US2 gene, UL47- like gene, or glycoprotein g60 gene. It is contemplated that a deletion in any one of these genes will attenuate the virus, rendering it suitable to be used as a vaccine against infectious laryngotracheitis virus. The present invention further provides a recombinant infectious laryngotracheitis virus which comprises a foreign gene inserted within the unique short region of the infectious laryngotracheitis viral genome, provided, however, that the insertion is not in the protein kinase gene, the glycoprotein gD gene, the glycoprotein gE gene and the ORF10 gene. Preferred insertion sites are the US2 gene, the UL47-like gene, the ORF4 gene and the glycoprotein g60 gene. A foreign gene may be inserted within any one of these sites in such a way that it may be expressed in a host cell which is infected which the recombinant infectious laryngotracheitis virus of the present invention. The foreign gene thus inserted may encode a screenable marker, such as E. coli β-galactosidase or E. coll B>- glucuronidase. The foreign gene thus inserted may encode an antigenic polypeptide which, when introduced into the host cell, induces production of protective antibodies against an avian disease causing agent from which the antigen is derived or derivable. Such antigenic polypeptide may be derived or derivable from infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus. Such antigenic polypeptide may also be derived or derivable from avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia agent. Salmonella spp. E. coli, Paster rella spp., Bordetella spp. Bimeria spp. Histomonas spp., Trichomonas spp, Poultry nematodes, cestodes, trematodes, poultry mites/lice, poultry protozoa. The foreign gene thus inserted may be put under control of an endogenous upstream infectious laryngotracheitis virus promoter, or it may be put under control of a heterologous upstream promoter. The heterologous upstream promoter may be the HCMV IE promoter, the PRV gX promoter or BHV-1.1 VP8 promoter. The present invention further provides a vaccine for infectious laryngotracheitis virus which comprises a suitable carrier and an effective immunizing amount of any of the recombinant infectious laryngotracheitis virus of the present invention. This vaccine may contain either inactivated or live recombinant virus. Suitable carriers for the recombinant virus are well known in the art and include proteins, sugars, etc. One example of such a suitable carrier is a physiologically balanced culture medium containing one or more stabilizing agents such as hydrolyzed proteins, lactose, etc. Preferably, the live vaccine is created by taking tissue culture fluids and adding stabilizing agents such as stablizing, hydrolyzed proteins. Preferably, the inactivated vaccine uses tissue culture fluids directly after inactivation of the virus. The present invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in the glycoprotein gG gene. A preferred embodiment of this invention is a vaccine which comprises a suitable carrier and an effective immunizing amount of any one of the following viruses: recombinant infectious laryngotracheitis viruses designated S-ILT-014, S-ILT- 002, S-ILT-009, S-ILT-015 and S-ILT-017. The present invention further provides a multivalent vaccine for infectious laryngotracheitis virus and for one or more of other avian diseases which comprises an effective immunizing amount of a recombinant virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region, wherein the deletion is in the glycoprotein gG gene, and an insertion of a foreign gene into a non-essential site of the viral genome. The foreign gene encodes an antigenic polypeptide which induces host cell production of protective antibodies against an avian disease causing agent from which the antigen is derived or derivable. The foreign gene may be derived or derivable from infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus, avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia agent, Salmonella spp. , E. coli, Pasteurella spp., Bordetella spp., Elmerla spp., Hlstomonas spp., Trichomonas spp. , poultry nematodes, cestodes, trematodes, poultry mites/lice, poultry protozoa. The present invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome containing a deletion or other alteration in the unique short region of the viral genome, wherein the deletion or alteration is in the glycoprotein gG gene, so that upon replication, the recombinant virus produces no glycoprotein gG. A preferred embodiment of this invention is a vaccine which comprises a suitable carrier and an effective immunizing amount of any one of the following viruses: recombinant infectious laryngotracheitis viruses designated S-ILT-014, S-ILT- 002, S-ILT-009, S-ILT-015 and S-ILT-017. The present invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion or other alteration in the unique short region of the viral genome, wherein the deletion or alteration is in the glycoprotein gl gene so that upon replication, the recombinant virus produces no glycoprotein gl. The present invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion or other alteration in the unique short region of the viral genome, wherein the deletion or alteration is in the glycoprotein gG gene and the glycoprotein gl gene so that upon replication, the recombinant virus produces no glycoprotein gG and glycoprotein gl. The present invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in the US2 gene, UL47-like gene, or glycoprotein g60 gene. The present invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in the US2 gene, ORF4 gene, UL47-like gene, or glycoprotein g60 gene, and insertion of a foreign gene into a non- essential site in the viral genome. The foreign gene encodes an antigenic polypeptide which induces host cell production of protective antibodies against an avian disease causing agent from which the antigen is derived or derivable. The foreign gene may be derived or derivable from infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus, avian encephalo yelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia agent. Salmonella spp. , E. coli, Paste rella spp., Bordetella spp., Eimeria spp., Histomonas spp., Trichomonas spp. , poultry nematodes, cestodes, trematodes, poultry mites/lice, poultry protozoa. The present invention further provides a vaccine which comprises a suitable carrier and an effective immunizing amount of a recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains an insertion of a foreign gene into a non-essential site in the viral genome. The foreign gene encodes an antigenic polypeptide which induces host cell production of protective antibodies against an avian disease causing agent from which the antigen is derived or derivable. The foreign gene may be derived or derivable from infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus, avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia agent. Salmonella spp. E. coll, Pasterurella spp. , Bordetella spp. Eimeria spp. Histomonas spp., Trichomonas spp, Poultry nematodes, cestodes, trematodes, poultry mites/lice, poultry protozoa. The present invention further provides a method of immunizing an animal against infectious laryngotracheitis virus which comprises administering to chickens or other poultry an effective immunizing dose of any of the vaccines of the present invention. The present invention further provides a method for distinguishing chickens or other poultry which are vaccinated with an effective immunizing amount of a recombinant virus which produces no glycoprotein gG from those which are infected with a naturally-occurring infectious laryngotracheitis virus. This method comprises analyzing a sample of body fluid from the chickens or other poultry for the presence of glycoprotein gG of the infectious laryngotracheitis virus and at least one other antigen normally expressed in chickens or other poultry infected by a naturally- occurring infectious laryngotracheitis virus. The presence of antigen which is normally expressed in chickens or other poultry infected by a naturally- occurring infectious laryngotracheitis virus and the absence of glycoprotein gG in the body fluid is indicative of being vaccinated with the recombinant vaccine and not infected with a naturally-occurring infectious laryngotracheitis virus. The presence of glycoprotein gG and the antigen in the body fluid may be determined by detecting in the body fluid antibodies specific for the antigen and glycoprotein gG. The present invention further provides a method for distinguishing chickens or other poultry which are vaccinated with an effective immunizing amount of a recombinant infectious laryngotracheitis virus which produces no glycoprotein gl from those which are infected with a naturally-occurring infectious laryngotracheitis virus. This method comprises analyzing a sample of body fluid from the chickens or other poultry for the presence of glycoprotein gl of the infectious laryngotracheitis virus and at least one other antigen normally expressed in chickens or other poultry infected by a naturally-occurring infectious laryngotracheitis virus. The presence of the antigen which is normally expressed in chickens or other poultry infected by a naturally-occurring infectious laryngotracheitis virus and the absence of glycoprotein gl in the body fluid is indicative of being vaccinated with the recombinant vaccine and not infected with a naturally-occurring infectious laryngotracheitis virus. The presence of the antigen and glycoprotein gl in the body fluid may be determined by detecting in the body fluid antibodies specific for the antigen and glycoprotein gl. The present invention further provides a method for distinguishing chickens or other poultry which are vaccinated with an effective immunizing amount of a recombinant virus which produces no glycoprotein gG and no glycoprotein gl from those which are infected with a naturally-occurring infectious laryngotracheitis virus. This method comprises analyzing a sample of body fluid from the chickens or other poultry for the presence of glycoprotein gG and gl of the infectious laryngotracheitis virus and at least one other antigen normally expressed in an animal infected by a naturally- occurring infectious laryngotracheitis virus. The presence of the antigen which is normally expressed in chickens or other poultry by a naturally-occurring infectious laryngotracheitis virus and the absence of glycoprotein gG and gl in the body fluid is indicative of being vaccinated with the vaccine and not infected with a naturally-occurring infectious laryngotracheitis virus. The presence of the antigen and glycoprotein gG and gl in the body fluid may be determined by detecting in the body fluid antibodies specific for the antigen and glycoprotein gG and gl. The present invention further provides a homology vector for producing a recombinant infectious laryngotracheitis virus by inserting a foreign DNA into the unique short region of the infectious laryngotracheitis genomic DNA, which comprises a double-stranded DNA molecule consisting * essentially of a double-stranded foreign gene, which is flanked on either side by the double-stranded DNA homologous to the DNA located in the unique short region of the genomic DNA, provided, however, that the flanking sequences are not homologous to the glycoprotein gD gene, the glycoprotein gE gene, the protein kinase gene, and the ORF10 gene. The foreign gene may encode a screenable marker, such as E. coll B-galactosidase or E. coll B- glucuronidase. The present invention further provides a homology vector for producing a recombinant infectious laryngotracheitis virus by deleting DNA which encodes a screenable marker, which has been inserted into the infectious laryngotracheitis virus genomic DNA, which comprises a double stranded DNA molecule consisting essentially of a double-stranded DNA to be deleted, which is flanked on each side by a double stranded DNA homologous to the infectious laryngotracheitis virus glycoprotein gG gene, glycoprotein gl gene, US2 gene, or UL-47 like gene. Preferred embodiments of this invention are the homology vectors designated Homology Vector 544-55.12, Homology Vector 562-61.IF, Homology Vector 472-73.27, Homology Vector 560-52.Fl and Homology Vector 579-14.G2. MATERIALS AND METHODS PREPARATION OF INFECTIOUS LARYNGOTRACHEITIS VIRUS STOCK SAMPLES. Infectious laryngotracheitis virus stock samples were prepared by infecting primary chicken embryo kidney cells (CEK; obtained from Spaf s, Inc.) or primary chicken kidney cells (CK; obtained from chicks hatched from fertile eggs supplied by Hyvac) (50) in 225 cm 2 flasks with 0.5 ml of viral stock containing 10 5 -10 6 pfu in IX Eagle's Basal Medium (modified) with Hank's salts (BME) , 10% bromoethylamine(BEI)-treated fetal bovine serum (FBS) , 1% glutamine stock, 2% pennicillin/streptomycin (P/S) stock, and 1% sodium bicarbonate stock (these components are obtained from Irvine Scientific or an equivalent supplier, and hereafter the growth medium is referred to as complete BME medium) . Viral stocks were then harvested 4-5 days later. Infected media and cells were resuspended in complete medium containing 20% sterile whole milk and stored frozen at -70*C. PREPARATION OF INFECTIOUS LARYNGOTRACHEITIS VIRUS DNA. Four to five days after viral infection, cells and media were scraped from each flask into 15 ml conical centrifuge tubes and pelleted at 1700 x g for 5 minutes at 4°C. Because as much as 50% of the virus may be in the media, the supernatants were saved and treated as will be described below. The cell pellets were resuspended in 1 l PBS per tube, combined and centrifuged again at 1700 x g for 5 minutes. The pellets were resuspended in 1 ml/flask of a buffer containing 10 mM Tris-HCl pH 7.5, 1 mM EDTA, and 1.5 mM MgCl 2 and were incubated for 15 minutes at 4°C. Twenty five μls of 20% NP40 per flask was added, and the mixture was then homogenized in a dounce homogenizer using an A pestle. The preparation was centrifuged at 1700 x g for 10 minutes at 4°C and the supernatant was retained. Ten μl of 0.5 M EDTA, 50 μl of 20% SDS, and 25 μl of 10 mg/ l proteinase K was added to the supernatant (per original flask) . In some cases, this was then combined with virus obtained from the cell media supernatants (see above) . The mixture was then treated at 65 β C for 1-16 hours, followed by two extractions with phenol saturated with 100 mM Tris-HCl, pH 8. DNA in the aqueous phase was then precipitated with added 3 M sodium acetate (1/lOth volume) and 2.5 vols of 100% ethanol. To obtain virus from the media, the cell media supernatants were centrifuged at 23,500 x g for 30 minutes, and drained well. The pellet was resuspended in the above proteinase K-containing mixture as described. The DNA pellets were resuspended in 20 μl TE/flask and could be used at this point for further experiments or treated further to remove RNA with pancreatic RNase A, followed by phenol extraction and ethanol precipitation to obtain the DNA. To prepare viral DNA minipreps, infected 10 cm. dishes were scraped into conical centrifuge tubes and centrifuged 5 minutes at 1000 x g. Cell media supernatants were kept and treated as above. The cell pellets were each resuspended in 0.5 ml of 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.5% NP40, and incubated 10 minutes at room temperature. Ten μl of 10 mg/ml RNase A was added, and the preparation was centrifuged 5 minutes at 1000 x g. Twenty-five μl of 20 % SDS and 25 μl of 10 mg/ml proteinase K was added to the supernatant, and the entire preparation was added to the viral pellet from the cell media if it was used. The mixture was incubated at 55- 65°C for one hour, extracted with buffer-saturated phenol and precipitated by the addition of 1 ml of ethanol. The DNA pellet was resuspended in 20 μl of TE and stored at 4 β C. POLYMERASE FILL-IN REACTION. DNA was resuspended in buffer containing 50 mM Tris pH 7.4, 50 mM KC1, 5 mM MgCl , and 400 micromolar each of the four deoxyribonucleotides. Ten units of Klenow DNA polymerase (Gibco BRL) were added and the reaction was allowed to proceed for 15 minutes at room temperature. The DNA was phenol extracted and ethanol precipitated as above. DNA SEQUENCING. Sequencing was performed using the Sequenase Kit (US Biochemicals) and c 35 S-dATP (New England Nuclear) . Reactions using both the dGTP mixes and the dITP mixes were performed to clarify areas of compression. Alternatively, compressed areas were resolved on forma ide gels. Templates were double- stranded plasmid subclones or single stranded M13 subclones, and primers were either made to the vector just outside the insert to be sequenced, or to previously obtained sequence. Sequence obtained was assembled and compared using Dnastar software. Manipulation and comparison of sequences obtained was performed with IBI MacVector, Superclone and Supersee Align programs from Coral Software. MOLECULAR BIOLOGICAL TECHNIQUES. Techniques for the manipulation of bacteria and DNA, including such procedures as digestion with restriction endonucleases, gel electrophoresis, extraction of DNA from gels, ligation, phosphorylation with kinase, treatment with phosphatase, growth of bacterial cultures, transformation of bacteria with DNA, and other molecular biological methods are described (42, 43). The polymerase chain reaction (PCR) was used to introduce restriction sites convenient for the manipulation of various DNAs (44) . In general amplified fragments were less than 500 base pairs in size and critical regions of amplified fragments were confirmed by DNA sequencing. Except as noted, these techniques were used with minor variation. SOUTHERN BLOTTING OF DNA. The general procedure for Southern blotting was taken from Maniatis et al . (1982) and Sambrook, et.al. (1989) (42, 43). DNA was blotted to nylon membrane (Biorad Zetaprobe) in 0.4M NaOH and prehybridized for 5 minutes in a solution containing 0.25 M Na 2 HP0 4 , pH 7.2, 1 mM EDTA, 7% SDS at 65°C. Labeled probe was added that had been labeled by random priming using a Genius" non-radioactive labeling kit from Boehringer-Mannheim. Hybridization was overnight at 65°C. Filters were washed twice with 40 mM Na 2 HP0 4 , pH 7.2, 1 mM EDTA, 5% SDS and then twice with 40 mM Na 2 HP0 4 , pH 7.2, 1 mM EDTA, 1% SDS for 30 minutes each at 65°C. Detection of bound probe was performed using the Boehringer Mannheim Genius" non-radioactive detection kit. DNA TRANSFECTION FOR GENERATING RECOMBINANT ILT VIRUS. The method is based upon the CaCl 2 procedure of Chen and Okayama (1987) (45) with the following modifications. Generation of recombinant ILT virus is dependent upon homologous recombination between ILT viral DNA and the plasmid homology vector containing the desired foreign DNA flanked by the appropriate herpesvirus cloned sequences. Plasmid DNA (10-40 mg) was added to 250 ml of a solution having a final concentration of 0.25 M CaCl 2 . An equal volume of a buffer containing 50 mM MOPS (pH 6.95), 280 mM NaCl, and 1.5 mM Na 2 HP0 4 was added to the DNA/CaCl 2 solution. After 10 minutes at room temperature. the mixture was added dropwise to a 6 cm dish of CEK cells on maintenance media, and placed at 39°C for 4 to 5 hours. The cells were rinsed once with PBS, once with 20% glycerol in PBS for 2 minutes, rinsed again with PBS and fed with maintenance media. 1.5 ml of ILT viral stock was added to the media, and the cells were incubated overnight. The next day, fresh maintenance media was added, and the cells were incubated for two more days. The transfection stock was harvested, aliquoted, and frozen at -70 β C. PROCEDURE FOR GENERATING ILTV SUBGENOMIC DNA FRAGMENTS. The ability to generate herpesviruses by cotransfection of cloned overlapping subgenomic fragments has been demonstrated for pseudorabies virus (46) . If deletions and/or insertions are engineered directly into the subgenomic fragments prior to the cotransfection, this procedure results in a high frequency of viruses containing the genomic alteration, greatly reducing the amount of screening required to purify the recombinant virus. We have used the procedure of overlapping cosmids to map restriction enzyme sites. A library of subclones containing overlapping ILTV subgenomic fragments was generated as follows. USDA ILTV Strain 83-2 has been designated S-ILT-001. Approximately 20 μg of ILTV DNA (obtained from S-ILT-001) in 0.5 ml of 10 mM Tris-HCl pH 8.0, 1 mM EDTA (TE) was sheared by passing it twice through a 25 guage needle as previously described (46) . The DNA was centrifuged through a 15-40% glycerol gradient in 50 mM Tris-HCl pH 8.0, 1 mM EDTA, and 0.3 M NaCl for 5.5 hours at 274,000 x g. Fractions were analyzed on a 0.3% agarose gel, and those containing DNA of 35-50 kb were pooled, diluted twofold with TE, and precipitated with one tenth volume of 3 M sodium acetate and 2.5 volumes of ethanol. The tubes were centrifuged for one hour at 109,000 x g at 10 β C . Pellets were resuspended, transferred to microfuge tubes, and precipitated with one tenth volume of 3 M sodium acetate and 2.5 volumes of ethanol. The DNA was resuspended in TE. DNA ends were made blunt ended by the POLYMERASE FILL-IN REACTION. The DNA was purified by extraction with both buffer saturated phenol and ether, precipitated with sodium acetate and ethanol as above, and resuspended in TE. Half of this material was ligated with 3 mg of vector, pSY1626, by the DNA ligation reaction. The vector used was pSY1626, which was made as follows. Cosmid pHC79 (Gibco BRL) was cut with Hlndlll and Aval to remove the tetracycline gene, and the ends were filled in with Klenow polymerase (FILL IN REACTION) . The polylinker from pWE15 (Stratagene) was ligated into this vector. The polylinker was isolated by digestion with EcόRl, the ends were filled in with Klenow polymerase (FILL IN REACTION) , and the fragment was purified on a LMP-agarose gel. DNA ligation was performed in the presence of melted agarose. The resulting cosmid, pSY1005, was modified at the EcόRl site to create pSY1626 by blunt-ended insertion of a 1.5 kb JϊiΛdlll—BaπHI fragment from pNEO (P-L Biochemicals) containing the neomycin resistance gene. pSY1626 was cut and made blunt at the BamHI site, and ligated with sheared ILTV fragments as described above. The ligation mixture was packaged using Gigapack XL (Stratagene) according to the manufacturers instructions. The packaging mixture was added to AG1 cells (Stratagene) grown in the presence of maltose, and colonies were selected on LB plates containing kanamycin. Cosmid subclones containing ILTV DNA were identified by comparing restriction enzyme maps of individual cosmid clones to each other and to ILVTV genomic DNA to obtain a contiguous sequence of ILTV genomic DNA. SCREEN FOR RECOMBINANT ILTV EXPRESSING ENZYMATIC MARKER GENES. When the B. coll ,9-galactosidase or β- glucuronidase (uidA) marker gene was incorporated into a recombinant virus the plaques containing the recombinants were visualized by a simple assay. The enzymatic substrate was incorporated (300 μg/ml) into the ag arose overlay during the plaque assay. For the lacZ marker gene the substrate Bluogal™ (halogenated indolyl- ,9-o-galactosidase, Gibco BRL) was used. For the uidA marker gene the substrate X-Glucuro Chx (5-bromo-4- chloro-3-indolyl-,9-D-glucuronic acid Cyclohexylammonium salt, Biosynth AG) was used. Plaques that expressed active marker enzyme turned blue. The blue plaques were then picked onto fresh cells and purified by further blue plaque isolation. In recombinant virus strategies in which the enzymatic marker gene was removed, the assay involves plaque purifying white plaques from a background of parental blue plaques. Viruses were typically purified with five to ten rounds of plaque purification. SCREEN FOR FOREIGN GENE EXPRESSION IN RECOMBINANT ILTV USING BLACK PLAQUE ASSAYS. To analyze expression of foreign antigens expressed by recombinant ILT viruses, monolayers of CEK cells were infected with recombinant ILT virus, overlaid with nutrient agarose media and incubated for 3-5 days at 39°C. Once plaques have developed, the agarose overlay was removed from the dish, the monolayer rinsed once with PBS, fixed with 100% methanol for 10 minutes at room temperature and the cells air dried. After re-hydrating the plate with PBS, the primary antibody was diluted to the appropriate dilution with PBS plus Blotto and incubated with the cell monolayer for 2 hours to overnight at room temperature. Unbound antibody was removed from the cells by washing four times with PBS at room temperature. The appropriate secondary antibody conjugate was diluted 1:500 with PBS and incubated with the cells for 2 hours at room temperature. Unbound secondary antibody was removed by washing the cells three times with PBS at room temperature.The monolayer was rinsed in color development buffer (lOOmM Tris pH 9.5/ lOOmM NaCl/ 5mM MgC12), and incubated 10 minutes to overnight at room temperature with freshly prepared substrate solution (0.3 mg/ml nitro blue tetrazolium + 0.15 mg/ml 5-bromo-4-chloro-3-indolyl phosphatase in color development buffer) .The reaction was stopped by replacing the substrate solution with TE (lOmM Tris, pH7.5/ 1 mM EDTA). Plaques expressing the correct antigen stain black. PURIFICATION OF ILTV gG FROM ILT VIRUS OR RECOMBINANT VIRUSES EXPRESSING ILTV gG. ILTV gG was purified from the media of cells infected with either wild type ILTV or with FPV or SPV vectors expressing ILTV gG. Cells were allowed to go to complete cytopathic effect (CPE) , the media was poured off, and cell debris was pelleted in a table-top centrifuge. The media was concentrated in an Amicon concentrator using a YM30 ultrafiltration membrane at 15 psi. The concentrate was dialyzed against 20 mM Tris-HCl, pH 7.0 and loaded onto a DEAE-Sephacel (Pharmacia) column equilibrated with the same buffer. The material was eluted using a salt gradient from 0 to 1.5 M NaCl in 20 mM Tris-HCl, pH 7.0. Three ml fractions were collected and assayed by Western blot. A peptide antibody against ILTV gG was used to identify fractions containing ILTV gG. Fractions were pooled and further concentrated in a Centricon-10 microconcentrator (Amicon) . HOMOLOGY VECTOR 501-94. The plasmid 501-94 was constructed for the purpose of deleting a portion of the thymidine kinase (TK) gene coding region from the ILT virus (28) . It incorporates the HCMV IE promoter and a screenable marker, the B. coli lacZ gene, flanked by ILT virus DNA. The HCMV IE promoter-^, coli lacZ gene is inserted in the opposite transcriptional orientation to the ILTV TK gene. Upstream of the marker gene is an approximately 1087 base pair fragment of ILTV DNA which includes the first 77 amino acid codons of the ILTV TK gene. Downstream of the lacZ gene is an approximately 675 base pair fragment of ILTV DNA which includes 80 amino acid codons at the 3* end of the ILTV TK gene. When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the DNA coding for amino acids 78 to 285 of the ILTV TK gene with DNA coding for the lacZ gene. The lacZ marker gene is under the control of the human cytomegalovirus (HCMV) immediate early (IE) gene promoter and also contains the pseudorabies virus (PRV) gX gene polyadenylation signal at the 3' end of the gene. A detailed description of the plasmid is given in Figure 5. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques (42, 43). The plasmid vector is derived from an approximately 3002 base pair HindJ.ll fragment of pSP64/65 (Promega) . Fragment 1 is an approximately 1087 base pair HindiII to Bell subfragment of the ILTV 2.4 kb Hindlll fragment. Fragment 2 is an approximately 5017 base pair Sail to Sail fragment containing the HCMV IE promoter, β- galactosidase (lacZ) marker gene, and PRV gX polyadenylation signal (see Figure 5) . Fragment 3 is an approximately 675 base pair Bσll to Hlndlll subfragment of the ILTV 2.4 kb HindiII fragment. HOMOLOGY VECTOR 544-55.12. The plasmid 544-55.12 was constructed for the purpose of deleting a portion of the US2 gene coding region from the ILT virus and inserting a foreign DNA. It incorporates a screenable marker, the E. coli uidA gene flanked by ILT virus DNA. The PRV gX promoter-J?. coli uidA gene is inserted in the opposite transcriptional orientation to the ILTV US2 gene. Upstream of the uidA gene is an approximately 2300 base pair fragment of ILTV DNA which includes 41 amino acid codons at the 3' end of the US2 gene (SEQ ID NO 2: aa. 188-229) . Downstream of the uidA gene is an approximately 809 base pair fragment of ILTV DNA which includes 22 amino acid codons it the 5* end of the US2 gene (SEQ ID NO 2: aa. 1-22). When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the ILTV US2 DNA coding for amino acids 23 to 187 with DNA coding for the E. coll uidA gene. The uidA marker gene is under the control of the pseudorabies virus (PRV) gX promoter and also contains the herpes simplex virus type 1 thymidine kinase (HSV-1 TK) gene polyadenylation signal at the 3' end of the gene. A detailed description of the plasmid is given in Figure 6. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques (42, 43). The plasmid vector is derived from an approximately 2958 base pair Asp718I restriction fragment of a pSP18/pSP19 fusion such that the multiple cloning site is EcόRl / Sad /Asp 181 /Sad /EcόRl. Fragment 1 is an approximately 2300 base pair Asp718I to Oral subfragment (SEQ ID NO 1: Nucl. 1-405) of the ILTV 2.5 kb Asp718I fragment. Fragment 2 is an approximately 3039 base pair XJal fragment containing the PRV gX promoter, the E. coli uidA gene, and the HSV-1 TK polyadenylation site (See Figure 6) . Fragment 3 is an approximately 809 base pair Xbal to Asp718I subfragment of the ILTV 1097 bp Asp718I fragment (SEQ ID NO 1: Nucl. 905-1714). HOMOLOGY VECTOR 562-61.IF. The plasmid 562-61.IF was constructed for the purpose of deleting part of the gl gene from the ILT virus and inserting a foreign DNA. It incorporates a screenable marker, the E. coli uidA gene, flanked by ILT virus DNA. The PRV gX promoter-^, coli uidA gene is transcribed in the opposite direction to the ILTV gl gene promoter. The 983 base pair deletion begins 12 base pairs upstream of the translation initiation codon and deletes 324 of 363 amino acid codons at the 5 1 end of the ILTV gl gene (SEQ ID NO 11: aa. 325-363) . When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the DNA coding for the ILTV gl gene with DNA coding for the E. coli uidA gene. A detailed description of the plasmid is given in Figure 7. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques (42, 43). The plasmid vector is derived from an approximately 2647 base pair Asp718I to HindiII fragment of pUC19. Fragment 1 is an approximately 1619 base pair Asp718I to Xbal subfragment of the ILTV 8.0 kb Asp718I fragment (SEQ ID NO 1: Nucl. 7556-9175). Fragment 2 is an approximately 691 base pair XJbal to Xhol fragment (SEQ ID NO 1: Nucl. 9175-9861) generated by the polymerase chain reaction (PCR) . The template was the ILTV 8.0 kb Asp718I fragment. The upstream primer 92.09 (S^CCTAGCACCCTTGTATCGCG-S•; SEQ ID NO. 55) sits down at a site 821 base pairs upstream of the ILTV gl gene and synthesizes DNA toward the 3' end of the gene. The downstream primer 92.11 (5'- CGC£ESSΔSTCCCAATGAATAGGCATTGG-3• ; SEQ ID NO. 56) sits down at a site 12 base pairs upstream of the translation start site of the ILTV gl gene and synthesizes DNA toward the 5' end of the gD gene. The product of the PCR reaction is 818 base pairs. This DNA fragment is digested with XJbal at the 5' end (a restriction enzyme site present in the ILTV DNA) and Xhol at the 3' end (a restriction enzyme site created in the PCR primer—see underlined sequence) to create an approximately 691 base pair XJbal to Xhol fragment. Fragment 3 is an approximately 3051 base pair Sail fragment containing the PRV gX promoter, the uidA gene, and the HSV-1 TK polyadenylation site (See Figure 6) . Fragment 4 is an approximately 624 base pair Xhol to Hindlll fragment generated by PCR (SEQ ID NO 1: Nucl. 10,847-11,461). The template was the ILTV 8.0 kb Asp718I fragment. The upstreamprimer 92.10 (5'-CGCCTCGAGGACCCATGGTTGCGTGCG-3• ; SEQ ID NO. 57) sits down at a site 117 base pairs upstream from the translation termination codon within the ILTV gl gene. The downstream primer 92.08 (5 1 - CTCGTCCGAACGAGTTACAG-3•; SEQ ID NO. 58) sits down at a site 604 base pairs downstream of the translation termination site of the ILTV gl gene and within the ILTV gE gene. The PCR product (729 base pairs) is digested with Xhol which is a unique site generated by the upstream PCR primer (underlined) and with Hindlll at a site within the ILTV gE gene. Restriction endonuclease digestion with Xhol and HindiII creates an approximately 624 base pair Fragment 4. Fragment 5 is an approximately 2700 base pair Hindi11 subfragment of the ILTV 8.0 kb Asp718I fragment (SEQ ID NO 1: Nucl. 11,461-13,473 plus unsequenced DNA) . HOMOLOGY VECTOR 472-73.27. The plasmid 472-73.27 was constructed for the purpose of deleting a portion of the glycoprotein G (gG) gene coding region from the ILT virus and inserting a foreign DNA. It incorporates a screenable marker, the E. coli lacZ gene, flanked by ILT virus DNA. The HCMV IE promoter-*, coli lacZ gene is transcribed in the same direction to the ILTV gG gene promoter. The 874 base pair deletion of the ILTV gG gene extends from 60 nucleotides upstream of the translation initiation site to 814 nucleotides into the amino acid coding sequence, removing the coding capacity of 271 of 292 amino acids of the gG protein (SEQ ID NO 7) . When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the DNA coding for amino acids 1 to 271 of the ILTV gG gene with DNA coding for the E. coll lacZ gene. A detailed description of the plasmid is given in Figure 4. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques (42, 43) . The plasmid vector is derived from an approximately 2686 base pair Asp718I restriction fragment of pUC 19 (Gibco, BRL) . Fragment 1 is an approximately 2830 base pair Asp7l8I to Nhel subfragment of the ILTV 5164 bp Asp718I fragment (SEQ ID NO 1: Nucl. 1714-4544) . Fragment 2 is an approximately 5017 base pair Sail to Sail fragment containing the HCMV IE promoter, E. coli ,9-galactosidase (lacZ) marker gene, and PRV gX polyadenylation signal (see Figure 4) . Fragment 3 is an approximately 1709 base pair Sail to Asp718I subfragment of the ILTV 5164 bp Asp718I fragment (SEQ ID NO 1: Nucl. 5419-6878). HOMOLOGY VECTOR 560-52.Fl. The plasmid 560-52.Fl was constructed for the purpose of deleting part of the UL47- like gene, all of ORF4, and part of the ILTV gG gene from the ILT virus and inserting a foreign DNA. It incorporates a screenable marker, the E. coll uidA gene. flanked by ILT virus DNA. The PRV gX promoter-*, coli uidA gene is transcribed in the opposite direction to the ILTV UL47-like, ORF4, and gG gene promoters. The 2640 base pair deletion removes 442 of 511 amino acid codons at the 3' end of the UL47-like gene (SEQ ID NO 4), the entire coding sequence of the ORF4 gene (SEQ ID NO 5) and 271 of 293 amino acid codons at the 5' end of the ILTV gG gene (SEQ ID NO 7) . When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the DNA coding for the ILTV UL47-like, ORF4 and gG genes with DNA coding for the PRV gX promoter-*, coli uidA gene. A detailed description of the plasmid is given in Figure 8. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques (42, 43). The plasmid vector is derived from an approximately 2958 base pair Asp7l8I restriction fragment of pSP18/pSP19 such that the multiple cloning site is EcoRl /Sad/ As p7181 /SacI/EcoRI . Fragment 1 is an approximately 1066 base pair Asp718I to BssHII subfragment of the ILTV 5164 bp Asp718I fragment (SEQ ID NO 1: Nucl. 1714-2777). Fragment 2 is an approximately 123 base pair Sail to Bell subfragment of the ILTV 5164 bp Asp718I fragment. Fragment 3 is an approximately 3027 base pair BamHI fragment containing the PRV gX promoter, the uidλ gene, and the HSV-1 TK polyadenylation site (See Figure 8) . Fragment 4 is an approximately 1334 base pair BelI to Asp718I subfragment of the ILTV,5164 bp Asp718I fragment (SEQ ID NO 1: Nucl. 5544-6878 ) . HOMOLOGY VECTOR 579-14.G2. The plasmid 579-14.G2 was constructed for the purpose of deleting the entire gG gene and a portion of the g60 gene from the ILT virus and inserting a foreign DNA. It incorporates a PRV gX promoter and a screenable marker, the E. coli uidA gene, flanked by ILT virus DNA. The PRV gX promoter-*, coll uidA gene is transcribed in the same direction to the ILTV gG and g60 gene promoters. The 3351 base pair deletion includes the entire coding sequence of the ILTV gG gene (SEQ ID NO 7) and 733 of 986 amino acid codons from the 5' end of the g60 gene (SEQ ID NO 8). When this plasmid is used according to the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT HERPESVIRUS, it will replace the DNA coding for the ILTV gG gene and amino acids 1 to 733 of the ILTV g60 gene with DNA coding for the *. coli uidA gene. A detailed description of the plasmid is given in Figure 9. It was constructed from the indicated DNA sources utilizing standard recombinant DNA techniques (42, 43). The plasmid vector pUC19 (Gibco, BRL) is derived from an approximately 2677 base pair Asp718I to BamHI fragment. Fragment 1 is an approximately 2830 base pair Asp7l8I to Nhel subfragment of the ILTV 5164 bp Asp718I fragment (SEQ ID NO 1: Nucl. 1714-4544) . Fragment 2 is an approximately 3051 base pair Sail fragment containing the PRV gX promoter, *. coli ?- glucuronidase (uidA) marker gene, and an HSV-1 TK polyadenylation site (See Figure 9) . Fragment 3 is an approximately 1709 base pair Sail to BamHI subfragment of the ILTV 4545 base pair BamHI fragment (SEQ ID NO 1: Nucl. 7895-9604). PLASMID 544-39.13. Plasmid 544-39.13 contains the β- glucuronidase expression cassette consisting of the PRV gX promoter, *. coli ,9-glucuronidase (uidA) marker gene, and an HSV-1 TK polyadenylation site. A detailed description of the marker gene is given in FIGURE 10. It was constructed utilizing standard recombinant DNA techniques (42, 43) by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in FIGURE 10. The plasmid vector pSP71 (Promega) is derived from an approximately 3066 base pair Xmal to Smal fragment. Fragment 1 is an approximately 422 base pair Sail to *coRI restriction subfragment of the PRV BamHI restriction fragment /10 (47) . Note that the *coRI site was introduced at the location indicated in FIGURE 12 by PCR cloning. Fragment 2 is an approximately 1826 base pair *coRI to Smal fragment of the plasmid pRAJ260 (Clonetech) . Note that the EcoRl and Xmal sites were introduced at the locations indicated in FIGURE 10 by PCR cloning. Fragment 3 is an approximately 784 base pair Xmal subfragment of the HSV-1 BamHI restriction fragment Q (48) . Note that this fragment is oriented such that the polyadenylation sequence (AATAAA) is located closest to the junction with the *. coli uidA gene. PLASMID 388-65.2. Plasmid 388-65.2 contains the β- galactosidase expression cassette consisting of the HCMV immediate early (IE) promoter, the *. coli lacZ marker gene, and the PRV gX gene polyadenylation site. A detailed description of the /9-galactosidase expression cassette is given in FIGURE 11. It was constructed utilizing standard recombinant DNA techniques (42, 43) by joining restriction fragments from the following sources with the synthetic DNA sequences indicated in FIGURE 11. The plasmid vector pSP72 (Promega) is derived from an approximately 3076 base pair PstI to PstI fragment. Fragment 1 is a 1154 base pair PstI to Avail fragment derived from a HCMV 2.1 kb PstI fragment containing the HCMV IE promoter. Fragment 2 is a 3010 base pair BamHI to PvuII fragment derived from plasmid pJF751 (49) containing the *. coll lacZ gene. Fragment 3 is an approximately 750 base pair iVdel to Sail fragment derived from PRV BamHI ≠7 which contains the carboxy-terminal 19 amino acids and the polyadenylation signal of the PRV gX gene. EXAKPLES Example l Complete sequence of the unique short region of Infectious Laryngotracheitis Virus (ILΗn We have determined the sequence of 13,473 base pairs of contiguous DNA from the short region of the ILT virus (SEQ. ID. NO. 1) . This sequence contains the entire 13,098 base pair unique short region as well as 273 base pairs of repeat region at one end and 102 base pairs of repeat region at the other end. The unique short region contains 13 methionine initiated open reading frames (ORF) of greater than or equal to 110 amino acids (excluding smaller nested ORFs) . All 13 ORFs were aligned to the Entrez release 6.0 virus division of the Genbank DNA database utilizing the IBI MacVector Protein to DNA alignment option (default settings) . Eight of the ORFs exhibited significant homology to one or more other virus genes (see table) . The nucleotide sequence numbers referred to below begin within the internal repeat sequence and end within the terminal repeat sequence. The unique short region begins at base pair 274 of SEQUENCE ID NO. 1. Seguence Homology between Infectious Laryngotracheitis Virus (ILTV) Open Reading Frames in the Unique Short Region and other Viral Proteins a Sequence allignment scored to the Entrez Release 6.0 of Genbank Virus Database. b RC=Reverse Complement. c NS=No score above 120 was found. Other Abbreviations: EHV- Equine herpesvirus; MDV- Mareks disease virus; HSV-l- Herpes Simplex virus 1; PRV- Pseudorabies virus; ILTV- Infectious laryngotracheitis virus; HSV-2- Herpes Simplex virus 2; VZV- Varicella-Zoster virus; BP- base pairs; aa- amino acids. us? gene The US2 gene consists of 690 base pairs and codes for a protein 229 amino acids in length and molecular weight approximately 25,272 daltons (SEQ. ID. NO. 12, 13). The ILTV US2 is homologous to the Equine herpesvirus(EHV)-1 and EHV-4 US2 proteins. The US2 gene is transcribed from nucleotide 970 to 281 on the reverse complement strand of the ILTV unique short region (SEQ. ID. NO. 1) . The function of the US2 gene product is unknown. Protein kinase gene The protein kinase gene consists of 1431 base pairs from nucleotide 1059 to 2489 and codes for a protein 476 amino acids in length and molecular weight approximately 54,316 daltons (SEQ. ID. NO. 2) . The ILTV protein kinase is homologous to the protein kinases from Mareks disease virus (MDV), Equine herpesvirus(EHV)-1 and -4, Pseudorabies virus (PRV) , Varicella-Zoster virus (VZV) , Simian varicella virus (SW) , and Herpes Simplex virus(HSV)-l and -2. UL47-like gene The UL47-like gene is unique in its location within the unique short region of ILT virus. The UL47-like gene in all other known herpesviruses is located within the unique long sequence. The UL47-like gene consists of 1533 base pairs from nucleotide 2575 to 4107 and codes for a protein 510 amino acids in length and molecular weight approximately 57,615 daltons (SEQ. ID. NO. 3). QRF4 ORF4 codes for a protein of unknown function. ORF4 consists of 333 base pairs from nucleotide 4113 to 4445 and codes for an open reading frame 110 amino acids in length and molecular weight approximately 12,015 daltons (SEQ. ID. NO. 4) . ORF4 Reverse Complement 0RF4 Reverse Complement (RC) codes for a protein of unknown function. 0RF4 RC consists of 380 base pairs from nucleotide 4519 to 4139 and codes for an open reading frame 126 amino acids in length and molecular weight approximately 13,860 daltons (SEQ. ID. NOS. 14, 15). gG gene The gG gene consists of 879 base pairs from nucleotide 4609 to 5487 and codes for a glycoprotein 292 amino acids in length and molecular weight approximately 31,699 daltons (SEQ. ID. NO. 5) . ILTV gG glycoprotein is homologous to PRV gX, Bovine herpesvirus(BHV)-1.3 gG, EHV-1 gG and EHV-4 gG. Recombinant ILTV gG protein produced in a Swinepox virus vector or a Fowlpox virus vector can be purified (see Materials and Methods) and reacts to peptide antisera to ILTV gG. The peptide antisera reacts to ILTV gG from wild type virus, but not to viruses deleted for the ILTV gG gene. Deletion of the gG gene results in an attenuated ILT virus that is useful as a vaccine against ILT disease in chickens (see table in Example 6) and also serves as a negative marker to distinguish vaccinated from infected animals. g60 gene The g60 gene has been identified as glycoprotein 60 (33, 53) . The g60 gene consists of 2958 base pairs from nucleotide 5697 to 8654 and codes for a glycoprotein 985 amino acids in length and molecular weight approximately 106,505 daltons (SEQ. ID. NO. 6). ORF6 Reverse Complement ORF6 RC consists of 878 base pairs from nucleotide 7826 to 6948 and codes for an open reading frame 292 amino acids in length and molecular weight approximately 32,120 daltons (SEQ. ID. NO. 16, 17) . The ILTV ORF6 RC shares limited homology to portions of the HSV-l and HSV-2 ribonucleotide reductase large subunit (UL39) . The expression of the gD glycoprotein in vectored fowlpox virus or herpesvirus of turkeys (33) is sufficient to raise a protective immune response in the chicken. The gD gene consists of 1305 base pairs from nucleotide 8462 to 9766 and codes for a glycoprotein 434 amino acids in length and molecular weight approximately 48,477 daltons (SEQ. ID. NO. 10, 11). The ILTV gD glycoprotein is homologous to the PRV g50, and the gD from HSV-l, MDV, IPV, and BHV-1.1. Monoclonal antibodies raised to ILT virus react specifically with gD protein from ILTV and also react to ILTV gD protein expressed in a Herpesvirus of Turkeys (HVT) virus vector. ILTV gD expressed in the HVT vector is useful as a subunit vaccine. gl gene The gl gene consists of 1089 base pairs from nucleotide 9874 to 10,962 and codes for a glycoprotein 362 amino acids in length and molecular weight approximately 39,753 daltons (SEQ. ID. NO. 7) . The ILTV gl glycoprotein is homologous to the VZV gl. Recombinant ILTV gl protein expressed in a swinepox virus vector reacts to convalescent sera from ILTV-infected chickens. Deletion of the gl gene results in an attenuated ILT virus that is useful as a vaccine against ILT disease in chickens. Recombinant viruses deleted for gl are safe in animal trials when vaccinated by a natural route directly into the respiratory tract, whereas parental virus causes lesions in 90% of the birds inoculated via the same route. Deletion of the gl gene serves as a negative marker to distinguish vaccinated from infected animals. ORF8 Reverse Complement ORF8 Reverse Complement codes for a protein of unknown function. ORF8 RC consists of 533 base pairs from nucleotide 11,150 to 10,617 and codes for an open reading frame 177 amino acids in length and molecular weight approximately 19,470 daltons (SEQ. ID. NO. 18, 19). The gE gene consists of 1500 base pairs from nucleotide 11,159 to 12,658 and codes for a glycoprotein 499 amino acids in length and molecular weight approximately 55,397 daltons (SEQ. ID. NO. 8) . The ILTV gE glycoprotein is homologous to the gE glycoproteins from VZV, Simian herpesvirus (SHV) , EHV-1, HSV-l, and PRV. The ILTV gE is a neutralizing antigen useful as a subunit vaccine. ORF10 ORFIO consists of 783 base pairs from nucleotide 12,665 to 13,447 and codes for a protein 261 amino acids in length and molecular weight approximately 27,898 daltons (SEQ. ID. NO. 9). Example 2 S-ILT-Q04 S-ILT-004 is an infectious laryngotracheitis virus (ILTV) that has an approximately 620 base pair deletion of the thymidine kinase (TK) gene (28) . The gene for *. coll β- galactosidase (lacZ) was inserted in the place of the TK gene and is under the control of the HCMV immediate early (IE) promoter. Transcription of the HCMV IE promoter-lac Z gene is in the opposite orientation to the TK promoter. S-ILT-004 was constructed using homology vector 501-94 (see Materials and Methods) and S-ILT-001 (USDA ILTV Strain 83-2) in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. The transfection stock was screened by the Bluogal" SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. The result of blue plaque purification was recombinant virus S-ILT- 004. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING OF DNA procedure. This analysis confirmed the presence of the β-galactosidase (lacZ) marker gene and the deletion of approximately 619 base pairs of the TK gene. The remaining TK gene sequence codes for protein including amino acids 1 to 77, and amino acids 286 to 363. The HCMV IE promoter-lacZ gene is in the opposite orientation to the TK gene transcription. S-ILT-004 is attenuated by deletion of the ILTV TK gene, but retains other genes known to be involved in the immune response in chickens to ILT virus. Therefore, S- ILT-004 may be useful as a killed vaccine to protect chickens from ILT disease. Example 3 S-ILT-009 S-ILT-009 is an infectious laryngotracheitis virus (ILTV) that has an approximately 498 base pair deletion of the ILTV US2 gene and an approximately 874 base pair deletion of the ILTV gG gene. The gene for *. coli ,9-glucuronidase (uidA) was inserted in the place of the US2 gene and is under the control of the pseudorabies virus (PRV) gX promoter. S-ILT-009 was constructed using homology vector 544-55.12 (see Materials and Methods) and S-ILT-002 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. S-ILT-002 was constructed as described in Example 5 (S-ILT-014) . The transfection stock was screened by the X-Gluc SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. The resulting purification of a blue plaque was recombinant virus S- ILT-009. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING OF DNA procedure. This analysis confirmed the presence of the PRV gX promoter-,6- glucuronidase (uidA) marker gene and the deletion of approximately 498 base pairs of the ILTV US2 gene and an approximately 874 base pair deletion of the ILTV gG gene. However, during the Bluogal" SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES, a deletion of the HCMV IE promoter-lacZ gene was detected within the existing ILTV gG deletion. The remaining insert into the ILTV gG deletion contains approximately 2000 base pairs of DNA of which all of the lacZ gene and part of the PRV gX polyadenylation site are missing. The deletion was characterized by detailed restriction mapping and determined to be slightly different from the S-ILT-014 deletion (See Example 5) . S-ILT-009 is attenuated by deletion of the ILTV US2 and gG genes, but retains other genes known to be involved in the immune response in chickens to ILT virus. Therefore, S-ILT-009 is useful as an attenuated live vaccine or as a killed vaccine to protect chickens from ILT disease as shown in the table. Since S-ILT-009 does not express the ILTV gG genes, it is utilized as a negative marker to distinguish vaccinated animals from infected animals as described previously. EFFICACY OF RECOMBINANT LIVE ILT VIRUS S-ILT-009 AGAINST VIRULENT INFECTIOUS LARYNGOTRACHEITIS VIRUS CHALLENGE Vaccine Gene(s) Dose Route Challenge* Protection 19 Deleted S-ILT- gG-, 7.8X10 3 IO c OS d 70% 009 US2- S-ILT- gG-, 1.56X1 10 OS 77% 009 US2- o 3 Controls OS 0% ASL 10 OS 90% embryo 14 day old chicks a: USDA Challenge virus -l.OxlO 4 * 5 pfu b: Protection - ≠ healthy birds/total (%) c: Intraocular d: Orbital Sinus Example 4 S - ILT- 011 S-ILT-Oil is an infectious laryngotracheitis virus (ILTV) that has an approximately 983 base pair deletion of the ILTV gl gene. The gene for *. coli β-glucuronidase (uidA) was inserted in the place of the gl gene and is under the control of the pseudorabies virus (PRV) gX promoter. The PRV gX promoter-uidA gene is in the opposite orientation to the direction of transcription of the ILTV gl promoter. S-ILT-011 was constructed using homology vector 562-61.IF (see Materials and Methods) and S-ILT-001 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. The transfection stock was screened by the X-Gluc SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. The result of blue plague purification was recombinant virus S-ILT-011. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING OF DNA procedure. This analysis confirmed the presence of the -glucuronidase (uidA) marker gene and the deletion of approximately 983 base pairs of the ILTV gl gene which deletes 325 of 363 amino acid codons from the 5' end of the gl gene. S-ILT-Oil is attenuated and is useful as a killed vaccine to protect chickens from ILT disease. S-ILT-011 shows a small plaque phenotype in tissue culture which is indicative of slow viral growth and attenuation. Since S-ILT-011 does not express the ILTV gl gene, it may be utilized as a negative marker to distinguish vaccinated animals from infected animals. As indicated in Example 1, ILTV-infected chickens make antibodies against ILTV gl protein. Example 5 S - ILT- 013 S-ILT-013 is an infectious laryngotracheitis virus (ILTV) that has an approximately 983 base pair deletion of the ILTV gl gene and an approximately 874 base pair deletion of the ILTV gG gene (and a deletion of the HCMV IE promoter lacZ marker gene making the lacZ gene nonfunctional) . The gene for E. coli / S-glucuronidase (uidA) was inserted in the place of the gl gene and is under the control of the pseudorabies virus (PRV) gX promoter. S-ILT-013 was constructed using homology vector 562-61.IF (see Materials and Methods) and S-ILT-014 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. The transfection stock was screened by the X-Gluc SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. The result of blue plaque purification was recombinant virus S-ILT-013. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING OF DNA procedure. This analysis confirmed the presence of the 3-glucuronidase (uidA) marker gene and the deletion of approximately 983 base pairs of the ILTV gl gene which removes 325 of 363 amino acid codons from the 5' end of the gl gene. This analysis also confirmed an approximately 874 base pair deletion of the ILTV gG gene and an approximately 1906 base pair insertion of a partial HCMV IE promoter-lacZ marker gene DNA, of which a portion of the HCMV IE promoter and almost none of the lacZ gene remains (see Example 6) . S-ILT-013 is attenuated and is useful as a killed vaccine to protect chickens from ILT disease. S-ILT-013 shows a small plaque phenotype in tissue culture which is indicative of slow viral growth and attenuation. Since S-ILT-013 does not express the ILTV gl or gG genes, ILTV gl and gG may be utilized as negative markers to distinguish vaccinated animals from infected animals. Example 6 S- ILT- 014 S-ILT-014 is an infectious laryngotracheitis virus (ILTV) that has an approximately 874 base pair deletion of the ILTV gG gene and a deletion of the inserted HCMV IE promoter lacZ marker gene making the lacZ gene nonfunctional. S-ILT-014 was derived from a purified S-ILT-002 virus stock in which a deletion of the HCMV IE promoter lacZ marker gene occurred. S-ILT-002 was constructed using homology vector 472-73.27 (See Materials and Methods) and S-ILT-001 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. The virus S-ILT-002 has a 874 base pair deletion within the ILTV gG gene and an insertion of the *. coli 3-galactosidase (lacZ) gene in place of the ILTV gG gene. However, during the Bluogal™ SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES, a white plaque was picked which contained a deletion of the lacZ gene within the ILTV gG deletion. This virus, S-ILT-014, was characterized by restriction mapping, DNA SEQUENCING and the SOUTHERN BLOTTING OF DNA procedure. This analysis confirmed the presence of an approximately 874 base pair deletion of the ILTV gG gene and approximately 1956 base pair insertion of a partial HCMV IE promoter lacZ marker gene DNA (2958 base pairs deleted) . The remaining HCMV IE promoter lacZ marker gene DNA consists of an approximately 686 base pair DNA fragment of the approximately 1154 base pair HCMV IE promoter and an approximately 1270 base pair DNA fragment containing approximately 520 base pairs of the 3010 base pair β- galactosidase (lacZ) marker gene and all of the approximately 750 base pair PRV gX polyadenylation signal. S-ILT-014 is useful as an attenuated live vaccine or as a killed vaccine to protect chickens from ILT disease as indicated in the table below. Since S-ILT-014 does not express the ILTV gG gene and ILTV-infected chickens make antibodies to gG as indicated in Example 1, ILTV gG is utilized as a negative marker to distinguish vaccinated animals from infected animals. EFFICACY OF RECOMBINANT LIVE ILT VIRUS S-ILT-014 AGAINST VIRULENT INFECTIOUS LARYNGOTRACHEITIS VIRUS CHALLENGE Vaccine Gene(s) Dose Route Challenge* Protection" Deleted S-ILT-014 gG- 1.08x10" 10 c OS d 97% S-ILT-014 gG- 2.16X10 3 10 OS 97% Controls OS 0% ASL 10 OS 90% embryo 14 day old chicks a: USDA Challenge virus =1.0xl0 4 - 5 pfu b: Protection = # healthy birds/total (%) c: Intraocular d: Orbitual Sinus Example 7 S - ILT- 015 S-ILT-015 is an infectious laryngotracheitis virus (ILTV) that has an approximately 2640 base pair deletion of the UL47-like gene, the ORF4 gene, and ILTV gG gene. The gene for E. coli /S-glucuronidase (uidA) was inserted in the place of the UL47-like, ORF4, and gG genes and is under the control of the pseudorabies virus (PRV) gX promoter. The PRV gX promoter-uidA gene is in the opposite orientation to the direction of transcription of the ILTV UL47-like, ORF4, and gG promoters. S-ILT-015 was constructed using homology vector 560-52.Fl (see Materials and Methods) and S-ILT-001 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. The transfection stock was screened by the X-Gluc SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. The result of blue plaque purification was recombinant virus S-ILT-015. This virus was characterized by restriction mapping and the SOUTHERN BLOTTING OF DNA procedure. These results confirmed the presence of a 2640 base pair deletion which includes 442 of a total 511 amino acid codons at the 3' end of the UL47-like gene, all of the ORF4 gene and 271 of 293 amino acid codons of the 5' end of the gG gene. S-ILT-015 is useful as an attenuated live vaccine or as a killed vaccine to protect chickens from ILT disease as indicated in the table below. Since S-ILT-015 does not express the ILTV gG gene, ILTV gG is utilized as a negative marker to distinguish vaccinated animals from infected animals. EFFICACY OF RECOMBINANT LIVE ILT VIRUS S-ILT-015 AGAINST VIRULENT INFECTIOUS LARYNGOTRACHEITIS VIRUS CHALLENGE Vaccine Gene(s) Dose Route Challenge 3 Protection" Deleted S-ILT-015 gG-, l .OxlO 5 IO c OS 70% UL47-like Controls OS 0% ASL IO OS 90% embryo 14 day old chicks a: USDA Challenge virus =1.0xl0 45 pfu b: Protection = # healthy birds/total (%) c: Intraocular d: Orbital Sinus Example 8 S - ILT- 017 S-ILT-017 is an infectious laryngotracheitis virus (ILTV) that has an approximately 3351 base pair deletion of the ILTV gG gene and the g60 gene. The gene for E. coli β- glucuronidase (uidA) was inserted in the place of the ILTV gG and g60 genes and is under the control of the pseudorabies virus (PRV) gX promoter. S-ILT-017 was constructed using homology vector 579-14.G2 (see Materials and Methods) and S-ILT-001 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. The transfection stock was screened by the X-Gluc SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES. The result of blue plaque purification was recombinant virus S-ILT-017. S-ILT-017 is attenuated by deletion of the ILTV g60 and gG genes, but retains other genes known to be involved in the immune response in chickens to ILT virus. Therefore, S-ILT- 017 may be used as a killed vaccine to protect chickens from ILT disease. Since S-ILT-017 does not express the ILTV gG or g60 genes, it is used as a negative marker to distinguish vaccinated animals from infected animals. Example 9 Recombinant infectious laryngotracheitis viruses that express infectious bronchitis virus (IBV) spike and matrix protein genes. A homology vector is used to generate ILT viruses containing the IBV Arkansas spike protein gene. The recombinant ILT virus contains a deletion of one or more ILTV genes, including gG, US2, UL47-like, and ORF4, and the insertion of two foreign genes: the E. coli 3-glucuronidase gene (uidA) and the IBV Arkansas spike protein gene. The uidA gene is under the control of the PRV gX promoter and the IBV Arkansas spike protein gene is under the control of the HCMV IE promoter. To construct a homology vector containing the foreign genes inserted into the ILT virus, a DNA fragment containing the HCMV-IE promoter, the IBV Arkansas spike protein and the HSV-l TK polyadenylation signal is inserted into a restriction enzyme site at the position of the deletion of the ILTV gG gene in the ILTV homology vector. A DNA fragment containing the PRV gX promoter and the E. coli β- glucuronidase (uidA) gene is inserted into a unique restriction enzyme site within the ILTV homology vector. A recombinant virus is constructed by combining the final homology vector containing the IBV Arkansas spike gene and the E. coli β-glucuronidase (uidA) gene and S-ILT-001 in the HOMOLOGOUS RECOMBINATION PROCEDURE FOR GENERATING RECOMBINANT VIRUS. The transfection stock is screened by the X-Gluc SCREEN FOR RECOMBINANT HERPESVIRUS EXPRESSING ENZYMATIC MARKER GENES to detect the presence of the uidA gene and by the BLACK PLAQUE ASSAY FOR FOREIGN GENE EXPRESSION to detect the presence of the IBV Arkansas spike protein. A similar strategy is used to construct recombinant ILT viruses carrying the IBV SI protein from Arkansas, Massachusetts,or Connecticut serotypes, IBV matrix protein from Arkansas, Massachusetts, or Connecticut serotypes, and IBV nucleocapsid from Arkansas, Massachusetts, or Connecticut serotypes. The strategy is also used to construct recombinant ILT viruses carrying the Newcastle Disease virus (NDV) HN and F genes and the Infectious Bursal Disease virus (IBDV) polyprotein or portions thereof. The strategy is also used to construct recombinant ILT viruses carrying the Mareks Disease virus (MDV) gA, gD, and gB genes. Recombinant ILT virus carrying these antigens are valuable as a multivalent vaccine to protect chickens from diseases caused by ILTV and one or more of the viruses IBV, NDV, IBDV, or MDV. Since the ILTV vaccines described here do not express ILTV gG, it is useful as a negative marker to distinguish vaccinated animals from infected animals. Example 10 Vaccines utilizing ILTV to express antigens from various disease causing microorganisms. Antigens from the following microorganisms are utilized to develop poultry vaccines: Chick anemia agent, Avian encephalomyelitis virus, Avian reovirus, Avian paramyxoviruses, Avian influenza virus ,Avian adenovirus, Fowl pox virus, Avian coronavirus, Avian rotavirus, Salmonella spp., E coli., Pasteurella spp., Haemophilus spp. , Chlamydia spp. , Mycoplasma spp. , Campylobacter spp. , Bordetella spp., Poultry nematodes, cestodes, trematodes, Poultry mites/lice, Poultry protozoa (Eimeria spp., Histomonas spp., Trichomonas spp.) . REFERENCES : I. L. Nicolson, et . al. , Virology 179, 378-387 (1990) . 2. R. . Price and A. Kahn, Infection and Immunity, 34, 571-580 (1981) . 3. M. P. Riggio, et. al . , Journal of Virology 63, 1123- 1133 (1989) . 4. G. R. Robertson and J.M. Whalley, Nucleic Acids Research 16, 11303-11317 (1988) . 5. B. Roizman, et. al. , Cold Spring Harbor Conference on New Approaches to Viral Vaccines (September 1983) . 6. B. Roizman, et. al. , Archives of Virology 123, 425-449 (1992) . 7. F. A. Ferrari, et. al. , Journal of Bacteriology 161, 556-562 (1985) . 8. R. A. Bhat, et . al . , Nucleic Acids Research 17, 1159- 1176 (1989) 9. The Herpesviruses, Volume 1, B. Roizman, ed. , Plenum Press, New York, (1982) . 10. Diseases of Poultry, Eighth Edition, M.S. Hofstad, Ed., pp 444-451, Iowa State University Press, 1984. II. M. C. Wark, et. al . , Journal of Biological Standardization 7: 73-80 (1979) . 12. S. Davison, et . al. , Avian Diseases 33: 18-23 (1989) . 13. S. Davison, et. al. , Avian Diseases 33: 24-29 (1989) . 14. J. R. Andreasen Jr., et . al. , Avian Diseases 33: 516-523 (1989) . 15. J. R. Andreasen Jr., et. al. , Avian Diseases 33: 524- 530 (1989) . 16. J. S. Guy, et. al. , Avian Diseases 34: 106-113 (1990) . 17. J. R. Andreasen Jr., et. al. , Avian Diseases 34: 185-192 (1990) . 18. J. J. York, and K.J. Fahey, Archives of Virology 115: 289-297 (1990) . 19. C. S. Hughes, et. al. , Archives of Virology 121: 213-218 (1991) . 20. T. J. Bagust, et. al . , Patent Application WO 91/02053 21. J. S. Guy, et. al. , Avian Diseases 35: 348-355 (1991) . 22. M. A. Johnson, et . al. , Archives of Virology 119: 181- 198 (1991) . 23. D. A. Leib, et. al. , Archives of Virology 93: 287-294 (1987) . 24. M. Kotiw, et. al. , Veterinary Microbiology 11 : 319-330 (1986) . 25. J. S. Guy, et. al . , Avian Diseases 33: 316-323 (1989) . 26. J. R. Andreasen Jr., et.al . , Avian Diseases 34: 646-656 (1990) . 27. M. M. Binns, et . al. , PCT Patent Application WO 90/02802. 28. A. M. Griffin and M.E.G. Boursnell, Journal of General Virology 71 841-850 (1990) . 29. D. J. Poulsen, et . al . , Virus Genes 5: 335-347 (1991) . 30. A. M. Griffin, Journal of General Virology 72: 393-398 (1991) 31. A. M. Griffin, Journal of General Virology 70: 3085-3089 (1989) . 32. A. M. Griffin, Nucleic Acids Research 18: 3664 (1990) . 33. . Y. M. Saif, et . al . , AVMA 130th Annual Meeting, July 17-21, 1993, Minneapolis, MN. 34. J. J. York, et. al . , Virology 161: 340-347 (1987) . 35. J. J. York, et. al . , Archives of Virology 115: 147-162 (1990) . 36. C. T. Prideaux, et . al . , Archives of Virology 123: 181-192 (1992) . 37. R. W. Honess, Journal of General Virology 65, 2077- 2107 (1984) . 38. M. L. Cook & J. G. Stevens, Journal of General Virology 31, 75-80 (1976) . 39. S. Joshi, et. al . , Journal of Virology 65, 5524-5530 (1991) . 40. M. Wachsman, et . al . , Journal of General Virology 70, 2513-2520 (1989) . 41. R. A. Bhat, et . al . , Nucleic Acids Research 17, 1159- 1176 (1989) 42. T. Maniatis, et . al. , Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1982) 43. J. Sambrook, et. al. , Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Press, Cold Spring Harbor, N.Y. (1989) . 44. M. A. Innis, et. al. , PCR Protocols: A Guide to Methods and Applications, Academic Press, San Diego (1990) . 45. C. Chen and Okayama, H. , Mol. Cell Biol . 7, 2745-2752 (1987) . 46. M. van Zijl, et . al. , Journal of Virology 62, 2191- 2195 (1988) . 47. B. Lomniczi, et. al . , Journal of Virology 49 970-979 (1984) . 48. D. J. McGeoch, et . al. , Journal of Molecular Biology 181, 1-13 (1985) . 49. F. A. Ferrari, et . al. , Journal of Bacteriology 161, 556-562 (1985) . 50. J. M. Sharma and L. G. Raggi, Avian Disease 13, 268-279 (1969) . 51. D. H. Kingsley, J. W. Hazel, and C. L. Keeler, Jr., Abstract from the 65th Northeastern Conference on Avian Diseases, June 9-11, 1993. University of Delaware, Newark, Delaware. 52. D. W. Key and E. Nagy, Abstract from the 65th Northeastern Conference on Avian Diseases, June 9-11, 1993. University of Delaware, Newark, Delaware. 53. M. G. Sheppard, et. al. , PCT Patent Application WO 92/03554. 54. T. Honda, et. al . , U.S. Patent No. 4,980,162. 55. Federal Register, Vol. 55, No. 90, pp. 19245-19253 56. T. Ben-Porat, et. al. , Virology 154 325-334 (1986) . 57. F. Zuckerman, et . al . in Vaccination and Control of Aujeszky's Disease, Ed. J. van Oirschot, Kluwer, London (1989) , pp. 107-117. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Cochran, Mark D. Wild, Martha A. (ii) TITLE OF INVENTION: RECOMBINANT INFECTIOUS LARYNGOTRACHEITIS VIRUS AND USES THEREOF (iii) NUMBER OF SEQUENCES: 58 (iv) CORRESPONDENCE .ADDRESS: (A) ADDRESSEE: John P. White, c/o Cooper & Dunham (B) STREET: 30 Rockefeller Plaza (C) CITY: New York (D) STATE: New York (E) COUNTRY: USA (F) ZIP: 10112 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentin Release #1.0, Version #1.25 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: US (B) FILING DATE: 23-SEP-1993 (C) CLASSIFICATION: (viii) ATTORNEY/AGENT INFORMATION: (A) NAME: White, John P. (B) REGISTRATION NUMBER: 28,678 (C) REFERENCE/DOCKET NUMBER: 39116/JPW/JEL (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (212) 977-9550 (B) TELEFAX: (212) 664-0525 (C) TELEX: 422523 COOP UI (2) INFORMATION FOR SEQ ID NO:1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 13473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1059..2489 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 2575..4107 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 4113..4445 SUBSTTTUTESHEET(RULE2© ( ix) FEATURE : (A) NAME /KEY : CDS (B) LOCATION : 4609 . .5487 (ix) FEATURE : (A) NAME /KEY : CDS (B) LOCATION : 5697 . .8654 (ix) FEATURE : (A) NAME/KEY : CDS (B) LOCATION : 9874 . .10962 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 11159..12658 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 12665..13447 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: CCCGTGCCCC TAAAGGCCGC CGAGAAAGCT AAGTCCAAAT GTGACGTCGG AGGTCTCGAC 60 ATGGTCGCCA ACCCTCCAAA TGCTACCCGC CGGCCCACGC AACGCGGGCT TTTATAAAGA 120 TGGCGCGCGA GACAATAACA CTTACTCATC CGCGTACGCG TTTATTATTG TCAATATTTG 180 TGTGGTTATT ATTACTGCTA CCGCCCTTGT TTCTGCAAGG CCCTCGCCGC GGCCCAGGCC 240 ACTATTCCGG CAGCGGCCGC CGACGCGGCG AGCGTCGCCG CTAACGTCGG CGCCGCGGGG 300 AGCGGGGTTT CTTCGACTTA AATAGACTCC CGAGAAAAAA TTTTGGCTGC CGTTCGCCAT 360 CATCCGAGTC GGAAACACAG TATGCGGCCG AGTTAGGTTT TACTTTTAAA AACTTTACCG 420 TGCTGTACGG CCAGGGCGTT CTCAGGCTCG AAGGGGCAAG AGTTGTCCAG ACTGATGGGT 480 GACTCAGAGA CAGCGTTGTC TTGTCTCCGT TTACCAAAAA TATTTCCACT CCTCTCTCAA 540 AATTTTTACC TCCGGTTTCG GTAATTAGGA AAGTTTTTGG CGCAGGGAGG TTTAAAGCTG 600 CCATGCATAT GTCAGCGGTA CCCAGCACCC ACAAATGGAA CTCTTTTGCG GCATACGCGC 660 CAGATGACAA ATGGTAAAAC CCTGCGTCCA AGCCGCTCCA CTCGGGACTT ACTCCAGGCG 720 GGTCGCCCCC CTCACCGAAC CGAATCACGG GTCTGCACAT CCTGGGAAGG GAAAACAGCT 780 CCCCGGAAAC TTCGTACAGA GATGCCGGGC GCACGATTAC CGATAATGTA CTCGGACGAT 840 CGTAACTCGC CATAGTTTTC ACTGCGTGAA CCAATTCTTT CCATCCAGAA TCCGAGAGCT 900 CAAATCTAGA ATTAGGTAGT TTGTAGTGCG AATCGACCGC AGAAACTATA GTCACTTTTA 960 CAGGCGCCAT CGCCGCTCAG ACTCCACCCC GCTATGATGT CAGAAATATA ACGCTCTTAT 1020 TCTAGCAGAG TCAGGCCAAT ATATACAGCT TAGAGAAG ATG CGG TTT CGG CGC 1073 Met Arg Phe Arg Arg 1 5 ATC TGT TCA CGC TCT AGG GCA GAA AAA CGA AGA AGA ACA ACC GAG AAT 1121 lie Cys Ser Arg Ser Arg Ala Glu Lys Arg Arg Arg Thr Thr Glu Asn 10 15 20 CCG CTT ACC TCA AAA CGC GTT TGC GTA TTG GAT AGT TTC TCA CGG ACA 1169 Pro Leu Thr Ser Lvs Arg Val Cys Val Leu Asp Ser Phe Ser Arg Thr 25 30 35 ATG TCA TTG CGC CCC TAT GCA GAA ATT TTG CCG ACC GCG GAA GGC GTC 1217 Met Ser Leu Arg Pro Tyr Ala Glu lie Leu Pro Thr Ala Glu Gly Val 40 45 50 GAG CGC CTC GCC GAA CTT GTT AGT GTG ACA ATG ACA GAA CGC GCG GAA 1265 Glu Arg Leu Ala Glu Leu Val Ser Val Thr Met Thr Glu Arg Ala Glu 55 60 65 CCT GTG ACA GAG AAT ACA GCT GTA AAC AGT ATC CCC CCG GCT AAC GAG 1313 Pro Val Thr Glu Asn Thr Ala Val Asn Ser He Pro Pro Ala Asn Glu 70 75 80 85 AAC GGG CAG AAC TTC GCA TAT GCA GGC GAT GGG CCC TCG ACT ACT GAA 1361 Asn Gly Gin Asn Phe Ala Tyr Ala Gly Asp Gly Pro Ser Thr Thr Glu 90 95 100 AAA GTT GAC GGC TCG CAT ACA GAC TTC GAT GAA GCA TCG AGC GAC TAC 1409 Lys Val Asp Gly Ser His Thr Asp Phe Asp Glu Ala Ser Ser Asp Tyr 105 110 115 GCC GGC CCT GTC CCG CTC GCG CAA ACT AGA TTG AAG CAT TCG GAT GAA 1457 Ala Gly Pro Val Pro Leu Ala Gin Thr Arg Leu Lys His Ser Asp Glu 120 125 130 TTT CTT CAG CAC TTC CGA GTT TTA GAC GAT TTG GTG GAG GGG GCT TAC 1505 Phe Leu Gin Kis Phe Arg Val Leu Asp Asp Leu Val Glu Gly Ala Tyr 135 140 145 GGG TTT ATC TGC GGC GTC CGT CGC TAC ACC GAG GAA GAG CAA CGT CGA 1553 Gly Phe He Cys Gly Val Arg Arg Tyr Thr Glu Glu Glu Gin Arg Arg 150 155 160 165 AGA GGG GTT AAC AGT ACT AAC CAG GGG AAA TCA AAA TGT AAG CGC CTG 1601 Arg Gly Val Asn Ser Thr Asn Gin Gly Lys Ser Lys Cys Lys Arg Leu 170 175 180 ATA GCT AAA TAT GTG AAA AAT GGA ACA AGG GCG GCC TCT CAG CTG GAA 1649 He Ala Lys Tyr Val Lys Asn Gly Thr Arg Ala Ala Ser Gin Leu Glu 185 190 195 AAT GAA ATT TTG GTT CTC GGG CGC CTA AAT CAC GAG AAT GTT CTC AAG 1697 Asn Glu lie Leu Val Leu Gly Arg Leu Asn His Glu Asn Val Leu Lys 200 205 210 ATC CAG GAA ATC CTT CGG TAC CCG GAT AAT ACG TAC ATG TTA ACG CAG 1745 He Gin Glu He Leu Arg Tyr Pro Asp Asn Thr Tyr Met Leu Thr Gin 215 220 225 AGG TAT CAG TTC GAC TTG TAC AGC TAC ATG TAC GAT GAA GCG TTC GAC 1793 Arg Tyr Gin Phe Asp Leu Tyr Ser Tyr Met Tyr Asp Glu Ala Phe Asp 230 235 240 245 TGG AAA GAC AGT CCA ' ATG CTT AAA CAG ACT AGA CGC ATC ATG AAG CAG 1841 Trp Lys Asp Ser Pro Met Leu Lys Gin Thr Arg Arg He Met Lys Gin 250 255 260 CTC ATG TCA GCG GTC TCG TAT ATC CAT TCA A.ZVG AAA CTG ATT CAC AGG 1889 Leu Met Ser Ala Val Ser Tyr He His Ser Lys Lys Leu He His Arg 265 270 275 GAC ATC AAA CTC GAA AAT ATT TTC TTA AAC TGC GAC GGC AAG ACA GTG 1937 Asp He Lys Leu Glu Asn He Phe Leu Asn Cys Asp Gly Lys Thr Val 280 265 290 CTG GGC GAC TTT GGA ACT GTC ACG CCT TTT GAA AAT GAG CGG GAG CCC 1985 Leu Gly Asp Phe Gly Thr Val Thr Pro Phe Glu Asn Glu Arg Glu Pro 295 300 305 TTC GAA TAT GGA TGG GTG GGG ACC GTG GCT ACT AAC TCT CCC GAG ATA 2033 Phe Glu Tyr Gly Trp Val Gly Thr Val Ala Thr .Asn Ser Pro Glu He 310 315 320 325 CTC GCC AGG GAT TCG TAC TGT GAA ATT ACA GAC ATT TGG AGC TGC GGA 2081 Leu Ala Arg Asp Ser Tyr Cys Glu He Thr Asp He Trp Ser Cys Gly 330 335 340 GTA GTA TTG CTG GAA ATG GTA AGC CAT GAA TTT TGC CCG ATC GGC GAT 2129 Val Val Leu Leu Glu Met Val Ser His Glu Phe Cys Pro He Gly Asp 345 350 355 GGC GGG GGA AAT CCG CAC CAG CAA TTG CTG AAA GTT ATC GAC TCT CTC 2177 Gly Gly Gly Asn Pro His Gin Gin Leu Leu Lys Val He Asp Ser Leu 360 365 370 TCA GTT TGT GAT GAA GAG TTC CCA GAC CCC CCG TGT AAT CTG TAC AAT 2225 Ser Val Cys Asp Glu Glu Phe Pro Asp Pro Pro Cys Asn Leu Tyr Asn 375 380 385 TAT TTG CAT TAT GCG AGC ATC GAT CGC GCC GGA CAT ACG GTC CCG TCG .. 2273 Tyr Leu His Tyr Ala Ser He Asp Arg Ala Gly His Thr Val Pro Ser 390 395 400 405 CTC ATA CGG AAC CTC CAC CTT CCG GCG GAT GTG GAA TAC CCT CTA GTT 2321 Leu He Arg Asn Leu His Leu Pro Ala Asp Val Glu Tyr Pro Leu Val 410 415 420 AAA ATG CTT ACT TTT GAC TGG CGT TTG AGA CCC AGC GCG GCC GAA GTA 2369 Lys Met Leu Thr Phe Asp Trp Arg Leu Arg Pro Ser Ala Ala Glu Val 425 430 435 TTG GCA ATG CCA CTG TTT TCG GCT GAA GAG GAA CGG ACC ATA ACA ATT 2417 Leu Ala Met Pro Leu Phe Ser Ala Glu Glu Glu Arg Thr He Thr He 440 445 450 ATT CAT GGA AAA CAT AAA CCC ATC CGA CCC GAA ATC CGT GCG CGG GTG 2465 He His Gly Lys Hit. Lys Pro He Arg Pro Glu He Arg Ala Arg Val 455 460 465 CCA CGG TCC ATG AGT GAA GGT TAATAATAAA GGACGGAGAT AGAGAACTGA 2516 Pro Arg Ser Met Ser Glu Gly 470 475 AGCGTCAGAT TTTTTTAAAA AAATAAATGA TCGAGAACTT ATGATTTGTC TTTCTTGA 2574 ATG ACC TTG CCC CAT CGA TTA ACG AAA AGA CCT TTC GCG CGT CGA TTC 2622 Met Thr Leu Pro His Arg Leu Thr Lys Arg Pro Phe Ala Arg Arg Phe 1 5 10 15 TGC TCG GTC TTT GTG ATA CAT TAT AGT GAG ACT AAA CTC GAC CGA TAT 2670 Cys Ser Val Phe Val He His Tyr Ser Glu Thr Lys Leu Asp Arg Tyr 20 25 30 AAC AAG ACA ATG TTA CTC TAT AGA CCG GAC TCA ACC ATG CGG CAT AGC 2718 Asn Lys Thr Met Leu Leu Tyr Arg Pro Asp Ser Thr Met Arg His Ser 35 40 45 GGA GGC GAC GCA AAT CAC AGA GGG ATA AGG CCG AGG CGG AAA TCT ATT 2766 Gly Gly Asp Ala Asn His Arg Gly He Arg Pro Arg Arg Lys Ser He 50 55 60 GGA GCG TTT AGC GCG CGC GAA AAG ACT GGA AAA CGA AAT GCG CTG ACG 2814 Gly Ala Phe Ser Ala Arg Glu Lys Thr Gly Lys Arg Asn Ala Leu Thr 65 70 75 80 GAA AGC AGC TCC TCC TCC GAC ATG CTA GAT CCG TTT TCC ACG GAT AAG 2862 Glu Ser Ser Ser Ser Ser Asp Met Leu Asp Pro Phe Ser Thr Asp Lys 85 90 95 GAA TTT GGC GGT AAG TGG ACG GTA GAC GGA CCT GCC GAC ATT ACT GCC 2910 Glu Phe Gly Gly Lys Trp Thr Val Asp Gly Pro Ala Asp He Thr Ala 100 105 110 GAG GTC CTT TCT CAG GCA TGG GAC GTT CTC CAA TTA GTG AAG CAT GAA 2958 Glu Val Leu Ser Gin Ala Trp Asp Val Leu Gin Leu Val Lys His Glu 115 120 125 GAT GCG GAG GAG GAG AGA GTG ACT TAT GAG TCC AAA CCG ACC CCG ATA 3006 Asp Ala Glu Glu Glu Arg Val Thr Tyr Glu Ser Lys Pro Thr Pro He 130 135 140 CAG CCG TTC AAT GCC TGG CCG GAC GGG CCG AGT TGG AAC GCG CAG GAT 3054 Gin Pro Phe Asn Ala Trp Pro Asp Gly Pro Ser Trp Asn Ala Gin Asp 145 150 155 160 TTT ACT CGA GCG CCA ATA GTT TAT CCC TCT GCG GAG GTA TTG GAC GCA 3102 Phe Thr Arg Ala Pro He Val Tyr Pro Ser Ala Glu Val Leu Asp Ala 165 170 175 GAG GCG TTG AAA GTA GGG GCA TTC GTT AGC CGA GTT TTA CAA TGT GTA 3150 Glu Ala Leu Lys Val Gly Ala Phe Val Ser Arg Val Leu Gin Cys Val 180 185 190 CCG TTC ACG CGA TCA AAG AAA AGC GTT ACG GTG CGG GAT GCG CAG TCG 3198 Pro Phe Thr Arg Ser Lys Lys Ser Val Thr Val Arg Asp Ala Gin Ser 195 200 205 TTT TTG GGG GAC TCG TTC TGG AGA ATA ATG CAG AAC GTT TAC ACG GTT 3246 Phe Leu Gly Asp Ser Phe Trp Arg He Met Gin Asn Val Tyr Thr Val 210 215 220 TGC TTA CGA CAG CAC ATA ACT CGA CTC AGG CAC CCT TCC AGC AAA AGC 3294 Cys Leu Arg Gin His He Thr Arg Leu Arg His Pro Ser Ser Lys Ser 225 230 235 240 ATT GTT AAC TGC AAC GAC CCT CTA TGG TAC GCC TAC GCG AAT CAA TTT 3342 He Val Asn Cys Asn Asp Pro Leu Trp Tyr Ala Tyr Ala Asn Gin Phe 245 250 255 CAC TGG AGA GGA ATG CGC GTG CCG TCG CTT AAA TTA GCC TCT CCC CCG 3390 His Trp Arg Gly Met Arg Val Pro Ser Leu Lys Leu Ala Ser Pro Pro 260 265 270 GAG GAG AAT ATT CAA CAC GGC CCA ATG GCC GCC GTT TTT AGA AAC GCG 3438 Glu Glu Asn He Gin His Gly Pro Met Ala Ala Val Phe Arg Asn Ala 275 280 285 GGG GCT GGT CTG TTC CTG TGG CCT GCC ATG CGC GCA GCC TTT GAA GAG 3486 Gly Ala Gly Leu Phe Leu Trp Pro Ala Met Arg Ala Ala Phe Glu Glu 290 295 300 CGC GAC AAG CGA CTG TTA AGA GCA TGC CTG TCT TCA CTC GAT ATC ATG 3534 Arg Asp Lys Arg Lεu Leu Arg Ala Cys Leu Ser Ser Leu Asp He Met 305 310 315 320 GAC GCA GCC GTC CTC GCG TCG TTT CCA TTT TAC TGG CGC GGC GTC CAA 3582 Asp Ala Ala Val Leu Ala Ser Phe Pro Phe Tyr Trp Arg Gly Val Gin 325 330 335 GAC ACC TCG CGC TTC GAG CCT GCG CTG GGC TGT TTG TCA GAG TAC TTT 3630 Asp Thr Ser Arg Phe Glu Pro Ala Leu Gly Cys Leu Ser Glu Tyr Phe 340 345 350 GCA CTA GTG GTG TTA CTG GCC GAG ACG GTC TTA GCG ACC ATG TTC GAC 3678 Ala Leu Val Val Leu Leu Ala Glu Thr Val Leu Ala Thr Met Phe Asp 355 360 365 CAC GCA CTG GTA TTC ATG AGG GCG CTG GCA GAC GGC AAT TTC GAT GAC 3726 His Ala Leu Val Phe Met Arg Ala Leu Ala Asp Gly Asn Phe Asp Asp 370 375 380 TAT GAC GAA ACT AGA TAT ATA GAC CCC GTT AAA AAC GAG TAC CTG AAC 3774 Tyr Asp Glu Thr Arg Tyr He Asp Pro Val Lys Asn Glu Tyr Leu Asn 385 390 395 400 GGA GCC GAG GGT ACT CTG TTA CGG GGC ATA GTG GCC TCC AAC ACC GCT 3822 Gly Ala Glu Gly Thr Leu Leu Arg Gly He Val Ala Ser Asn Thr Ala 405 410 415 CTG GCG GTG GTT TGC GCA AAC ACC TAT TCG ACG ATA AGA AAA CTC CCG 3870 Leu Ala Val Val Cys Ala Asn Thr Tyr Ser Thr He Arg Lvs Leu Pro 420 425 430 TCC GTG GCA ACT AGC GCG TGC AAT GTT GCC TAC AGG ACC GAA ACG CTG 3918 Ser Val Ala Thr Ser Ala Cys Asn Val Ala Tyr Arg Thr Glu Thr Leu 435 440 445 AAA GCG AGG CGC CCT GGC ATG AGC GAC ATA TAC CGG ATA TTA CAA AAA 3966 Lys Ala Arg Arg Pro Gly Met Ser Asp He Tyr Arg He Leu Gin Lys 450 455 460 GAG TTT TTC TTT TAC ATT GCG TGG CTC CAG AGG GTT GCA ACA CAC GCA 4014 Glu Phe Phe Phe Tyr He Ala Trp Leu Gin Arg Val Ala Thr His Ala 465 470 475 480 AAT TTC TGT TTA AAC ATT CTG AAG AGA AGC GTG GAT ACG GGC CCC CGC 4062 Asn Phe Cys Leu Asn He Leu Lys Arg Ser Val Asp Thr Gly Pro Arg 485 490 495 CAT TTT TGT TCA GGG CCA GCT CGG .AGA AGC GGC TGC AGC AGT TAAATAAA 4112 His Phe Cys Ser Gly Pro Ala Arg Arg Ser Gly Cys Ser Ser 500 505 510 ATG CTC TGC CCC CTT CTC GTG CCG ATT CAA TAT GAA GAC TTT TCG AAG 4160 Met Leu Cys Pro Leu Leu Val Pro He Gin Tyr Glu Asp Phe Ser Lys 1 5 10 15 GCC ATG GGG TCT GAG CTC AAG AGG GAA AAG TTA GAG ACA TTC GTT AAA 4208 Ala Met Gly Ser Glu Leu Lys Arg Glu Lys Leu Glu Thr Phe Val Lys 20 25 30 GCT ATT TCC AGC GAC AGG GAC CCG AGG GGG TCC TTA AGA TTT CTC ATT 4256 Ala He Ser Ser Asp Arg Asp Pro Arg Gly Ser Leu Arg Phe Leu He 35 40 45 TCG GAC CAT GCA AGG GAA ATT ATT GCA GAC GGA GTA CGG TTT AAG CCG 4304 Ser Asp His Ala Arg Glu He He Ala Asp Gly Val Arg Phe Lys Pro 50 55 60. GTG ATA GAC GAG CCG GTT CGG GCT TCA GTT GCG CTG AGT ACC GCT GCC 4352 Val He Asp Glu Pro Val Arg Ala Ser Val Ala Leu Ser Thr Ala Ala 65 70 75 80 GCT GGG AAA GTG AAA GCG CGA CGC TTA ACC TCA GTT CGC GCG CCC GTA 4400 Ala Gly Lys Val Lys Ala Arg Arg Leu Thr Ser Val Arg Ala Pro Val 85 90 95 CCG CCC GCA GGC GCC GTT TCC GCG CGC CGG AAA TCG GAA ATA TGA TA 4447 Pro Pro Ala Gly Ala Val Ser Ala Arg Arg Lys Ser Glu He * 100 105 110 AAAATGCTTG GCATTTGCGG GCGAAGAGGC GTGATCTGAA GGGCTCCACA ATGACGTAAC 4507 TGAGCTACGC ATCCCTATAA AGTGTACSCG CTGACCGCTA GCCCATACAG TGTTACAGGA 4567 GGGGAGAGAG ACAACTTCAG CTCGAAGTCT GAAGAGACAT C ATG AGC GGC 4617 Met Ser Gly 1 TTC AGT AAC ATA GGA TCG ATT GCC ACC GTT TCC CTA GTA TGC TCG CTT 4665 Phe Ser Asn He Gly Ser He Ala Thr Val Ser Leu Val Cys Ser Leu 5 10 15 TTG TGC GCA TCT GTA TTA GGG GCG CCG GTA CTG GAC GGG CTC GAG TCG 4713 Leu Cys Ala Ser Val Leu Gly Ala Pro Val Leu Asp Gly Leu Glu Ser 20 25 30 35 AGC CCT TTC CCG TTC GGG GGC AAA ATT ATA GCC CAG GCG TGC AAC CGC 4761 Ser Pro Phe Pro Phe Gly Gly Lys He He Ala Gin Ala Cys Asn Arg 40 45 50 ACC ACG ATT GAG GTG ACG GTC CCG TGG AGC GAC TAC TCT GGT CGC ACC 4809 Thr Thr He Glu Val Thr Val Pro Trp Ser Asp Tyr Ser Gly Arg Thr 55 60 65 GAA GGA GTG TCA GTC GAG GTG AAA TGG TTC TAC GGG AAT AGT AAT CCC 4857 Glu Gly Val Ser Val Glu Val Lys Trp Phe Tyr Gly Asn Ser Asn Pro 70 75 80 GAA AGC TTC GTG TTC GGG GTG GAT AGC GAA ACG GGC AGT GGA CAC GAG 4905 Glu Ser Phe Val Phe Gly Val Asp Ser Glu Thr Gly Ser Gly His Glu 85 90 95 GAC CTG TCT ACG TGC TGG GCT CTA ATC CAT AAT CTG AAC GCG TCT GTG 4953 Asp Leu Ser Thr Cys Trp Ala Leu He His Asn Leu Asn Ala Ser Val 100 105 110 115 TGC AGG GCG TCT GAC GCC GGG ATA CCT GAT TTC GAC AAG CAG TGC GAA 5001 Cys Arg Ala Ser Asp Ala Gly He Pro Asp Phe Asp Lys Gin Cys Glu 120 125 130 AAA GTG CAG AGA AGA CTG CGC TCC -GGG GTG GAA CTT GGT AGT TAC GTG 5049 Lys Val Gin Arg Arg Leu Arg Ser Gly Val Glu Leu Gly Ser Tyr Val 135 140 145 TCT GGC AAT GGA TCC CTG GTG CTG TAC CCA GGG ATG TAC GAT GCC GGC 5097 Ser Gly Asn Gly Ser Leu Val Leu Tyr Pro Gly Met Tyr Asp Ala Gly 150 155 160 ATC TAC GCC TAC CAG CTC TCA GTG GGT GGG AAG GGA TAT ACC GGG TCT 5145 He Tyr Ala Tyr Gin Leu Ser Val Gly Gly Lys Gly Tyr Thr Gly Ser 165 170 175 GTT TAT CTA GAC GTC GGA CCA AAC CCC GGA TGC CAC GAC CAG TAT GGG 5193 Val Tyr Leu Asp Val Gly Pro Aεn Pro Gly Cys His -Asp Gin Tyr Gly 180 185 190 195 TAC ACC TAT TAC AGC CTG GCC GAC GAG GCG TCA GAC TTA TCA TCT TAT 5241 Tyr Thr Tyr Tyr Ser Leu Ala Asp Glu Ala Ser Asp Leu Ser Ser Tyr 200 205 210 GAC GTA GCC TCG CCC GAA CTC GAC GGT CCT ATG GAG GAA GAT TAT TCC 5289 Asp Val Ala Ser Pro Glu Leu Asp Gly Pro Met Glu Glu Asp Tyr Ser 215 220 225 AAT TGT CTA GAC ATG CCC CCG CTA CGC CCA TGG ACA ACC GTT TGT TCG 5337 Asn Cys Leu Asp Met Pro Pro Leu Arg Pro Trp Thr Thr Val Cys Ser 230 235 240 CAT GAC GTC GAG GAG CAG GAA AAC GCC ACG GAC GAG CTT TAC CTA TGG 5385 His Asp Val Glu Glu Gin Glu Asn Ala Thr Asp Glu Leu Tyr Leu Trp 245 250 255 GAC GAG GAA TGC GCC GGT CCG CTG GAC GAG TAC GTC GAC GAA AGG TCA 5433 Asp Glu Glu Cys Ala Gly Pro Leu Asp Glu Tyr Val Asp Glu Arg Ser 260 265 270 275 GAG ACG ATG CCC AGG ATG GTT GTC TTT TCA CCG CCC TCT ACG CTC CAG 5481 Glu Thr Met Pro Arg Met Val Val Phe Ser Pro Pro Ser Thr Leu Gin 280 285 290 CAG TAGCCACCCG AGAGTGTTTT TTGTGAGCGC CCACGCAACA TACCTAACTG 5534 Gin CTTCATTTCT GATCAATTAT TGCGTATTGA ATAAATAAAC AGTACAAAAG CATCAGGTGT 5594 GGTTTGCGTG TCTGTGCTAA ACCATGGCGT GTGCGGGTGA AACCGTAAAT TACGTGATAA 5654 TAAATAGCAT AGGAGTTGGC GTGCAGCGTA TTTCGCCGAG AG ATG GGG ACA ATG 5708 Met Gly Thr Met 1 TTA GTG TTG CGC CTT TTC CTA CTT GCA GTA GCG GAC GCG GCG TTG CCG 5756 Leu Val Leu Arg Leu Phe Leu Leu Ala Val Ala Asp Ala Ala Leu Pro 5 10 15 20 ACC GGC AGA TTC TGC CGA GTT TGG AAG GTG CCT CCG GGA GGA ACC ATC 5804 Thr Gly Arg Phe Cys Arg Val Trp Lys Val Pro Pro Gly Gly Thr He 25 30 35 CAA GAG AAC CTG GCG GTG CTC GCG GAA TCG CCG GTC ACG GGA CAC GCG 5852 Gin Glu Asn Leu Ala Val Leu Ala Glu Ser Pro Val Thr Gly His Ala 40 45 50 ACA TAT CCG CCG CCT GAA GGC GCC GTC AGC TTT CAG ATT TTT GCG GAC 5900 Thr Tyr Pro Pro Pro Glu Gly Ala Val Ser Phe Gin He Phe Ala Asp 55 60 65 ACC CCT ACT TTG CGC ATT CGC TAC GGG CCT ACG GAG GAC GAA CTT GCA 5948 Thr Pro Thr Leu Arg He Arg Tyr Gly Pro Thr Glu Asp Glu Leu Ala 70 75 80 CTG GAG CGC GGG ACG TCC GCC TCA GAC GCG GAC AAC GTG ACA TTT TCG 5996 Leu Glu .Arg Gly Thr Ser -Ala Ser Asp Ala Asp Asn Val Thr Phe Ser 85 90 95 100 CTG TCA TAT CGC CCG CGC CCA GAA ATT CAC GGA GCA TAC TTC ACC ATA 6044 Leu Ser Tyr Arg Pro Arg Pro Glu He His Gly Ala Tyr Phe Thr He 105 110 115 GGG GTA TTC GCT ACT GGC CAG AGC ACG GAA AGC AGC TAT TCG GTC ATC 6092 Gly Val Phe Ala Thr Gly Gin Ser Thr Glu Ser Ser Tyr Ser Val He 120 125 130 AGT CGG GTC TTA GTT AAC GCC TCT CTG GAA CGG TCC GTG CGC CTG GAA 6140 Ser Arg Val Leu Val Asn Ala Ser Leu Glu Arg Ser Val Arg Leu Glu 135 140 145 ACG CCG TGC GAT GAA AAT TTT TTG CAG AAC GAG CCT ACA TGG GGC TCG 6188 Thr Pro Cys Asp Glu Asn Phe Leu Gin Asn Glu Pro Thr Trp Gly Ser 150 155 160 AAG CGT TGG TTA GGC CCC CCG TCG CCT TAT GTG CGA GAT AAC GAT GTC 6236 Lys Arg Trp Leu Gly Pro Pro Ser Pro Tyr Val Arg Asp Asn Asp Val 165 170 175 180 GCC GTG TTG ACA AAA GCG CAG TAC ATT GGG GAG TGC TAC TCC AAC TCG 6284 Ala Val Leu Thr Lys Ala Gin Tyr He Gly Glu Cys Tyr Ser Asn Ser 185 190 195 GCG GCC CAG ACG GGG CTC ACG TCT CTC AAC ATG ACC TTT TTC TAT TCG 6332 Ala Ala Gin Thr Gly Leu Thr Ser Leu Asn Met Thr Phe Phe Tyr Ser 200 205 210 CCT -AAA AGA ATA GTA AAC GTC ACG TGG ACA ACC GGC GGC CCC TCC CCC 6380 Pro Lys Arg He Val Asn Val Thr Trp Thr Thr Gly Gly Pro Ser Pro 215 220 225 TCG CGC ATA ACG GTA TAC TCG TCG CGG GAG AAC GGG CAG CCC GTG TTG 6428 Ser Arg He Thr Val Tyr Ser Ser Arg Glu Asn Gly Gin Pro Val Leu 230 235 240 AGG AAC GTT TCT GAC GGG TTC TTG GTT AAG TAC ACT CCC GAC ATT GAC 6476 Arg Asn Val Ser Asp Gly Phe Leu Val Lys Tyr Thr Pro Asp He Asp 245 250 255 260 GGC CGG GCC ATG ATA AAC GTT ATT GCC AAT TAT TCG CCG GCG GAC TCC 6524 Gly Arg Ala Met He Asn Val He Ala Asn Tyr Ser Pro Ala Asp Ser 265 270 275 GGC AGC GTC CTC GCG TTT ACG GCC TTT AGG GAA GGA AAA CTC CCA TCC 6572 Gly Ser Val Leu Ala Phe Thr Ala Phe Arg Glu Gly Lys Leu Pro Ser 280 285 290 GCG ATT CAA CTG CAC CGG ATA GAT ATG TCC GGG ACT GAG CCG CCG GGG 6620 Ala He Gin Leu His Arg He Asp Met Ser Gly Thr Glu Pro Pro Gly 295 300 305 ACT GAA ACG ACC TTC GAC TGT CAA AAA ATG ATA GAA ACC CCG TAC CGA 6668 Thr Glu Thr Thr Phe Asp Cys Gin Lys Met He Glu Thr Pro Tyr Arg 310 315 320 GCG CTC GGG AGC AAT GTT CCC AGG GAC GAC TCT ATC CGT CCG GGG GCC 6716 Ala Leu Gly Ser Asn Val Pro Arg Asp Asp Ser He Arg Pro Gly Ala 325 330 335 340 ACT CTG CCT CCG TTC GAT ACC GCA GCA CCT GAT TTC GAT ACA GGT ACT 6764 Thr Leu Pro Pro Phe Asp Thr Ala Ala Pro Asp Phe Asp Thr Gly Thr 345 350 355 TCC CCG ACC CCC ACT ACC GTG CCA GAG CCA GCC ATT ACT ACA CTC ATA 6812 Ser Pro Thr Pro Thr Thr Val Pro Glu Pro Ala He Thr Thr Leu He 360 365 370 CCG CGC AGC ACT AGC GAT ATG GGA TTC TTC TCC ACG GCA CGT GCT ACC 6860 Pro Arg Ser Thr Ser Asp Met Gly Phe Phe Ser Thr Ala Arg Ala Thr 375 380 385 GGA TCA GAA ACT CTT TCG GTA CCC GTC CAG GAA ACG GAT AGA ACT CTT 6908 Gly Ser Glu Thr Leu Ser Val Pro Val Gin Glu Thr Asp Arg Thr Leu 390 395 400 TCG ACA ACT CCT CTT ACC CTT CCA CTG ACT CCC GGT GAG TCA GAA AAT 6956 Ser Thr Thr Pro Leu Thr Leu Pro Leu Thr Pro Gly Glu Ser Glu Asn 405 410 415 420 ACA CTG TTT CCT ACG ACC GCG CCG GGG ATT TCT ACC GAG ACC CCG AGC 7004 Thr Leu Phe Pro Thr Thr Ala Pro Gly He Ser Thr Glu Thr Pro Ser 425 430 435 GCG GCA CAT GAA ACT ACA CAG ACC CAG AGT GCA GAA ACG GTG GTC TTT 7052 Ala Ala His Glu Thr Thr Gin Thr Gin Ser -Ala Glu Thr Val Val Phe 440 445 450 ACT CAG AGT CCG AGT ACC GAG TCG GAA ACC GCG CGG TCC CAG AGT CAG 7100 Thr Gin Ser Pro Ser Thr Glu Ser Glu Thr Ala Arg Ser Gin Ser Gin 455 460 465 GAA CCG TGG TAT TTT ACT CAG ACT CCG AGT ACT GAA CAG GCG GCT CTT 7148 Glu Pro Trp Tyr Phe Thr Gin Thr Pro Ser Thr Glu Gin Ala Ala Leu 470 475 480 ACT CAG ACG CAG ATC GCA GAA ACG GAG GCG TTG TTT ACT CAG ACT CCG 7196 Thr Gin Thr Gin He Ala Glu Thr Glu Ala Leu Phe Thr Gin Thr Pro 485 490 495 500 AGT GCT GAA CAG ATG ACT TTT ACT CAG ACT CCG GGT GCA GAA ACC GAG 7244 Ser Ala Glu Gin Met Thr Phe Thr Gin Thr Pro Gly Ala Glu Thr Glu 505 510 515 GCA CCT GCC CAG ACC CCG AGC ACG ATA CCC GAG ATA TTT ACT CAG TCT 7292 Ala Pro Ala Gin Thr Pro Ser Thr He Pro Glu He Phe Thr Gin Ser - 520 525 530 CGT AGC ACG CCC CCC GAA ACC GCT CGC GCT CCG AGC GCG GCG CCG GAG 7340 Arg Ser Thr Pro Pro Glu Thr -Ala Arg Ala Pro Ser Ala Ala Pro Glu 535 540 545 GTT TTT ACA CAG AGT TCG AGT ACG GTA ACG GAG GTG TTT ACT CAG ACC 7388 Val Phe Thr Gin Ser Ser Ser Thr Val Thr Glu Val Phe Thr Gin Thr 550 555 560 CCG AGC ACG GTA CCG AAA ACT ACT CTG AGT TCG AGT ACT GAA CCG GCG 7436 Pro Ser Thr Val Pro Lys Thr Thr Leu Ser Ser Ser Thr Glu Pro Ala 565 570 575 580 ATT TTT ACT CGG ACT CAG AGC GCG GGA ACT GAG GCC TTT ACT CAG ACT 7484 He Phe Thr Arg Thr Gin Ser Ala Gly Thr Glu Ala Phe Thr Gin Thr 585 590 595 TCG AGT GCC GAG CCG GAC ACT ATG CGA ACT CAG AGT ACT GAA ACA CAC 7532 Ser Ser Ala Glu Pro Asp Thr Met Arg Thr Gin Ser Thr Glu Thr His 600 605 610 TTT TTC ACT CAG GCC CCG AGT ACG GTA CCG AAA GCT ACT CAG ACT CCG 7580 Phe Phe Thr Gin Ala Pro Ser Thr Val Pro Lys Ala Thr Gin Thr Pro 615 620 625 AGT ACA GAG CCG GAG GTG TTG ACT CAG AGT CCG AGT ACC GAA CCT GTG 7628 Ser Thr Glu Pro Glu Val Leu Thr Gin Ser Pro Ser Thr Glu Pro Val 630 635 640 CCT TTC ACC CGG ACT CTG GGC GCA GAG CCG GAA ATT ACT CAG ACC CCG 7676 Pro Phe Thr Arq Thr Leu Gly Ala Glu Pro Glu He Thr Gin Thr Pro 645 " 650 655 660 AGC GCG GCA CCG GAG GTT TAT ACT CGG -AGT TCG AGT ACG ATG CCA GAA 7724 Ser Ala Ala Pro Glu Val Tyr Thr Arg Ser Ser Ser Thr Met Pro Glu 665 670 675 ACT GCA CAG AGC ACA CCC CTG GCC TCG CAA AAC CCT ACC AGT TCG GGA 7772 Thr Ala Gin Ser Thr Pro Leu Ala Ser Gin Asn Pro Thr Ser Ser Gly 680 685 690 ACC GGG ACG CAT AAT ACT GAA CCG AGG ACT TAT CCA GTG CAA ACG ACA 7820 Thr Gly Thr His Asn Thr Glu Pro Arg Thr Tyr Pro Val Gin Thr Thr 695 700 705 CCA CAT ACC CAG AAA CTC TAC ACA GAA AAT AAG ACT TTA TCG TTT CCT 7868 Pro His Thr Gin Lys Leu Tyr Thr Glu Asn Lys Thr Leu Ser Phe Pro 710 715 720 ACT GTT GTT TCA GAA TTC CAT GAG ATG TCG ACG GCA GAG TCG CAG ACG 7916 Thr Val Val Ser Glu Phe His Glu Met Ser Thr Ala Glu Ser Gin Thr 725 730 735 740 CCC CTA TTG GAC GTC AAA ATT GTA GAG GTG AAG TTT TCA AAC GAT GGC 7964 Pro Leu Leu Asp Val Lys He Val Glu Val Lys Phe Ser Asn Asp Gly 745 750 755 GAA GTA ACG GCG ACT TGC GTT TCC ACC GTC AAA TCT CCC TAT AGG GTA 8012 Glu Val Thr -Ala Thr Cys Val Ser Thr Val Lys Ser Pro Tyr Arg Val 760 765 770 GAA ACT AAT TGG AAA GTA GAC CTC GTA GAT GTA ATG GAT GAA ATT TCT 8060 Glu Thr Asn Trp Lys Val Asp Leu Val Asp Val Met Asp Glu He Ser 775 780 7 * 85 GGG AAC AGT CCC GCC GGG GTT TTT AAC AGT AAT GAG AAA TGG CAG AAA 8108 Gly Asn Ser Pro Ala Gly Val Phe Asn Ser Asn Glu Lys Trp Gin Lys 790 795 800 CAG CTG TAC TAC AGA GTA ACC GAT GGA AGA ACA TCG GTC CAG CTA ATG 8156 Gin Leu Tyr Tyr Arg Val Thr Asp Gly Arg Thr Ser Val Gin Leu Met 805 810 815 820 TGC CTG TCG TGC ACG AGC CAT TCT CCG GAA CCT TAC TGT CTT TTC GAC 8204 Cys Leu Ser Cys Thr Ser His Ser Pro Glu Pro Tyr Cys Leu Phe Asp 825 830 835 ACG TCT CTT ATA GCG AGG GAA AAA GAT ATC GCG CCA GAG TTA TAC TTT 8252 Thr Ser Leu He Ala Arg Glu Lys Asp He Ala Pro Glu Leu Tyr Phe 840 845 850 ACC TCT GAT CCG CAA ACG GCA TAC TGC ACA ATA ACT CTG CCG TCC GGC 8300 Thr Ser Asp Pro Gin Thr Ala Tyr Cys Thr He Thr Leu Pro Ser Gly 855 860 865 GTT GTT CCG AGA TTC GAA TGG AGC CTT -AAT AAT GTT TCA CTG CCG GAA 8348 Val Val Pro Arg Phe Glu Trp Ser Leu Asn Asn Val Ser Leu Pro Glu 870 875 880 TAT TTG ACG GCC ACG ACC GTT GTT TCG CAT ACC GCT GGC CAA AGT ACA 8396 Tyr Leu Thr Ala Thr Thr Val Val Ser His Thr Ala Gly Gin Ser Thr 885 890 895 900 GTG TGG AAG AGC AGC GCG AGA GCA GGC GAG GCG TGG ATT TCT GGC CGG 8444 Val Trp Lys Ser Ser Ala Arg Ala Gly Glu Ala Trp He Ser Gly Arg 905 910 915 GGA GGC AAT ATA TAC GAA TGC ACC GTC CTC ATC TCA GAC GGC ACT CGC 8492 Gly Gly Asn He Tyr Glu Cys Thr Val Leu He Ser Asp Gly Thr Arg 920 925 930 GTT ACT ACG CGA AAG GAG AGG TGC TTA ACA AAC ACA TGG ATT GCG GTG 8540 Val Thr Thr Arg Lys Glu Arg Cys Leu Thr Asn Thr Trp He Ala Val 935 940 945 GAA AAC GGT GCT GCT CAG GCG CAG CTG TAT TCA CTC TTT TCT GGA CTT 8588 Glu -Asn Gly Ala Ala Gin Ala Gin Leu Tyr Ser Leu Phe Ser Gly Leu 950 955 960 GTG TCA GGA TTA TGC GGG AGC ATA TCT GCT TTG TAC GCA ACG CTA TGG 8636 Val Ser Gly Leu Cys Gly Ser He Ser Ala Leu Tyr Ala Thr Leu Trp 965 970 975 980 ACC GCC ATT TAT TTT TGAGGAATGC TTTTTGGACT ATCGTACTGC TTTCTTCCTT 8691 Thr Ala He Tyr Phe 985 CGCTAGCCAG AGCACCGCCG CCGTCACGTA CGACTACATT TTAGGCCGTC GCGCGCTCGA 8751 CGCGCTAACC ATACCGGCGG TTGGCCCGTA TAACAGATAC CTCACTAGGG TATCAAGAGG 8811 CTGCGACGTT GTCGAGCTCA ACCCGATTTC TAACGTGGAC GACATGATAT CGGCGGCCAA 8871 AGAAAAAGAG AAGGGGGGCC CTTTCGAGGC CTCCGTCGTC TGGTTCTACG TGATTAAGGG 8931 CGACGACGGC GAGGACAAGT ACTGTCCAAT CTATAGAAAA GAGTACAGGG AATGTGGCGA 8991 CGTACAACTG CTATCTGAAT GCGCCGTTCA ATCTGCACAG ATGTGGGCAG TGGACTATGT 9051 TCCTAGCACC CTTGTATCGC GAAATGGCGC GGGACTGACT ATATTCTCCC CCACTGCTGC 9111 GCTCTCTGGC CAATACTTGC TGACCCTGAA AATCGGGAGA TTTGCGCAAA CAGCTCTCGT 9171 AACTCTAGAA GTTAACGATC GCTGTTTAAA GATCGGGTCG CAGCTTAACT TTTTACCGTC 9231 GAAATGCTGG ACAACAGAAC AGTATCAGAC TGGATTTCAA GGCGAACACC TTTATCCGAT 9291 CGCAGACACC AATACACGAC ACGCGGACGA CGTATATCGG GGATACGAAG ATATTCTGCA 9351 GCGCTGGAAT AATTTGCTGA GGAAAAAGAA TCCTAGCGCG CCAGACCCTC GTCCAGATAG 9411 CGTCCCGCAA GAAATTCCCG CTGTAACCAA GAAAGCGGAA GGGCGCACCC CGGACGCAGA 9471 AAGCAGCGAA AAGAAGGCCC CTCCAGAAGA CTCGGAGGAC GACATGCAGG CAGAGGCTTC 9531 TGGAGAAAAT CCTGCCGCCC TCCCCGAAGA CGACGAAGTC CCCGAGGACA CCGAGCACGA 9591 TGATCCAAAC TCGGATCCTG ACTATTACAA TGACATGCCC GCCGTGATCC CGGTGGAGGA 9651 GACTACTAAA AGTTCTAATG CCGTCTCCAT GCCCATATTC GCGGCGTTCG TAGCCTGCGC 9711 GGTCGCGCTC GTGGGGCTAC TGGTTTGGAG CATCGTAAAA TGCGCGCGTA GCTAATCGAG 9771 CCTAGAATAG GTGGTTTCTT CCTACATGCC ACGCCTCACG CTCATAATAT AAATCACATG 9831 GAATAGCATA CCAATGCCTA TTCATTGGGA CGTTCGAAAA GC 9873 ATG GCA TCG CTA CTT GGA ACT 9894 Met Ala Ser Leu Leu Gly Thr 1 5 CTG GCT CTC CTT GCC GCG ACG CTC GCA CCC TTC GGC GCG ATG GGA ATC 9942 Leu Ala Leu Leu Ala Ala Thr Leu Ala Pro Phe Gly Ala Met Gly He 10 15 20 GTG ATC ACT GGA AAT CAC GTC TCC GCC AGG ATT GAC GAC GAT CAC ATC 9990 Val He Thr Gly Asn His Val Ser Ala Arg He Asp Asp Asp His He 25 30 35 GTG ATC GTC GCG CCT CGC CCC GAA GCT ACA ATT CAA CTG CAG CTA TTT 10038 Val He Val Ala Pro Arg Pro Glu Ala Thr He Gin Leu Gin Leu Phe 40 45 50 55 TTC ATG CCT GGC CAG AGA CCC CAC AAA CCC TAC TCA GGA ACC GTC CGC 10086 Phe Met Pro Gly Gin Arg Pro His Lys Pro Tyr Ser Gly Thr Val Arg 60 65 70 GTC GCG TTT CGG TCT GAT ATA ACA AAC CAG TGC TAC CAG GAA CTT AGC 10134 Val Ala Phe Arg Ser Asp He Thr Asn Gin Cys Tyr Gin Glu Leu Ser 75 80 85 GAG GAG CGC TTT GAA AAT TGC ACT CAT CGA TCG TCT TCT GTT TTT GTC 10182 Glu Glu -Arg Phe Glu Asn Cys Thr His Arg Ser Ser Ser Val Phe Val 90 95 100 GGC TGT AAA GTG ACC GAG TAC ACG TTC TCC GCC TCG AAC AGA CTA ACC 10230 Gly Cys Lys Val Thr Glu Tyr Thr Phe Ser .Ala Ser Asn Arg Leu Thr 105 110 115 GGA CCT CCA CAC CCG TTT AAG CTC ACT ATA CGA AAT CCT CGT CCG AAC 10278 Gly Pro Pro His Pro Phe Lys Leu Thr He Arg Asn Pro Arg Pro Asn 120 125 130 135 GAC AGC GGG ATG TTC TAC GTA ATT GTT CGG CTA GAC GAC ACC AAA GAA 10326 Asp Ser Gly Met Phe Tyr Val He Val Arg Leu Asp Asp Thr Lys Glu 140 145 150 CCC ATT GAC GTC TTC GCG ATC CAA CTA TCG GTG TAT CAA TTC GCG AAC 10374 Pro He Asp Val Phe Ala He Gin Leu Ser Val Tyr Gin Phe Ala Asn 155 160 165 ACC GCC GCG ACT CGC GGA CTC TAT TCC AAG GCT TCG TGT CGC ACC TTC 10422 Thr Ala Ala Thr Arg Gly Leu Tyr Ser Lys Ala Ser Cys Arg Thr Phe 170 175 180 GGA TTA CCT ACC GTC CAA CTT GAG GCC TAT CTC AGG ACC GAG GAA AGT 10470 Gly Leu Pro Thr Val Gin Leu Glu Ala Tyr Leu Arg Thr Glu Glu Ser 185 190 195 TGG CGC AAC TGG CAA GCG TAC GTT GCC ACG GAG GCC ACG ACG ACC AGC 10518 Trp Arg Asn Trp Gin Ala Tyr Val Ala Thr Glu Ala Thr Thr Thr Ser 200 205 210 215 GCC GAG GCG ACA ACC CCG ACG CCC GTC ACT GCA ACC AGC GCC TCC GAA 10566 Ala Glu Ala Thr Thr Pro Thr Pro Val Thr -Ala Thr Ser Ala Ser Glu 220 225 230 CTT GAA GCG GAA CAC TTT ACC TTT CCC TGG CTA GAA AAT GGC GTG GAT 10614 Leu Glu Ala Glu His Phe Thr Phe Pro Trp Leu Glu Asn Gly Val Asp 235 240 245 CAT TAC GAA CCG ACA CCC GCA AAC GAA AAT TCA AAC GTT ACT GTC CGT 10662 His Tyr Glu Pro Thr Pro Ala Asn Glu Asn Ser Asn Val Thr Val Arg 250 255- 260 CTC GGG ACA ATG AGC CCT ACG CTA ATT GGG GTA ACC GTG GCT GCC GTC 10710 Leu Gly Thr Met Ser Pro Thr Leu lie Gly Val Thr Val Ala Ala Val 265 270 275 GTG AGC GCA ACG ATC GGC CTC GTC ATT GTA ATT TCC ATC GTC ACC AGA 10758 Val Ser Ala Thr He Gly Leu Val He Val He Ser He Val Thr Arg 280 285 290 295 AAC ATG TGC ACC CCG CAC CGA AAA TTA GAC ACG GTC TCG CAA GAC GAC 1080S Asn Met Cys Thr Pro His Arg Lys Leu Asp Thr Val Ser Gin Asp Asp 300 305 310 GAA GAA CGT TCC CAA ACT AGA AGG GAA TCG CGA AAA TTT GGA CCC ATG 10854 Glu Glu Arg Ser Gin Thr Arg Arg Glu Ser Arg Lys Phe Gly Pro Met 315 320 325 GTT GCG TGC GAA ATA AAC AAG GGC GCT GAC CAG GAT AGT GAA CTT GTG 10902 Val Ala Cys Glu He Asn Lys Gly Ala Asp Gin Asp Ser Glu Leu Val 330 335 340 GAA CTG GTT GCG ATT GTT AAC CCG TCT GCG CTA AGC TCG CCC GAC TCA 10950 Glu Leu Val Ala He Val Asn Pro Ser Ala Leu Ser Ser Pro Asp Ser • 345 350 355 ATA AAA ATG TGATTAAGTC TGAATGTGGC TCTCCAATCA TTTCGATTCT 10999 He Lys Met 360 CTAATCTCCC AATCCTCTCA AAAGGGGCAG TATCGGACAC GGACTGGGAG GGGCGTACTA 11059 CACGATAGTT ATATGGTACA GCAGAGGCCT CTGAACACTT AGGAGGAGAA TTCAGCCGGG 11119 GAGAGCCCCT GTTGAGTAGG CTTGGGAGCA TATTGCAGG ATG AAC ATG TTA GTG 11173 Met Asn Met Leu Val 1 5 ATA GTT CTC GCC TCT TGT CTT GCG CGC CTA ACT TTT GCG ACG CGA CAC 11221 He Val Leu Ala Ser Cys Leu Ala Arg Leu Thr Phe Ala Thr Arg His 10 15 20 GTC CTC TTT TTG GAA GGC ACT CAG GCT GTC CTC GGG GAA GAT GAT CCC 11269 Val Leu Phe Leu Glu Gly Thr Gin Ala Val Leu Gly Glu Asp Asp Pro 25 30 35 AGA AAC GTT CCG GAA GGG ACT GTA ATC AAA TGG ACA AAA GTC CTG CGG 11317 Arg Asn Val Pro Glu Gly Thr Val He Lys Trp Thr Lys Val Leu Arg 40 45 50 AAC GCG TGC AAG ATG AAG GCG GCC GAT GTC TGC TCT TCG CCT AAC TAT 11365 Asn Ala Cys Lys Met Lys Ala Ala Asp Val Cys Ser Ser Pro Asn Tyr 55 60 65 TGC TTT CAT GAT TTA ATT TAC GAC GGA GGA AAG AAA GAC TGC CCG CCC 11413 Cys Phe His Asp Leu He Tvr Asp Gly Gly Lys Lys Asp Cys Pro Pro 70 75 80 85 GCG GGA CCC CTG TCT GCA AAC CTG GTA ATT TTA CTA AAG CGC GGC GAA 11461 Ala Gly Pro Leu Ser Ala Asn Leu Val He Leu Leu Lys Arg Gly Glu 90 95 100 AGC TTC GTC GTG CTG GGT TCT GGG CTA CAC AAC AGC AAT ATA ACT AAT 11509 Ser Phe Val Val Leu Gly Ser Gly Leu His Asn Ser Asn He Thr Asn 105 110 115 ATC ATG TGG ACA GAG TAC GGA GGC CTG CTC TTT GAT CCT GTA ACT CGT 11557 He Met Trp Thr Glu Tyr Gly Gly Leu Leu Phe Asp Pro Val Thr -Arg 120 125 130 TCG GAC GAG GGA ATC TAT TTT CGA CGG ATC TCT CAG CCA GAT CTG GCC 11605 Ser Asp Glu Gly He Tyr Phe Arg Arg He Ser Gin Pro Asp Leu Ala 135 140 145 ATG GAA ACT ACA TCG TAC AAC GTC AGC GTT CTT TCG CAC GTA GAC GAG 11653 Met Glu Thr Thr Ser Tyr Asn Val Ser Val Leu Ser His Val Asp Glu 150 155 160 165 AAG GCT CCA GCA CCG CAC GAG GTG GAG ATA GAC ACC ATC AAG CCG TCA 11701 Lys Ala Pro Ala Pro His Glu Val Glu He Asp Thr He Lys Pro Ser 170 175 180 GAG GCC CAC GCG CAC GTG GAA TTA CAA ATG CTG CCG TTT CAT GAA CTC 11749 Glu Ala His Ala His Val Glu Leu Gin Met Leu Pro Phe His Glu Leu 185 190 195 AAC GAC AAC AGC CCC ACC TAT GTG ACC CCT GTT CTT AGA GTC TTC CCA 11797 Asn Asp Asn Ser Pro Thr Tyr Val Thr Pro Val Leu Arg Val Phe Pro 200 205 210 CCG ACC GAG CAC GTA AAA TTT AAC GTT ACG TAT TCG TGG TAT GGG TTT 11845 Pro Thr Glu His Val Lys Phe Asn Val Thr Tyr Ser Trp Tyr Gly Phe 215 220 225 GAT GTC AAA GAG GAG TGC GAA GAA GTG AAA CTG TTC GAG CCG TGC GTA 11893 Asp Val Lys Glu Glu Cys Glu Glu Val Lys Leu Phe Glu Pro Cys Val 230 235 240 245 TAC CAT CCT ACA GAC GGC AAA TGT CAG TTT CCC GCA ACC AAC CAG AGA 11941 Tyr His Pro Thr Asp Gly Lys Cys Gin Phe Pro Ala Thr Asn Gin Arg 250 255 260 TGC CTC ATA GGA TCT GTC TTG ATG GCG GAA TTC TTG GGC GCG GCC TCT 11989 Cys Leu He Gly Ser Val Leu Met Ala Glu Phe Leu Gly Ala Ala Ser 265 270 275 TTG CTG GAT TGT TCC-CGC GAT ACT CTA GAA GAC TGC CAC GAA AAT CGC 12037 Leu Leu Asp Cys Ser Arg Asp Thr Leu Glu Asp Cys His Glu Asn Arg 280 285 290 GTG CCG AAC CTA CGG TTC GAT TCG CGA CTC TCC GAG TCA CGC GCA GGC 12085 Val Pro Asn Leu Arg Phe Asp Ser Arg Leu Ser Glu Ser Arg Ala Gly 295 300 305 CTG GTG ATC AGT CCT CTT ATA GCC ATC CCC AAA GTT TTG ATT ATA GTC 12133 Leu Val He Ser Pro Leu He Ala He Pro Lys Val Leu He He Val 310 315 320 325 GTT TCC GAC GGA GAC ATT TTG GGA TGG AGC TAC ACG GTG CTC GGG AAA 12181 Val Ser Asp Gly Asp He Leu Gly Trp Ser Tyr Thr Val Leu Gly Lys 330 335 340 CGT -AAC AGT CCG CGC GTA GTA GTC GAA ACG CAC ATG CCC TCG AAG GTC 12229 Arg Asn Ser Pro Arg Val Val Val Glu Thr His Met Pro Ser Lys Val 345 350 355 CCG ATG AAC AAA GTA GTA ATT GGC AGT CCC GGA CCA ATG GAC GAA ACG 12277 Pro Met Asn Lye Val Val He Gly Ser Pro Gly Pro Met Asp Glu Thr 360 365 370 GGT AAC TAT AAA ATG TAC TTC GTC GTC GCG GGG GTG GCC GCG ACG TGC 12325 Gly Asn Tyr Lys Met Tyr Phe Val Val Ala Gly Val Ala Ala Thr Cys 375 380 385 GTA ATT CTT ACA TGC GCT CTG CTT GTG GGG AAA AAG AAG TGC CCC GCG 12373 Val He Leu Thr Cys Ala Leu Leu Val Gly Lys Lys Lys Cys Pro Ala 390 395 400 405 CAC CAA ATG GGT ACT TTT TCC AAG ACC GAA CCA TTG TAC GCG CCG CTC 12421 His Gin Met Gly Thr Phe Ser Lys Thr Glu Pro Leu Tyr Ala Pro Leu 410 415 420 CCC AAA AAC GAG TTT GAG GCC GGC GGG CTT ACG GAC GAT GAG GAA GTG 12469 Pro Lys Asn Glu Phe Glu Ala Gly Gly Leu Thr Asp Asp Glu Glu Val 425 430 435 ATT TAT GAC GAA GTA TAC GAA CCC CTA TTT CGC GGC TAC TGT AAG CAG 12517 lie Tyr Asp Glu Val Tyr Glu Pro Leu Phe Arg Gly Tyr Cys Lys Gin 440 445 450 GAA TTC CGC GAA GAT GTG AAT ACC TTT TTC GGT GCG GTC GTG GAG GGA 12565 Glu Phe Arg Glu Asp Val Asn Thr Phe Phe Gly Ala Val Val Glu Gly 455 460 465 GAA AGG GCC TTA AAC TTT AAA TCC GCC ATC GCA TCA ATG GCA GAT CGC 12613 Glu Arg Ala Leu Asn Phe Lys Ser Ala lie Ala Ser Met Ala Asp Arg 4'70 475 480 485 ATC CTG GCA AAT AAA AGC GGC AGA AGG AAT ATG GAT AGC TAT TAGTTGGTC 12664 lie Leu Ala Asn Lys Ser Gly Arg Arg Asn Met Asp Ser Tyr 490 495 500 ATG CCT TTT AAG ACC AGA GGG GCC GAA GAC 12694 Met Pro Phe Lys Thr Arg Gly Ala Glu Asp 1 5 10 GCG GCC GCG GGC AAG AAC AGG TTT AAG AAA TCG AGA AAT CGG GAA ATC 12742 Ala Ala Ala Gly Lys Asn Arg Phe Lys Lys Ser Arg Asn Arg Glu lie 15 20 25 TTA CCG ACC AGA CTG CGT GGC ACC GGT AAG AAA ACT GCC GGA TTG TCC 12790 Leu Pro Thr Arg Leu Arg Gly Thr Gly Lys Lys Thr Ala Gly Leu Ser 30 35 40 AAT TAT ACC CAG CCT ATT CCC TGG AAC CCT AAA TTC TGC AGC GCG CGC 12838 Asn Tyr Thr Gin Pro lie Pro Trp Asn Pro Lys Phe Cys Ser Ala Arg 45 50 55 GGG GAA TCT GAC AAC CAC GCG TGT AAA GAC ACT TTT TAT CGC AGG ACG 12886 Gly Glu Ser Asp Aεn His Ala Cys Lys Asp Thr Phe Tyr Arg Arg Thr 60 65 70 TGC TGC GCA TCG CGC TCT ACC GTT TCC AGT CAA CCC GAT TCC CCC CAC 12934 Cys Cys Ala Ser Arg Ser Thr Val Ser Ser Gin Pro Asp Ser Pro His 75 80 85 90 ACA CCC ATG CCT ACT GAG TAT GGG CGC GTG CCC TCC GCA AAG CGC AAA 12982 Thr Pro Met Pro Thr Glu Tyr Gly Arg Val Pro Ser Ala Lys Arg Lys 95 100 105 AAA CTA TCA TCT TCA GAC TSS GAG GGC GCG CAC CAA CCC CTA GTA TCC 13030 Lys Leu Ser Ser Ser Asp Xaa Glu Gly Ala His Gin Pro Leu Val Ser 110 115 120 TGT AAA CTT CCG GAT TCT CAA GCA GCA CCG GCG CGA ACC TAT AGT TCT 13078 Cys Lys Leu Pro Asp Ser Gin Ala Ala Pro Ala Arg Thr Tyr Ser Ser 125 130 135 GCG CAA AGA TAT ACT GTT GAC GAG GTT TCG TCG CCA ACT CCG CCA GGC 13126 Ala Gin Arg Tyr Thr Val -Asp Glu Val Ser Ser Pro Thr Pro Pro Gly 140 145 150 GTC GAC GCT GTT GCG GAC TTA GAA ACG CGC GCG GAA CTT CCT GGC GCT 13174 Val Asp Ala Val Ala Asp Leu Glu Thr Arg Ala Glu Leu Pro Gly Ala 155 160 165 170 ACG ACG GAA CAA ACG GAA AGT AAA AAT AAG CTC CCC AAC CAA CAA TCG 13222 Thr Thr Glu Gin Thr Glu Ser Lyε Aεn Lys Leu Pro Asn Gin Gin Ser 175 180 185 CGC CTG AAG CCG AAA CCC ACA AAC GAG CAC GTC GGA GGG GAG CGG TGC 13270 Arg Leu Lys Pro Lys Pro Thr Asn Glu His Val Gly Gly Glu Arg Cys 190 195 200 CCC TCC GAA GGC ACG GTC GAG GCG CCA TCG CTC GGC ATC CTC TCG CGC 13318 Pro Ser Glu Gly Thr Val Glu Ala Pro Ser Leu Gly He Leu Ser Arg 205 210 215 GTC GGG GCA GCG ATA GCA AAC GAG CTG GCT CGT ATG CGG AGG GCG TGT 13366 Val Gly Ala Ala He Ala Asn Glu Leu Ala Arg Met Arg Arg Ala Cys 220 225 230 CΪT CCG CTC GCC GCG TCG GCG GCC GCT GCC GGA ATA GTG GCC TGG GCC 13414 Leu Pro Leu Ala Ala Ser Ala Ala Ala Ala Gly He Val Ala Trp Ala 235 240 245 250 GCG GCG AGG GCC TTG CAG AAA CAA GGG CGG TAG CAGTAATAATA ACCACACAA 13467 Ala Ala Arg Ala Leu Gin Lys Gin Gly Arg * 255 260 ATATTG 13473 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 476 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Arg Phe Arg Arg He Cys Ser Arg Ser Arg Ala Glu Lys Arg Arg 1 5 10 15 Arg Thr Thr Glu Asn Pro Leu Thr Ser Lys -Arg Val Cys Val Leu Asp 20 25 30 Ser Phe Ser Arg Thr Met Ser Leu Arg Pro Tyr Ala Glu He Leu Pro 35 40 45 Thr Ala Glu Gly Val Glu Arg Leu Ala Glu Leu Val Ser Val Thr Met 50 55 60 Thr Glu Arg Ala Glu Pro Val Thr Glu Asn Thr Ala Val Asn Ser He 65 70 75 80 Pro Pro Ala Asn Glu Asn Gly Gin Asn Phe Ala Tyr Ala Gly Asp Gly 85 90 95 Pro Ser Thr Thr Glu Lys Val Asp Gly Ser His Thr Asp Phe Asp Glu 100 105 110 Ala Ser Ser Asp Tyr Ala Gly Pro Val Pro Leu Ala Gin Thr Arg Leu 115 120 125 Lys His Ser Asp Glu Phe Leu Gin His Phe Arg Val Leu Asp Asp Leu 130 135 140 Val Glu Gly Ala Tyr Gly Phe He Cys Gly Val Arg Arg Tyr Thr Glu 145 150 155 160 Glu Glu Gin Arg Arg Arg Gly Val Asn Ser Thr Asn Gin Gly Lys Ser 165 170 175 Lys Cys Lys Arg Leu He Ala Lys Tyr Val Lys Asn Gly Thr Arg Ala 180 185 190 Ala Ser Gin Leu Glu Asn Glu He Leu Val Leu Gly Arg Leu Asn His 195 200 205 Glu Asn Val Leu Lys He Gin Glu He Leu Arg Tyr Pro Asp Asn Thr 210 215 220 Tyr Met Leu Thr Gin Arg Tyr Gin Phe Asp Leu Tyr Ser Tyr Met Tyr 225 230 235 240 Asp Glu Ala Phe Asp Trp Lys Asp Ser Pro Met Leu Lys Gin Thr Arg 245 250 255 Arg He Met Lys Gin Leu Met Ser Ala Val Ser Tyr He His Ser Lys 260 265 270 Lys Leu He His Arg Asp He Lys Leu Glu Asn He Phe Leu Asn Cys 275 280 285 Asp Gly Lys Thr Val Leu Gly Asp Phe Gly Thr Val Thr Pro Phe Glu 290 295 300 Asn Glu Arg Glu Pro Phe Glu Tyr Gly Trp Val Gly Thr Val Ala Thr 305 310 . 315 320 Asn Ser Pro Glu He Leu Ala Arg Asp Ser Tyr Cys Glu He Thr -Asp 325 330 335 He Trp Ser Cys Gly Val Val Leu Leu Glu Met Val Ser His Glu Phe 340 345 350 Cys Pro He Gly Asp Gly Gly Gly Asn Pro His Gin Gin Leu Leu Lys 355 360 365 Val He Asp Ser Leu Ser Val Cys Asp Glu Glu Phe Pro Asp Pro Pro 370 375 380 Cys Aεn Leu Tyr Aεn Tyr Leu His Tyr Ala Ser He Asp Arg Ala Gly 385 390 395 400 His Thr Val Pro Ser Leu He Arg Asn Leu His Leu Pro Ala Asp Val 405 410 415 Glu Tyr Pro Leu Val Lys Met Leu Thr Phe Asp Trp Arg Leu Arg Pro 420 425 430 Ser Ala Ala Glu Val Leu Ala Met Pro Leu Phe Ser Ala Glu Glu Glu 435 440 445 Arg Thr He Thr He He His Gly Lys His Lys Pro He Arg Pro Glu 450 455 460 He Arg Ala Arg Val Pro Arg Ser Met Ser Glu Gly 465 470 475 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 510 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3: Met Thr Leu Pro His Arg Leu Thr Lys Arg Pro Phe Ala Arg Arg Phe 1 5 10 15 Cys Ser Val Phe Val He His Tyr Ser Glu Thr Lys Leu Asp Arg Tyr 20 25 30 Asn Lys Thr Met Leu Leu Tyr Arg Pro Asp Ser Thr Met Arg His Ser 35 40 45 Gly Gly Asp Ala Asn His Arg Gly He Arg Pro Arg Arg Lys Ser He 50 55 60 Gly Ala Phe Ser Ala Arg Glu Lys Thr Gly Lys Arg Asn Ala Leu Thr 65 70 75 80 Glu Ser Ser Ser Ser Ser -Asp Met Leu -Asp Pro Phe Ser Thr Asp Lys 85 90 95 Glu Phe Gly Gly Lys Trp Thr Val Asp Gly Pro Ala Asp He Thr Ala 100 105 110 Glu Val Leu Ser Gin Ala Trp Asp Val Leu Gin Leu Val Lys His Glu 115 120 125 Asp Ala Glu Glu Glu Arg Val Thr Tyr Glu Ser Lys Pro Thr Pro He 130 135 140 Gin Pro Phe Asn Ala Trp Pro Asp Gly Pro Ser Trp Asn Ala Gin Asp 145 150 155 160 Phe Thr Arg Ala Pro He Val Tyr Pro Ser Ala Glu Val Leu Asp Ala 165 170 175 Glu Ala Leu Lys Val Gly Ala Phe Val Ser Arg Val Leu Gin Cys Val 180 185 190 Pro Phe Thr .Arg Ser Lys Lys Ser Val Thr Val Arg Asp Ala Gin Ser 195 200 205 Phe Leu Gly Asp Ser Phe Trp Arg He Met Gin Asn Val Tyr Thr Val 210 215 220 Cys Leu Arg Gin His He Thr Arg Leu Arg His Pro Ser Ser Lys Ser 225 230 235 240 He Val Asn Cys Asn Asp Pro Leu Trp Tyr Ala Tyr Ala Asn Gin Phe 245 250 255 His Trp Arg Gly Met Arg Val Pro Ser Leu Lys Leu Ala Ser Pro Pro 260 265 270 Glu Glu Asn He Gin His Gly Pro Met Ala Ala Val Phe Arg Asn Ala 275 280 285 Gly Ala Gly Leu Phe Leu Trp Pro Ala Met Arg Ala Ala Phe Glu Glu 290 295 300 Arg Asp Lys Arg Leu Leu Arg Ala Cys Leu Ser Ser Leu Asp He Met 305 310 315 320 Asp Ala Ala Val Leu Ala Ser Phe Pro Phe Tyr Trp Arg Gly Val Gin 325 330 335 Asp Thr Ser Arg Phe Glu Pro Ala Leu Gly Cys Leu Ser Glu Tyr Phe 340 345 350 Ala Leu Val Val Leu Leu Ala Glu Thr Val Leu Ala Thr Met Phe Asp 355 360 365 His Ala Leu Val Phe Met Arg Ala Leu Ala Asp Gly Asn Phe Asp Asp 370 375 380 Tyr Asp Glu Thr Arg Tyr He Asp Pro Val Lys Asn Glu Tyr Leu Asn 365 390 395 400 Gly Ala Glu Gly Thr Leu Leu Arg Gly He Val Ala Ser Asn Thr Ala 405 410 415 Leu Ala Val Val Cys Ala Asn Thr Tyr Ser Thr He Arg Lys Leu Pro 420 425 430 Ser Val Ala Thr Ser Ala Cys Asn Val Ala Tyr Arg Thr Glu Thr Leu 435 440 445 Lys Ala Arg Arg Pro Gly Met Ser Asp He Tyr Arg He Leu Gin Lys 450 455 . 460 Glu Phe Phe Phe Tyr He Ala Trp Leu Gin Arg Val Ala Thr His Ala 465 470 475 480 Asn Phe Cys Leu Asn He Leu Lys Arg Ser Val Asp Thr Gly Pro Arg 485 490 495 His Phe Cys Ser _Gly Pro Ala Arg Arg Ser Gly Cys Ser Ser 500 505 510 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 110 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Leu Cys Pro Leu Leu Val Pro He Gin Tyr Glu Asp Phe Ser Lys 1 5 10 15 Ala Met Gly Ser Glu Leu Lys Arg Glu Lys Leu Glu Thr Phe Val Lys 20 25 30 Ala He Ser Ser Asp Arg Asp Pro Arg Gly Ser Leu Arg Phe Leu He 35 40 45 Ser Asp His Ala Arg Glu He He Ala Asp Gly Val Arg Phe Lyε Pro 50 55 60 Val He Asp Glu Pro Val Arg Ala Ser Val Ala Leu Ser Thr Ala Ala 65 70 75 80 Ala Gly Lys Val Lys Ala Arg Arg Leu Thr Ser Val .Arg Ala Pro Val 85 90 95 Pro Pro Ala Gly Ala Val Ser Ala Arg Arg Lys Ser Glu He 100 105 110 (2) INFORMATION FOR SEQ ID NO:5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Ser Gly Phe Ser Asn He Gly Ser He Ala Thr Val Ser Leu Val 1 5 10 15 Cys Ser Leu Leu Cys Ala Ser Val Leu Gly Ala Pro Val Leu Asp Gly 20 25 30 Leu Glu Ser Ser Pro Phe Pro Phe Gly Gly Lys lie ' lie Ala Gin Ala 35 40 45 Cys Asn Arg Thr Thr He Glu Val Thr Val Pro Trp Ser Asp Tyr Ser 50 55 60 Gly Arg Thr Glu Gly Val Ser Val Glu Val Lys Trp Phe Tyr Gly Asn 65 70 75 80 Ser Asn Pro Glu Ser Phe Val Phe Gly Val Asp Ser Glu Thr Gly Ser 85 90 95 Gly His Glu Asp Leu Ser Thr Cys Trp Ala Leu He His Asn Leu Asn 100 105 110 Ala Ser Val Cys Arg Ala Ser Asp Ala Gly He Pro Asp Phe Asp Lys 115 120 125 Gin Cys Glu Lys Val Gin Arg Arg Leu Arg Ser Gly Val Glu Leu Gly 130 135 140 Ser Tyr Val Ser Gly Asn Gly Ser Leu Val Leu Tyr Pro Gly Met Tyr 145 150 155 160 Asp Ala Gly He Tyr Ala Tyr Gin Leu Ser Val Gly Gly Lys Gly Tyr 165 170 175 Thr Gly Ser Val Tyr Leu Asp Val Gly Pro Asn Pro Gly Cys His Asp 180 185 190 Gin Tyr Gly Tyr Thr Tyr Tyr Ser Leu Ala Asp Glu Ala Ser Asp Leu 195 200 205 Ser Ser Tyr Asp Val Ala Ser Pro Glu Leu Asp Gly Pro Met Glu Glu 210 215 220 Asp Tyr Ser Asn Cys Leu Asp Met Pro Pro Leu Arg Pro Trp Thr Thr 225 230 235 240 Val Cys Ser His Asp Val Glu Glu Gin Glu Asn Ala Thr Asp Glu Leu 245 250 255 Tyr Leu Trp Asp Glu Glu Cys Ala Gly Pro Leu Asp Glu Tyr Val Asp 260 265 270 Glu Arg Ser Glu Thr Met Pro Arg Met Val Val Phe Ser Pro Pro Ser 275 280 285 Thr Leu Gin Gin 290 (2) INFORMATION FOR SEQ ID NO:6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 985 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6: Met Gly Thr Met Leu Val Leu Arg Leu Phe Leu Leu Ala Val Ala Asp 1 5 10 15 Ala Ala Leu Pro Thr Gly Arg Phe Cys Arg Val Trp Lys Val Pro Pro 20 - 25 30 Gly Gly Thr He Gin Glu Asn Leu Ala Val Leu Ala Glu Ser Pro Val 35 40 45 Thr Gly His Ala Thr Tyr Pro Pro Pro Glu Gly Ala Val Ser Phe Gin 50 55 60 He Phe Ala Asp Thr Pro Thr Leu Arg He Arg Tyr Gly Pro Thr Glu 65 70 75 80 Asp Glu Leu Ala Leu Glu Arg Gly Thr Ser Ala Ser Asp Ala Asp Asn .85 90 95 Val Thr Phe Ser Leu Ser Tyr Arg Pro Arg Pro Glu He His Gly Ala 100 105 110 Tyr Phe Thr He Gly Val Phe Ala Thr Gly Gin Ser Thr Glu Ser Ser 115 120 125 Tyr Ser Val He Ser Arg Val Leu Val Asn Ala Ser Leu Glu Arg Ser 130 135 140 Val Arg Leu Glu Thr Pro Cys Asp Glu Asn Phe Leu Gin Asn Glu Pro 145 150 155 160 Thr Trp Gly Ser Lys Arg Trp Leu Gly Pro Pro Ser Pro Tyr Val Arg 165 170 175 Asp Asn Asp Val Ala Val Leu Thr Lys Ala Gin Tyr He Gly Glu Cys 180 185 190 Tyr Ser Asn Ser Ala Ala Gin Thr Gly Leu Thr Ser Leu Asn Met Thr 195 200 205 Phe Phe Tyr Ser Pro Lys Arg He Val Asn Val Thr Trp Thr Thr Gly 210 215 220 Gly Pro Ser Pro Ser Arg He Thr Val Tyr Ser Ser Arg Glu Asn Gly 225 230 235 240 Gln Pro Val Leu Arg Aεn Val Ser Aεp Gly Phe Leu Val Lys Tyr Thr 245 250 255 Pro Asp He Aεp Gly Arg Ala Met He Asn Val He Ala Aεn Tyr Ser 260 265 270 Pro Ala Asp Ser Gly Ser Val Leu Ala Phe Thr Ala Phe Arg Glu Gly 275 280 285 Lys Leu Pro Ser Ala He Gin Leu His Arg He Asp Met Ser Gly Thr 290 295 300 Glu Pro Pro Gly Thr Glu Thr Thr Phe Asp Cys Gin Lys Met He Glu 305 310 315 320 Thr Pro Tyr Arg Ala Leu Gly Ser Asn Val Pro Arg Asp Asp Ser He 325 330 335 Arg Pro Gly Ala Thr Leu Pro Pro Phe Asp Thr Ala Ala Pro Asp Phe 340 345 350 Asp Thr Gly Thr Ser Pro Thr Pro Thr Thr Val Pro Glu Pro Ala He 355 360 365 Thr Thr Leu He Pro ' Arg Ser Thr Ser Asp Met Gly Phe Phe Ser Thr 370 375 380 Ala Arg Ala Thr Gly Ser Glu Thr Leu Ser Val Pro Val Gin Glu Thr 385 390 395 400 Asp Arg Thr Leu Ser Thr Thr Pro Leu Thr Leu Pro Leu Thr Pro Gly 405 410 415 Glu Ser Glu Asn Thr Leu Phe Pro Thr Thr Ala Pro Gly He Ser Thr 420 425 430 Glu Thr Pro Ser Ala Ala His Glu Thr Thr Gin Thr Gin Ser Ala Glu 435 440 445 Thr Val Val Phe Thr Gin Ser Pro Ser Thr Glu Ser Glu Thr Ala Arg 450 455 460 Ser Gin Ser Gin Glu Pro Trp Tyr Phe Thr Gin Thr Pro Ser Thr Glu 465 470 475 480 Gin Ala Ala Leu Thr Gin Thr Gin He Ala Glu Thr Glu Ala Leu Phe 485 490 495 Thr Gin Thr Pro Ser Ala Glu Gin Met Thr Phe Thr Gin Thr Pro Gly 500 505 510 Ala Glu Thr Glu Ala Pro Ala Gin Thr Pro Ser Thr He Pro Glu He 515 520 525 Phe Thr Gin Ser Arg Ser Thr Pro Pro Glu Thr Ala Arg Ala Pro Ser 530 535 540 Ala Ala Pro Glu Val Phe Thr Gin Ser Ser Ser Thr Val Thr Glu Val 545 550 555 560 Phe Thr Gin Thr Pro Ser Thr Val Pro Lys Thr Thr Leu Ser Ser Ser 565 570 575 Thr Glu Pro Ala He Phe Thr Arg Thr Gin Ser Ala Gly Thr Glu Ala 580 585 590 Phe Thr Gin Thr Ser Ser Ala Glu Pro Aεp Thr Met Arg Thr Gin Ser 595 600 605 Thr Glu Thr Hiε Phe Phe Thr Gin Ala Pro Ser Thr Val Pro Lys Ala 610 615 620 Thr Gin Thr Pro Ser Thr Glu Pro Glu Val Leu Thr Gin Ser Pro Ser 625 630 635 640 Thr Glu Pro Val Pro Phe Thr Arg Thr Leu Gly Ala Glu Pro Glu He 645 650 655 Thr Gin Thr Pro Ser Ala Ala Pro Glu Val Tyr Thr Arg Ser Ser Ser 660 665 670 Thr Met Pro Glu Thr Ala Gin Ser Thr Pro Leu Ala Ser Gin Asn Pro 675 680 685 Thr Ser Ser Gly Thr Gly Thr His Asn Thr Glu Pro Arg Thr Tyr Pro 690 695 700 Val Gin Thr Thr Pro His Thr Gin Lys Leu Tyr Thr Glu Asn Lys Thr 705 710 715 720 Leu Ser Phe Pro Thr Val Val Ser Glu Phe His Glu Met Ser Thr Ala 725 730 735 Glu Ser Gin Thr Pro Leu Leu Asp Val Lys He Val Glu Val Lys Phe 740 745 750 Ser Asn Asp Gly Glu Val Thr Ala Thr Cys Val Ser Thr Val Lys Ser 755 760 765 Pro Tyr Arg Val Glu Thr Asn Trp Lys Val Asp Leu Val Asp Val Met 770 775 780 Asp Glu He Ser Gly Asn Ser Pro Ala Gly Val Phe Asn Ser Asn Glu 785 790 795 800 Lys Trp Gin Lys Gin Leu Tyr Tyr Arg Val Thr Asp Gly Arg Thr Ser 805 810 815 Val Gin Leu Met Cys Leu Ser Cvs Thr Ser His Ser Pro Glu Pro Tyr 820 325 830 Cys Leu Phe Asp Thr Ser Leu He Ala Arg Glu Lys Asp He Ala Pro 835 840 845 Glu Leu Tyr Phe Thr Ser Asp Pro Gin Thr Ala Tyr Cys Thr He Thr 850 855 860 Leu Pro Ser Gly Val Val Pro Arg Phe Glu Trp Ser Leu Asn Asn Val 865 870 875 880 Ser Leu Pro Glu Tyr Leu Thr Ala Thr Thr Val Val Ser His Thr Ala 885 890 895 Gly Gin Ser Thr Val Trp Lys Ser Ser Ala Arg Ala Gly Glu Ala Trp 900 905 910 He Ser Gly Arg Gly Gly Asn He Tyr Glu Cys Thr Val Leu He Ser 915 920 925 Asp Gly Thr Arg Val Thr Thr Arg Lys Glu Arg Cys Leu Thr Asn Thr 930 935 940 Trp He Ala Val Glu Aεn Gly Ala Ala Gin Ala Gin Leu Tyr Ser Leu 945 950 955 960 Phe Ser Gly Leu Val Ser Gly Leu Cyε Gly Ser He Ser Ala Leu Tyr 965 970 975 Ala Thr Leu Trp Thr Ala He Tyr Phe 980 985 (2) INFORMATION FOR SEQ ID NO:7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 362 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7: Met Ala Ser Leu Leu Gly Thr Leu Ala Leu Leu Ala Ala Thr Leu Ala 1 5 10 15 Pro Phe Gly Ala Met Gly He Val He Thr Gly Asn His Val Ser Ala 20 25 30 Arg He Asp Aεp Asp His He Val He Val Ala Pro Arg Pro Glu Ala 35 40 45 Thr He Gin Leu Gin Leu Phe Phe Met Pro Gly Gin Arg Pro His Lys 50 55 60 Pro Tyr Ser Gly Thr Val Arg Val Ala Phe Arg Ser Asp He Thr Asn 65 70 75 80 Gin Cys Tyr Gin Glu Leu Ser Glu Glu Arg Phe Glu Asn Cys Thr His 85 90 95 Arg Ser Ser Ser Val Phe Val Gly Cys Lys Val Thr Glu Tyr Thr Phe 100 105 110 Ser Ala Ser Asn Arg Leu Thr Gly Pro Pro His Pro Phe Lys Leu Thr 115 120 125 He Arg Aεn Pro Arg Pro Aεn Aεp Ser Gly Met Phe Tyr Val He Val 130 135 140 Arg Leu Asp Asp Thr Lys Glu Pro He Asp Val Phe Ala He Gin Leu 145 150 155 160 Ser Val Tyr Gin Phe Ala Asn Thr Ala Ala Thr Arg Gly Leu Tyr Ser 165 170 175 Lys Ala Ser Cys Arg Thr Phe Gly Leu Pro Thr Val Gin Leu Glu Ala 180 • 185 190 Tyr Leu Arg Thr Glu Glu Ser Trp Arg Asn Trp Gin Ala Tyr Val Ala 195 200 205 Thr Glu Ala Thr Thr Thr Ser Ala Glu Ala Thr Thr Pro Thr Pro Val 210 215 220 Thr Ala Thr Ser Ala Ser Glu Leu Glu Ala Glu His Phe Thr Phe Pro 225 230 235 240 Trp Leu Glu Asn Gly Val Aεp His Tyr Glu Pro Thr Pro Ala Asn Glu 245 250 255 Asn Ser Asn Val Thr Val Arg Leu Gly Thr Met Ser Pro Thr Leu He 260 265 270 Gly Val Thr Val Ala Ala Val Val Ser Ala Thr He Gly Leu Val He 275 280 285 Val He Ser He Val Thr Arg Asn Met Cys Thr Pro His Arg Lys Leu 290 295 300 Asp Thr Val Ser Gin Asp Asp Glu Glu Arg Ser Gin Thr Arg Arg Glu 305 310 315 320 Ser Arg Lyε Phe Gly Pro Met Val Ala Cys Glu He Asn Lys Gly Ala 325 330 335 Aεp Gin Aεp Ser Glu Leu Val Glu Leu Val.Ala He Val Asn Pro Ser 340 345 350 Ala Leu Ser Ser Pro Asp Ser He Lyε Met 355 360 (2) INFORMATION FOR SEQ ID NO:8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 499 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8: Met Asn Met Leu Val He Val Leu Ala Ser Cys Leu Ala Arg Leu Thr 1 5 10 15 Phe Ala Thr Arg His Val Leu Phe Leu Glu Gly Thr Gin Ala Val Leu 20 25 30 Gly Glu Aεp Aεp Pro Arg Asn Val Pro Glu Gly Thr Val He Lys Trp 35 40 45 Thr Lyε Val Leu -Arg Asn Ala Cys Lys Met Lyε Ala Ala Asp Val Cys 50 55 60 Ser Ser Pro Asn Tyr Cys Phe His Asp Leu lie Tyr Asp Gly Gly Lys 65 70 75 80 Lys Asp Cys Pro Pro Ala Gly Pro Leu Ser Ala Asn Leu Val He Leu 85 90 95 Leu Lys Arg- Gly Glu Ser Phe Val Val Leu Gly Ser Gly Leu His Asn 100 105 110 Ser Asn He Thr Asn He Met Trp Thr Glu Tyr Gly Gly Leu Leu Phe 115 120 125 Asp Pro Val Thr Arg Ser Asp Glu Gly He Tyr Phe Arg Arg He Ser 130 135 140 Gin Pro Aεp Leu Ala Met Glu Thr Thr Ser Tyr Asn Val Ser Val Leu 145 150 155 160 Ser His Val Asp Glu Lyε Ala Pro Ala Pro His Glu Val Glu He Asp 165 170 175 Thr He Lyε Pro Ser Glu Ala His Ala His Val Glu Leu Gin Met Leu 180 185 190 Pro Phe His Glu Leu Asn Asp Asn Ser Pro Thr Tyr Val Thr Pro Val 195 200 205 Leu Arg Val Phe Pro Pro Thr Glu His Val Lys Phe Asn Val Thr Tyr 210 215 220 Ser Trp Tyr Gly Phe Asp Val Lys Glu Glu Cys Glu Glu Val Lys Leu 225 230 235 240 Phe Glu Pro Cys Val Tyr His Pro Thr .Asp Gly Lys Cys Gin Phe Pro 245 250 255 Ala Thr Asn Gin Arg Cys Leu lie Gly Ser Val Leu Met Ala Glu Phe 260 265 270 Leu Gly Ala Ala Ser Leu Leu Asp Cys Ser Arg Asp Thr Leu Glu Asp 275 280 285 Cys His Glu Asn Arg Val Pro Asn Leu Arg Phe Asp Ser Arg Leu Ser 290 295 300 Glu Ser Arg Ala Gly Leu Val He Ser Pro Leu He Ala He Pro Lys 305 310 315 320 Val Leu He He Val Val Ser Asp Gly Asp He Leu Gly Trp Ser Tyr 325 330 335 Thr Val Leu Gly Lys Arg Asn Ser Pro Arg Val Val Val Glu Thr His 340 345 350 Met Pro Ser Lyε Val Pro Met Asn Lys Val Val He Gly Ser Pro Gly 355 360 365 Pro Met Asp Glu Thr Gly Asn Tyr Lys Met Tyr Phe Val Val Ala Gly 370 375 380 Val Ala Ala Thr Cys Val He Leu Thr Cys Ala Leu Leu Val Gly Lys 385 390 395 400 Lys Lys Cys Pro Ala His Gin Met Gly Thr Phe Ser Lys Thr Glu Pro 405 410 415 Leu Tyr Ala Pro Leu Pro Lys Asn Glu Phe Glu Ala Gly Gly Leu Thr 420 425 430 Asp Asp Glu Glu Val He Tyr Asp Glu Val Tyr Glu Pro Leu Phe Arg 435 440 445 Gly Tyr Cys Lys Gin Glu Phe Arg Glu Asp Val Asn Thr Phe Phe Gly 450 455 460 Ala Val Val Glu Gly Glu Arg Ala Leu Asn Phe Lys Ser Ala He Ala 465 470 475 480 Ser Met Ala Asp Arg He Leu Ala Asn Lys Ser Gly Arg Arg Asn Met 485 490 495 Aεp Ser Tyr (2) INFORMATION FOR SEQ ID NO:9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Pro Phe Lys Thr Arg Gly Ala Glu Asp Ala Ala Ala Gly Lys Asn 1 5 10 15 Arg Phe Lys Lys Ser Arg Asn Arg Glu He Leu Pro Thr Arg Leu Arg 20 25 30 Gly Thr Gly Lys Lys Thr Ala Gly Leu Ser Asn Tyr Thr Gin Pro He 35 40 45 Pro Trp Asn Pro Lys Phe Cys Ser Ala Arg Gly Glu Ser Asp Asn His 50 55 60 Ala Cys Lys Aεp Thr Phe Tyr Arg Arg Thr Cys Cys Ala Ser Arg Ser 65 70 75 80 Thr Val Ser Ser Gin Pro Asp Ser Pro His Thr Pro Met Pro Thr Glu 85 90 95 Tyr Gly -Arg Val Pro Ser Ala Lys Arg Lys Lys Leu Ser Ser Ser Asp 100 105 110 Xaa Glu Gly Ala His Gin Pro Leu Val Ser Cys Lys Leu Pro Asp Ser 115 120 125 Gin Ala Ala Pro Ala Arg Thr Tyr Ser Ser Ala Gin Arg Tyr Thr Val 130 135 140 Asp Glu Val Ser Ser Pro Thr Pro Pro Gly Val Asp Ala Val Ala Asp 145 150 155 160 Leu Glu Thr Arg Ala Glu Leu Pro Gly Ala Thr Thr Glu Gin Thr Glu 165 170 175 Ser Lys Asn Lys Leu Pro Asn Gin Gin Ser Arg Leu Lys Pro Lys Pro 180 185 190 Thr Asn Glu His Val Gly Gly Glu Arg Cys Pro Ser Glu Gly Thr Val 195 200 205 Glu Ala Pro Ser Leu Gly He Leu Ser Arg Val Gly Ala Ala He Ala 210 215 220 Asn Glu Leu Ala Arg Met Arg Arg Ala Cys Leu Pro Leu Ala Ala Ser 225 230 235 240 Ala Ala Ala Ala Gly He Val Ala Trp Ala Ala Ala Arg Ala Leu Gin 245 250 255 Lys Gin Gly Arg 260 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1305 base pairs (B) TYPE: nucleic acid (C) ST ANDEDNESS : single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1305 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: ATG CAC CGT CCT CAT CTC AGA CGG CAC TCG CGT TAC TAC GCG AAA GGA 48 Met His Arg Pro His Leu Arg Arg His Ser Arg Tyr Tyr Ala Lys Gly 1 5 10 15 GAG GTG CTT AAC AAA CAC ATG GAT TGC GGT GGA AAA CGG TGC TGC TCA 96 Glu Val Leu Asn Lys His Met Asp Cys Gly Gly Lys Arg Cys Cys Ser 20 25 30 GGC GCA GCT GTA TTC ACT CTT TTC TGG ACT TGT GTC AGG ATT ATG CGG 144 Gly .Ala Ala Val Phe Thr Leu Phe Trp Thr Cys Val Arg lie Met Arg 35 40 45 GAG CAT ATC TGC TTT GTA CGC AAC GCT ATG GAC CGC CAT TTA TTT TTG 192 Glu His lie Cys Phe Val Arg Asn Ala Met Asp Arg His Leu Phe Leu 50 55 60 AGG AAT GCT TTT TGG ACT ATC GTA CTG CTT TCT TCC TTC GCT AGC CAG 240 Arg Asn Ala Phe Trp Thr lie Val Leu Leu Ser Ser Phe Ala Ser Gin 65 70 75 80 AGC ACC GCC GCC GTC ACG TAC GAC TAC ATT TTA GGC CGT CGC GCG CTC 288 Ser Thr Ala Ala Val Thr Tyr Asp Tyr lie Leu Gly Arg Arg Ala Leu 85 90 95 GAC GCG CTA ACC ATA CCG GCG GTT GGC CCG TAT AAC AGA TAC CTC ACT 336 Asp Ala Leu Thr lie Pro Ala Val Gly Pro Tyr Asn Arg Tyr Leu Thr 100 105 110 AGG GTA TCA AGA GGC TGC GAC GTT GTC GAG CTC AAC CCG ATT TCT AAC 384 Arg Val Ser Arg Gly Cys Asp Val Val Glu Leu Asn Pro lie Ser Asn 115 120 125 GTG GAC GAC ATG ATA TCG GCG GCC AAA GAA AAA GAG AAG GGG GGC CCT 432 Val Asp Asp Met lie Ser Ala Ala Lys Glu Lys Glu Lys Gly Gly Pro 130 135 140 TTC GAG GCC TCC GTC GTC TGG TTC TAC GTG ATT AAG GGC GAC GAC GGC 480 Phe Glu Ala Ser Val Val Trp Phe Tyr Val lie Lys Gly Asp Asp Gly 145 150 155 160 GAG GAC AAG TAC TGT CCA ATC TAT AGA AAA GAG TAC AGG GAA TGT GGC 528 Glu Asp Lys Tyr Cys Pro lie Tyr Arg Lys Glu Tyr Arg Glu Cys Gly 165 170 175 GAC GTA CAA CTG CTA TCT GAA TGC GCC GTT CAA TCT GCA CAG ATG TGG 576 Asp Val Gin Leu Leu Ser Glu Cys Ala Val Gin Ser Ala Gin Met Trp 180 185 190 GCA GTG GAC TAT GTT CCT AGC ACC CTT GTA TCG CGA AAT GGC GCG GGA 624 Ala Val Asp Tyr Val Pro Ser Thr Leu Val Ser Arg Asn Gly Ala Gly 195 200 205 CTG ACT ATA TTC TCC CCC ACT GCT GCG CTC TCT GGC CAA TAC TTG CTG 672 Leu Thr He Phe Ser Pro Thr Ala Ala Leu Ser Gly Gin Tyr Leu Leu 210 215 220 ACC CTG AAA ATC GGG AGA TTT GCG CAA ACA GCT CTC GTA ACT CTA GAA 720 Thr Leu Lys He Gly Arg Phe Ala Gin Thr Ala Leu Val Thr Leu Glu 225 230 235 240 GTT AAC GAT CGC TGT TTA AAG ATC GGG TCG CAG CTT AAC TTT TTA CCG 768 Val Asn Asp Arg Cys Leu Lys He Gly Ser Gin Leu Asn Phe Leu Pro 245 250 255 TCG AAA TGC TGG ACA ACA GAA CAG TAT CAG ACT GGA TTT CAA GGC GAA 816 Ser Lys Cys Trp Thr Thr Glu Gin Tyr Gin Thr Gly Phe Gin Gly Glu 260 265 270 CAC CTT TAT CCG ATC GCA GAC ACC AAT ACA CGA CAC GCG GAC GAC GTA 864 His Leu Tyr Pro He Ala Asp Thr -Asn Thr Arg His Ala Asp Asp Val 275 280 285 TAT CGG GGA TAC GAA GAT ATT CTG CAG CGC TGG AAT AAT TTG CTG AGG 912 Tyr Arg Gly Tyr Glu Asp He Leu Gin Arg Trp Asn Asn Leu Leu Arg 290 295 300 AAA AAG AAT CCT AGC GCG CCA GAC CCT CGT CCA GAT AGC GTC CCG CAA 960 Lys Lys Asn Pro Ser Ala Pro Asp Pro Arg Pro Asp Ser Val Pro Gin 305 310 315 320 GAA ATT CCC GCT GTA ACC AAG AAA GCG GAA GGG CGC ACC CCG GAC GCA 1008 Glu He Pro Ala Val Thr Lys Lys Ala Glu Gly Arg Thr Pro Asp Ala 325 330 335 GAA AGC AGC GAA AAG AAG GCC CCT CCA GAA GAC TCG GAG GAC GAC ATG 1056 Glu Ser Ser Glu Lys Lys Ala Pro Pro Glu Asp Ser Glu Asp Asp Met 340 345 350 CAG GCA GAG GCT TCT GGA GAA AAT CCT GCC GCC CTC CCC GAA GAC GAC 1104 Gin Ala Glu Ala Ser Gly Glu Asn Pro Ala Ala Leu Pro Glu Asp Asp 355 360 365 GAA GTC CCC GAG GAC ACC GAG CAC GAT GAT CCA AAC TCG GAT CCT GAC 1152 Glu Val Pro Glu Asp Thr Glu His Asp Asp Pro Asn Ser Asp Pro Asp 370 375 380 TAT TAC AAT GAC ATG CCC GCC GTG ATC CCG GTG GAG GAG ACT ACT AAA 1200 Tyr Tyr Asn Asp Met Pro Ala Val He Pro Val Glu Glu Thr Thr Lys 385 390 395 400 AGT TCT AAT GCC GTC TCC ATG CCC ATA TTC GCG GCG TTC GTA GCC TGC 1248 Ser Ser Asn Ala Val Ser Met Pro He Phe Ala Ala Phe Val Ala Cys 405 410 415 GCG GTC GCG CTC GTG GGG CTA CTG GTT TGG AGC ATC GTA AAA TGC GCG 1296 Ala Val Ala Leu Val Gly Leu Leu Val Trp Ser He Val Lys Cys Ala 420 425 430 CGT AGC TAA 1305 Arg Ser 435 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 434 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:11: Met His Arg Pro His Leu Arg Arg His Ser Arg Tyr Tyr Ala Lys Gly 1 ' 5 10 15 Glu Val Leu Asn Lys His Met Asp Cys Gly Gly Lys Arg Cys Cys Ser 20 25 30 Gly Ala Ala Val Phe Thr Leu Phe Trp Thr Cys Val Arg He Met Arg 35 40 45 Glu His He Cys Phe Val Arg Asn Ala Met Asp Arg His Leu Phe Leu 50 55 60 Arg Asn Ala Phe Trp Thr He Val Leu Leu Ser Ser Phe -Ala Ser Gin 65 70 75 80 Ser Thr Ala Ala Val Thr Tyr -Asp Tyr He Leu Gly -Arg Arg Ala Leu 85 90 95 Asp Ala Leu Thr He Pro Ala Val Gly Pro Tyr Asn Arg Tyr Leu Thr 100 105 110 -Arg Val Ser Arg Gly Cys Asp Val Val Glu Leu Asn Pro He Ser Asn 115 120 125 Val Asp Asp Met He Ser Ala Ala Lys Glu Lys Glu Lys Gly Gly Pro 130 135 140 Phe Glu Ala Ser Val Val Trp Phe Tyr Val He Lys Gly Asp Asp Gly 145 150 155 160 Glu Asp Lys Tyr Cys Pro He Tyr Arg Lys Glu Tyr Arg Glu Cys Gly 165 170 175 Asp Val Gin Leu Leu Ser Glu Cys Ala Val Gin Ser Ala Gin Met Trp 180 185 190 Ala Val Asp Tyr Val Pro Ser Thr Leu Val Ser Arg Asn Gly Ala Gly 195 200 205 Leu Thr He Phe Ser Pro Thr Ala Ala Leu Ser Gly Gin Tyr Leu Leu 210 215 220 Thr Leu Lys He Gly Arg Phe Ala Gin Thr Ala Leu Val Thr Leu Glu 225 230 235 240 Val Asn Asp Arg Cys Leu Lys He Gly Ser Gin Leu Asn Phe Leu Pro 245 250 255 Ser Lys Cys Trp Thr Thr Glu Gin Tyr Gin Thr Gly Phe Gin Gly Glu 260 265 270 His Leu Tyr Pro He Ala Asp Thr Asn Thr Arg His Ala Asp Asp Val 275 280 285 Tyr Arg Gly Tyr Glu Asp He Leu Gin Arg Trp Asn Asn Leu Leu Arg 290 295 300 Lys Lys Asn Pro Ser Ala Pro Asp Pro Arg Pro Asp Ser Val Pro Gin 305 310 315 320 Glu He Pro Ala Val Thr Lys Lys Ala Glu Gly Arg Thr Pro Asp Ala 325 330 335 Glu Ser Ser Glu Lys Lys Ala Pro Pro Glu Asp Ser Glu Asp Asp Met 340 345 350 Gin Ala Glu Ala Ser Gly Glu Asn Pro Ala Ala Leu Pro Glu Asp Asp 355 360 365 Glu Val Pro Glu Asp Thr Glu His Asp Asp Pro Asn Ser Asp Pro Asp 370 375 380 Tyr Tyr Asn Asp Met Pro Ala Val He Pro Val Glu Glu Thr Thr Lys 385 390 395 400 Ser Ser Asn Ala Val Ser Met Pro He Phe Ala Ala Phe Val Ala Cys 405 410 415 Ala Val Ala Leu Val Gly Leu Leu Val Trp Ser He Val Lys Cys Ala 420 425 430 Arg Ser (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 690 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..689 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:12: ATG GCG CCT GTA AAA GTG ACT ATA GTT TCT GCG GTC GAT TCG CAC TAC 48 Met Ala Pro Val Lys Val Thr He Val Ser Ala Val .Asp Ser His Tyr 1 5 10 15 AAA CTA CCT AAT TCT AGA TTT GAG CTC TCG GAT TCT GGA TGG AAA GAA 96 Lys Leu Pro Asn Ser Arg Phe Glu Leu Ser Asp Ser Gly Trp Lys Glu 20 25 30 TTG GTT CAC GCA GTG AAA ACT ATG GCG AGT TAC GAT CGT CCG AGT ACA 144 Leu Val His Ala Val Lys Thr Met Ala Ser Tyr Asp Arg Pro Ser Thr 35 40 45 TTA TCG GTA ATC GTG CGC CCG GCA TCT CTG TAC GAA GTT TCC GGG GAG 192 Leu Ser Val He Val Arg Pro Ala Ser Leu Tyr Glu Val Ser Gly Glu 50 55 60 CTG TTT TCC CTT CCC AGG ATG TGC AGA CCC GTG ATT CGG TTC GGT GAG 240 Leu Phe Ser Leu Pro Arg Met Cys Arg Pro Val He Arg Phe Gly Glu 65 70 75 80 GGG GGC GAC CCG CCT GGA GTA AGT CCC GAG TGG AGC GGC TTG GAC GCA 288 Gly Gly Aεp Pro Pro Gly Val Ser Pro Glu Trp Ser Gly Leu Aεp Ala 85 90 95 GGG TTT TAC CAT TTG TCA TCT GGC GCG TAT GCC GCA AAA GAG TTC CAT 336 Gly Phe Tyr His Leu Ser Ser Gly Ala Tyr Ala Ala Lys Glu Phe His 100 105 110 TTG TGG GTG CTG GGT ACC GCT GAC ATA TGC ATG GCA GCT TTA AAC CTC 384 Leu Trp Val Leu Gly Thr Ala Asp He Cys Met Ala Ala Leu Asn Leu 115 120 125 CCT GCG CCA AAA ACT TTC CTA ATT ACC GAA ACC GGA GGT AAA AAT TTT 432 Pro Ala Pro Lys Thr Phe Leu He Thr Glu Thr Gly Gly Lyε Asn Phe 130 135 140 GAG AGA GGA GTG GAA ATA TTT TTG GTA AAC GGA GAC AAG ACA ACG CTG 480 Glu Arg Gly Val Glu He Phe Leu Val Asn Gly Asp Lys Thr Thr Leu 145 150 155 160 TCT CTG AGT CAC CCA TCA GTC TGG ACA ACT CTT GCC CCT TCG AGC CTG 528 Ser Leu Ser His Pro Ser Val Trp Thr Thr Leu Ala Pro Ser Ser Leu 165 170 175 AGA ACG CCC TGG CCG TAC AGC ACG GTA AAG TTT TTA AAA GTA AAA CCT 576 Arg Thr Pro Trp Pro Tyr Ser Thr Val Lys Phe Leu Lys Val Lys Pro 180 185 190 AAC TCG GCC GCA TAC TGT GTT TCC GAC TCG GAT GAT GGC GAA CGG CAG 624 Asn Ser Ala Ala Tyr Cys Val Ser Asp Ser Asp Asp Gly Glu Arg Gin 195 200 205 CCA AAA TTT TTT CTC GGG AGT CTA TTT AAG TCG AAG AAA CCC CGC TCC 672 Pro Lys Phe Phe Leu Gly Ser Leu Phe Lys Ser Lys Lys Pro Arg Ser 210 215 220 CCG CGG CGC CGA CGT TA G 690 Pro Arg Arg Arg Arg 225 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 229 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:13: Met Ala Pro Val Lys Val Thr He Val Ser Ala Val Asp Ser His Tyr 1 5 10 15 Lys Leu Pro Asn Ser Arg Phe Glu Leu Ser Asp Ser Gly Trp Lys Glu 20 25 30 Leu Val His Ala Val Lys Thr Met Ala Ser Tyr Asp Arg Pro Ser Thr 35 40 45 Leu Ser Val He Val Arg Pro Ala Ser Leu Tyr Glu Val Ser Gly Glu 50 55 60 Leu Phe Ser Leu Pro Arg Met Cys Arg Pro Val He Arg Phe Gly Glu 65 70 75 80 Gly Gly Asp Pro Pro Gly Val Ser Pro Glu Trp Ser Gly Leu Asp Ala 85 90 95 Gly Phe Tyr His Leu Ser Ser Gly Ala Tyr Ala Ala Lys Glu Phe His 100 105 110 Leu Trp Val Leu Gly Thr Ala Asp He Cys Met Ala Ala Leu Asn Leu 115 120 125 Pro Ala Pro Lys Thr Phe Leu He Thr Glu Thr Gly Gly Lys Asn Phe 130 135 140 Glu Arg Gly Val Glu He Phe Leu Val Asn Gly Asp Lys Thr Thr Leu 145 150 155 160 Ser Leu Ser His Pro Ser Val Trp Thr Thr Leu Ala Pro Ser Ser Leu 165 170 175 Arg Thr Pro Trp Pro Tyr Ser Thr Val Lys Phe Leu Lys Val Lys Pro 180 185 190 Asn Ser Ala Ala Tyr Cys Val Ser Asp Ser Asp Asp Gly Glu Arg Gin 195 200 205 Pro Lys Phe Phe Leu Gly Ser Leu Phe Lys Ser Lys Lys Pro Arg Ser 210 215 220 Pro Arg Arg Arg Arg 225 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 381 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..380 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:14: ATG CGT AGC TCA GTT ACG TCA TTG TGG AGC CCT TCA GAT CAC GCC TCT 48 Met Arg Ser Ser Val Thr Ser Leu Trp Ser Pro Ser Asp His Ala Ser 1 5 10 15 TCG CCC GCA AAT GCC AAG CAT TTT TAT CAT ATT TCC GAT TTC CGG CGC 96 Ser Pro Ala Asn Ala Lys His Phe Tyr His He Ser Asp Phe Arg Arg 20 25 30 GCG GAA ACG GCG CCT GCG GGC GGT ACG GGC GCG CGA ACT GAG GTT AAG 144 Ala Glu Thr Ala Pro Ala Gly Gly Thr Gly Ala Arg Thr Glu Val Lys 35 40 45 CGT CGC GCT TTC ACT TTC CCA GCG GCA GCG GTA CTC AGC GCA ACT GAA 192 Arg Arg Ala Phe Thr Phe Pro Ala Ala Ala Val Leu Ser Ala Thr Glu 50 55 60 GCC CGA ACC GGC TCG TCT ATC ACC GGC TTA AAC CGT ACT CCG TCT GCA 240 Ala Arg Thr Gly Ser Ser lie Thr Gly Leu Asn Arg Thr Pro Ser Ala 65 70 75 80 ATA ATT TCC CTT GCA TGG TCC GAA ATG AGA AAT CTT AAG GAC CCC CTC 288 lie lie Ser Leu Ala Trp Ser Glu Met Arg Asn Leu Lys Asp Pro Leu 85 90 95 GGG TCC CTG TCG CTG GAA ATA GCT TTA ACG AAT GTC TCT AAC TTT TCC 336 Gly Ser Leu Ser Leu Glu lie Ala Leu Thr Asn Val Ser Asn Phe Ser 100 105 110 CTC TTG AGC TCA GAC CCC ATG GCC TTC GAA AAG TCT TCA TAT TG 380 Leu Leu Ser Ser Asp Pro Met Ala Phe Glu Lys Ser Ser Tyr 115 120 125 381 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 126 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:15: Met Arg Ser Ser Val Thr Ser Leu Trp Ser Pro Ser Asp His Ala Ser 1 5 10 15 Ser Pro Ala Asn Ala Lys His Phe Tyr His lie Ser Asp Phe Arg Arg 20 25 30 Ala Glu Thr -Ala Pro Ala Gly Gly Thr Gly Ala Arg Thr Glu Val Lys 35 40 45 Arg Arg Ala Phe Thr Phe Pro Ala Ala Ala Val Leu Ser Ala Thr Glu 50 55 60 Ala Arg Thr Gly Ser Ser lie Thr Gly Leu Asn Arg Thr Pro Ser Ala 65 70 75 80 lie lie Ser Leu Ala Trp Ser Glu Met Arg Asn Leu Lys Asp Pro Leu 85 90 95 Gly Ser Leu Ser Leu Glu lie Ala Leu Thr Asn Val Ser Asn Phe Ser 100 105 110 Leu Leu Ser Ser Asp Pro Met Ala Phe Glu Lys Ser Ser Tyr 115 120 125 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 879 base pairs (B- TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO ' (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..878 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: ATG TGG TGT CGT TTG CAC TGG ATA AGT CCT CGG TTC AGT ATT ATG CGT 48 Met Tro Cys Arg Leu His Trp lie Ser Pro Arg Phe Ser lie Met Arg • 1 5 10 15 CCC GGT TCC CGA ACT GGT AGG GTT TTG CGA GGC CAG GGG TGT GCT CTG 96 Pro Gly Ser Arg Thr Gly Arg Val Leu Arg Gly Gin Gly Cys Ala Leu 20 25 30 TGC AGT TTC TGG CAT CGT ACT CGA ACT CCG AGT ATA AAC CTC CGG TGC 144 Cys Ser Phe Trp His Arg Thr Arg Thr Pro Ser lie Asn Leu Arg Cys 35 40 45 CGC GCT CGG GGT CTG AGT AAT TTC CGG CTC TGC GCC CAG AGT CCG GGT 192 Arg Ala Arg Gly Leu Ser Asn Phe Arg Leu Cys Ala Gin Ser Pro Gly 50 55 60 GAA AGG CAC AGG TTC GGT ACT CGG ACT CTG AGT CAA CAC CTC CGG CTC 240 Glu Arg His Arg Phe Gly Thr Arg Thr Leu Ser Gin His Leu Arg Leu 65 70 75 80 TGT ACT CGG AGT CTG AGT AGC TTT CGG TAC CGT ACT CGG GGC CTG AGT 288 Cys Thr Arg Ser Leu Ser Ser Phe Arg Tyr Arg Thr Arg Gly Leu Ser 85 90 95 GAA AAA GTG TGT TTC AGT ACT CTG AGT TCG CAT AGT GTC CGG CTC GGC 336 Glu Lys Val Cys Phe Ser Thr Leu Ser Ser His Ser Val Arg Leu Gly 100 105 110 ACT CGA AGT CTG AGT AAA GGC CTC AGT TCC CGC GCT CTG AGT CCG AGT 384 Thr Arg Ser Leu Ser Lys Gly Leu Ser Ser Arg Ala Leu Ser Pro Ser 115 120 125 AAA AAT CGC CGG TTC AGT ACT CGA ACT CAG AGT AGT TTT CGG TAC CGT 432 Lys Asn Arg Arg Phe Ser Thr Arg Thr Gin Ser Ser Phe Arg Tyr Arg 130 135 140 GCT CGG GGT CTG AGT AAA CAC CTC CGT TAC CGT ACT CGA ACT CTG TGT 480 Ala Arg Gly Leu Ser Lys His Leu Arg Tyr Arg Thr Arg Thr Leu Cys 145 150 155 160 AAA AAC CTC CGG CGC CGC GCT CGG AGC GCG AGC GGT TTC GGG GGG CGT 528 Lys Asn Leu Arg Arg Arg Ala Arg Ser Ala Ser Gly Phe Gly Gly Arg 165 170 175 GCT ACG AGA CTG AGT AAA TAT CTC GGG TAT CGT GCT CGG GGT CTG GGC 576 Ala Thr Arg Leu Ser Lys Tyr Leu Gly Tyr Arg Ala Arg Gly Leu Gly 180 185 190 AGG TGC CTC GGT TTC TGC ACC CGG AGT CTG AGT AAA AGT CAT CTG TTC 624 Arg Cys Leu Gly Phe Cys Thr Arg Ser Leu Ser Lys Ser His Leu Phe 195 200 205 AGC ACT CGG AGT CTG AGT AAA CAA CGC CTC CGT TTC TGC GAT CTG CGT 672 Ser Thr Arg Ser Leu Ser Lys Gin Arg Leu Arg Phe Cys Asp Leu Arg 210 215 220 CTG AGT AAG AGC CGC CTG TTC AGT ACT CGG AGT CTG AGT AAA ATA CCA 720 Leu Ser Lys Ser Arg Leu Phe Ser Thr Arg Ser Leu Ser Lys lie Pro 225 230 235 240 CGG TTC CTG ACT CTG GGA CCG CGC GGT TTC CGA CTC GGT ACT CGG ACT 768 Arg Phe Leu Thr Leu Gly Pro Arg Gly Phe Arg Leu Gly Thr Arg Thr 245 250 255 CTG AGT AAA GAC CAC CGT TTC TGC ACT CTG GGT CTG TGT AGT TTC ATG 816 Leu Ser Lys Asp His Arg Phe Cys Thr Leu Gly Leu Cys Ser Phe Met 260 265 270 TGC CGC GCT CGG GGT CTC GGT -AGA AAT CCC CGG CGC GGT CGT AGG AAA 864 Cys Arg Ala Arg Gly Leu Gly Arg Asn Pro Arg Arg Gly Arg Arg Lys 275 280 285 CAG TGT ATT TTC TG A 879 Gin Cys lie Phe 290 (2) INFORMATION FOR SEQ ID NO:17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 292 amino acids (B) TYPE: amino acid (D) TOPOLOGY:. linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:17: Met Trp Cys Arg Leu His Trp lie Ser Pro Arg Phe Ser lie Met Arg 1 5 10 15 Pro Gly Ser Arg Thr Gly Arg Val Leu Arg Gly Gin Gly Cys Ala Leu 20 25 30 Cys Ser Phe Trp His Arg Thr Arg Thr Pro Ser lie Asn Leu Arg Cys 35 40 45 Arg Ala Arg Gly Leu Ser Asn Phe Arg Leu Cys Ala Gin Ser Pro Gly 50 55 60 Glu Arg His Arg Phe Gly Thr Arg Thr Leu Ser Gin His Leu Arg Leu 65 70 75 80 Cys Thr Arg Ser Leu Ser Ser Phe Arg Tyr Arg Thr Arg Gly Leu Ser 85 90 95 Glu Lys Val Cys Phe Ser Thr Leu Ser Ser His Ser Val Arg Leu Gly 100 105 110 Thr Arg Ser Leu Ser Lys Gly Leu Ser Ser Arg Ala Leu Ser Pro Ser 115 120 125 Lys Asn Arg Arg Phe Ser Thr Arg Thr Gin Ser Ser Phe Arg Tyr Arg 130 135 140 Ala Arg Gly Leu Ser Lys His Leu Arg Tyr Arg Thr Arg Thr Leu Cys 145 150 155 160 Lys Asn Leu Arg Arg Arg Ala Arg Ser Ala Ser Gly Phe Gly Gly Arg 165 170 175 Ala Thr Arg Leu Ser Lys Tyr Leu Gly Tyr Arg .._a Arg Gly Leu Gly 180 185 190 Arg Cys Leu Gly Phe Cys Thr Arg Ser Leu Ser Lys Ser His Leu Phe 195 200 205 Ser Thr Arg Ser Leu Ser Lys Gin Arg Leu Arg Phe Cys Asp Leu Arg 210 215 220 Leu Ser Lyε Ser Arg Leu Phe Ser Thr Arg Ser Leu Ser Lys lie Pro 225 230 235 240 Arg Phe Leu Thr Leu Gly Pro Arg Gly Phe Arg Leu Gly Thr Arg Thr 245 250 255 Leu Ser Lys Asp His Arg Phe Cys Thr Leu Gly Leu Cys Ser Phe Met 260 265 270 Cys Arg Ala Arg Gly Leu Gly Arg Asn Pro Arg Arg Gly Arg Arg Lys 275 280 285 Gin Cys He Phe 290 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 534 base pairs (B) TYPE: nucleic acid !C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..533 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:18: ATG CTC CCA AGC CTA CTC AAC AGG GGC TCT CCC CGG CTG AAT TCT CCT 48 Met Leu Pro Ser Leu Leu Asn Arg Gly Ser Pro Arg Leu Asn Ser Pro 1 5 10 " 15 CCT AAG TGT TCA GAG GCC TCT GCT GTA CCA TAT AAC TAT CGT GTA GTA 96 Pro Lys Cys Ser Glu Ala Ser Ala Val Pro Tyr Asn Tyr Arg Val Val 20 25 30 CGC CCC TCC CAG TCC GTG TCC GAT ACT GCC CCT TTT GAG AGG ATT GGG 144 Arg Pro Ser Gin Ser Val Ser Asp Thr Ala Pro Phe Glu Arg He Gly 35 40 45 AGA TTA GAG AAT CGA AAT GAT TGG AGA GCC ACA TTC AGA CTT AAT CAC 192 Arg Leu Glu Asn Arg Asn Asp Trp Arg Ala Thr Phe Arg Leu Asn His 50 55 60 ATT TTT ATT GAG TCG GGC GAG CTT AGC GCA GAC GGG TTA ACA ATC GCA 240 He Phe He Glu Ser Gly Glu Leu Ser Ala Aεp Gly Leu Thr He Ala 65 " "> 75 80 ACC AGT TCC ACA AGT TCA CTA TCC TGG TCA GCG CCC TTG TTT ATT TCG 288 Thr Ser Ser Thr Ser Ser Leu Ser Trp Ser Ala Pro Leu Phe He Ser 85 90 95 CAC GCA ACC ATG GGT CCA AAT TTT CGC GAT TCC CTT CTA GTT TGG GAA 336 His Ala Thr Met Gly Pro Asn Phe Arg Asp Ser Leu Leu Val Trp Glu 100 105 110 CGT TCT TCG TCG TCT TGC GAG ACC GTG TCT AAT TTT CGG TGC GGG GTG 384 Arg Ser Ser Ser Ser Cys Glu Thr Val Ser Asn Phe Arg Cys Gly Val 115 120 125 CAC ATG TTT CTG GTG ACG ATG GAA ATT ACA ATG ACG AGG CCG ATC GTT 432 His Met Phe Leu Val Thr Met Glu He Thr Met Thr Arg Pro He Val 130 135 140 GCG CTC ACG ACG GCA GCC ACG GTT ACC CCA ATT AGC GTA GGG CTC ATT 480 Ala Leu Thr Thr Ala Ala Thr Val Thr Pro He Ser Val Gly Leu He 145 150 155 160 GTC CCG AGA CGG ACA GTA ACG TTT GAA TTT TCG TTT GCG GGT GTC GGT 528 Val Pro Arg Arg Thr Val Thr Phe Glu Phe Ser Phe Ala Gly Val Gly 165 170 175 TCG TA A 534 Ser (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 177 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:19: Met Leu Pro Ser Leu Leu Asn Arg Gly Ser Pro Arg Leu Asn Ser Pro 1 5 10 15 Pro Lys Cys Ser Glu Ala Ser Ala Val Pro Tyr Asn Tyr Arg Val Val 20 25 30 Arg Pro Ser Gin Ser Val Ser Asp Thr Ala Pro Phe Glu Arg He Gly 35 40 45 Arg Leu Glu Asn Arg Asn Asp Trp Arg Ala Thr Phe Arg Leu Asn His 50 55 60 He Phe He Glu Ser Gly Glu Leu Ser Ala Asp Gly Leu Thr He Ala 65 70 75 80 Thr Ser Ser Thr Ser Ser Leu Ser Trp Ser -Ala Pro Leu Phe He Ser 85 90 95 His Ala Thr Met Gly Pro Asn Phe Arg Asp Ser Leu Leu Val Trp Glu 100 105 110 Arg Ser Ser Ser Ser Cys Glu Thr Val Ser Asn Phe Arg Cys Gly Val 115 120 125 -11 - Hiε Met Phe Leu Val Thr Met Glu He Thr Met Thr Arg Pro He Val 130 135 140 Ala Leu Thr Thr Ala Ala Thr Val Thr Pro He Ser Val Gly Leu He 145 150 155 160 Val Pro Arg Arg Thr Val Thr Phe Glu Phe Ser Phe Ala Gly Val Gly 165 170 175 Ser (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: GAATTCGAGC TCGGTACCCG GATAATACGT ACATGTTAAC GCAGAGGT 48 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: GCTGACCGCT AGTCGACCTG CAGTGAATAA TAAAAT 36 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:22: TGTCCGTCGA GATCCTCTAG AGTCGACGAA AGGTCAGAGA CGATGCCC 48 (2) INFORMATION FOR SEQ ID NO:23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 38 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: CGGATCAGAA ACTCTTTCGG TACCCGGGAT CCTCTAGA 38 (2) INFORMATION FOR SEQ ID NO:24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: GAATACAAGC TTAGATGCAT ATTTACTCGA GCC 33 (2) INFORMATION FOR SEQ ID NO:25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: GGTTTGGCGG AGCGGATATG ATCTCGACCT GCAGTGAATA ATAAAATGTG T 51 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:26: TGTCCGTCGA GATCCTCTAG AGTCGAGATC AGCAAAATGT TCACGGGG 48 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: AAGCTTGGCG TAATCATG 18 (2) INFORMATION FOR SEQ ID NO:28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 39 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: GGAATTCGAG CTCGGTACCT CGTGGCGAGC GCAGGCGGC 39 (2) INFORMATION FOR SEQ ID NO:29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GGCCGAGTTA GGTTTTACTT TTCTAGAGGA TCCCCTCGAC GTCTGGGGCG C 51 (2) INFORMATION FOR SEQ ID NO:30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:30: TTGCTGCGTT CCCGGGGATC CTCTAGAATT AGGTAGTTTG TAGTGCGA 48 (2) INFORMATION FOR SEQ ID NO:31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:31: TCAAGATCCA GGAAATCCTT CGGTACCGAG CTCGAATTCG TA 42 (2) INFORMATION FOR SEQ ID NO:32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) ■ (iii) HYPOTHETICAL: NO (iv) ANTI -SENSE : NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: GAATTCGAGC TCGGTACCGA AAGCTACTCA GAC 33 (2) INFORMATION FOR SEQ ID NO:33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: CGCAAACAGC TCTCGTAACT CTAGAAGTTA ACGATCGCTG TT 42 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 57 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:34: GAATAGCATA CCAATGCCTA TTCATTGGGA CTCGACTCTA GAGGATCCCC GGGAACG 57 (2) INFORMATION FOR SEQ ID NO:35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: TCGAGGGGAT CCTCTAGAGT CGAGGGACCC ATGGTTGCGT GC 42 (2) INFORMATION FOR SEQ ID NO:36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: TTTACTAAAG CGCGGCGAAA GCTTCGTCGT GCTGGGTTCT GG 42 (2) INFORMATION FOR SEQ ID NO:37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: AAGCTTGGCG TAATCATGGT C - 21 (2) INFORMATION FOR SEQ ID NO:38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:38: GGAATTCGAG CTCGGTACCC GGATAATACG TACATGTTAA CGCAGAGG 48 (2) INFORMATION FOR SEQ ID NO:39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: ATCTATTGGA GCGTTTAGCG CGCGTCGACG AAAGGTCAGA GACGA 45 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: CTGCTTCATT TCTGATCCCC GGGAACG 27 (2) INFORMATION FOR SEQ ID NO:41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 51 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: ACCACCCCCG CGCCCCAGAC GTCGAGGGGA TCAATTATTG CGTATTGAAT A 51 (2) INFORMATION FOR SEQ ID NO:42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: ATCAGAAACT CTTTCGGTAC CGAGCTCGAA TTC 33 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ. ID NO:43: GAATTCGAGC TCGGTACCCG GATAATACGT ACATGTTAAC GCAGAGGT 48 (2) INFORMATION FOR SEQ ID NO:44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: GCTGACCGCT AGTCGACTCT AGAGGATCCC CTC 33 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 42 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: CGTTCCCGGG GATCCTCTAG AGTCGACGGC AGAGTCGCAG AC 42 (2) INFORMATION FOR SEQ ID NO:46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:46: TGATCCAAAC TCGGATCCTC TAGAGTCGAC 30 (2) INFORMATION FOR SEQ ID NO:47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ -ID NO:47: AAGCTTGGGC TGCAGGTCGA CTCTAGAGGA TCCCCTCGAC GTCTGGGG 48 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: CACACCTTTG CGCATCTCCA CAGCTCAACA ATGAATTCCA TGTTACGTCC TGTAGAAACC 60 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 60 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: CAGGGAGGCA AACAATGAAT CAACAACTCT CCCGGGAGAT GGGGGAGGCT AACTGAAACA 60 (2) INFORMATION FOR SEQ ID NO:50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: TGCTGCGTTC CCGGGGATCC TCTAGAGTCG ACCTGCAGCC CAAGC 45 (2) INFORMATION FOR SEQ ID NO:51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: TCTAGAGTCG ACCTGCAGTG AATAATAAAA TGTGTGTTTG TCCGAAAT 48 (2) INFORMATION FOR SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 45 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:52: CTCCATAGAA GACACCGGGA CCATGGATCC CGTCGTTTTA CAACG 45 (2) INFORMATION FOR SEQ ID NO:53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 105 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:53: TCGGCGGAAA TCCAGCTGAG CGCCGGTCGC TACCATTACC AGTTGGTCTG GTGTCAAAAA 60 GATCTAGAAT AAGCTAGAGG ATCGATCCCC TATGGCGATC ATCAG 105 (2) INFORMATION FOR SEQ ID NO:54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 36 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: CCGTCGAGAT CCTCTAGAGT CGACCTGCAG GTCGAC 36 (2) INFORMATION FOR SEQ ID NO:55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: CCTAGCACCC TTGTATCGCG 20 (2) INFORMATION FOR SEQ ID NO:56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:56: CGCCTCGAGT CCCAATGAAT AGGCATTGG 29 (2) INFORMATION FOR SEQ ID NO:57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:57: CGCCTCGAGG ACCCATGGTT GCGTGCG 27 (2) INFORMATION FOR SEQ ID NO:58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: N (iv) ANTI-SENSE: N (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: CTCGTCCGAA CGAGTTACAG 20

Claims: hat is claimed is: 1. A recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, where in the deletion is in the glycoprotein gG gene. 2. The recombinant infectious laryngotracheitis virus of claim 1, designated S-ILT-014. 3. The recombinant infectious laryngotracheitis virus of claim 1, designated S-ILT-002. 4. The recombinant infectious laryngotracheitis virus of claim 1, further characterized by a deletion in the US2 gene. 5. The recombinant infectious laryngotracheitis virus of claim 4, designated S-ILT-009. 6. The recombinant infectious laryngotracheitis virus of claim 1, further characterized by a deletion in the OR! i gene and a deletion in the UL47-li e gene. 7. The recombinant infectious laryngotracheitis virus of claim 6, designated S-ILT-015. 8. The recombinant infectious laryngotracheitis virus of claim 1, further characterized by a deletion in the glycoprotein g60 gene. 9. The recombinant infectious laryngotracheitis virus of claim 8, designated S-ILT-017. -131- 10. The recombinant infectious laryngotracheitis virus of claim 1, further characterized by a deletion in the glycoprotein gl gene. •5 11. The recombinant infectious laryngotracheitis virus of claim 1, further characterized by a deletion in the thymidine kinase (TK) gene. 12. The recombinant infectious laryngotracheitis virus 0 of claim 1, which further comprises a foreign gene inserted within a non-essential site of the infectious laryngotracheitis viral genome, wherein the foreign gene is capable of being expressed in a recombinant infectious laryngotracheitis infected 5 host cell. 13. The recombinant infectious laryngotracheitis virus of claim 12, wherein a foreign gene is inserted within the unique short region of the viral genome, 0 provided, however, that the foreign gene is not inserted within the glycoprotein gD gene, the glycoprotein gl gene, the protein kinase gene and the ORF 10 gene. 5 14. The recombinant infectious laryngotracheitis virus of claim 13, wherein the foreign gene is inserted into a gene selected from a group consisting of the US2 gene, UL47-like gene, ORF4 gene, glycoprotein gG gene, glycoprotein g60 gene, and glycoprotein gl 0 gene. 15. The recombinant infectious laryngotracheitis virus of claim 12, wherein the foreign gene encodes a screenable marker. 5 16. The recombinant infectious laryngotracheitis virus of claim 15, wherein the screenable marker is E. coli B-galactosidase. 17. The recombinant infectious laryngotracheitis virus of claim 15, wherein the screenable marker is E. coli B-glucuronidase. 18. The recombinant infectious laryngotracheitis virus of claim 12, wherein the foreign gene encodes an antigenic polypeptide. 19. The recombinant infectious laryngotracheitis virus of claim 18, wherein the antigenic polypeptide, when introduced into the host cell, induces production of protective antibodies against an avian disease causing agent from which the antigen is derived or derivable. 20. The recombinant infectious laryngotracheitis virus of claim 19, wherein the antigenic polypeptide is derived or derivable from a group consisting of infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus. 21. The recombinant infectious laryngotracheitis virus of claim 19, wherein the antigenic polypeptide is derived or derivable from a group consisting of avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia agent, Salmonella spp. E. coli, Pasteurella spp. , Bordetella spp. , Eimeria spp. , Histomonas spp. , Trichomonas spp. , Poultry nematodes, cestodes, trematodes, poultry mites/lice, poultry protozoa. 22. The recombinant infectious laryngotracheitis virus of claim 12, wherein the foreign gene is under control of an endogenous upstream infectious laryngotracheitis virus promoter. 23. The recombinant infectious laryngotracheitis virus of claim 12, wherein the foreign gene is under control of a heterologous upstream promoter. 24. The recombinant infectious laryngotracheitis virus of claim 23, wherein the promoter is selected from a group consisting of the HCMV IE promoter, PRV gX promoter, and BHV-l.l VP8 promoter. 25. A recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in the glycoprotein gG gene, so that upon replication the recombinant infectious laryngotracheitis virus produces no glycoprotein gG. 26. A recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in the glycoprotein gl gene, so that upon replication, the recombinant infectious virus produces no glycoprotein gl. 27. A recombinant infectious laryngotracheitis virus of claim 26, which further comprises a deletion in the glycoprotein gG gene so that upon replication, the recombinant virus produces no glycoprotein gG. 28. The recombinant infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the unique short region of the viral genome, wherein the deletion is in a gene selected from a group consisting of the US2 gene, the UL47-like gene, and the glycoprotein g60 gene. 29. The recombinant infectious laryngotracheitis virus of claim 28, wherein the deletion is in the US2 gene. 30. The recombinant infectious laryngotracheitis virus of claim 28, wherein the deletion is in the UL47- like gene. 31. The recombinant infectious laryngotracheitis virus of claim 28, wherein the deletion is in the glycoprotein g60 gene. 32. A recombinant infectious laryngotracheitis virus which comprises a foreign gene inserted within the unique short region of the infectious laryngotracheitis viral genome, provided, however, that the insertion is not in the protein kinase gene, the glycoprotein gD gene, the glycoprotein gE gene and the ORFIO gene, wherein the foreign gene is capable of being expressed in the recombinant infectious laryngotracheitis virus infected host cell. 33. A recombinant infectious laryngotracheitis virus of claim 32, wherein the foreign gene is inserted in the gene selected from a group consisting of the US2 gene, UL-47 like gene, ORF4 gene and glycoprotein g60 gene. 34. The recombinant infectious laryngotracheitis virus of claim 32, wherein the foreign gene encodes a screenable marker. 35. The recombinant infectious laryngotracheitis virus of claim 34, wherein the screenable marker is E. coli B-galactosidase. 36. The recombinant infectious laryngotracheitis virus of claim 34, wherein the screenable marker is E. coli -B-glucuronidase. 37. The recombinant infectious laryngotracheitis virus of claim 32, wherein the foreign gene encodes an antigenic polypeptide. 38. The recombinant infectious laryngotracheitis virus of claim 37, wherein the antigenic polypeptide, when introduced into the host cell, induces production of protective antibodies against an avian disease causing agent from which the antigen is derived or derivable. 39. The recombinant infectious laryngotracheitis virus of claim 38, wherein the antigenic polypeptide is derived from or derivable from a group consisting of infectious bronchitis virus, Newcastle disease virus, infectious bursal disease virus, and Marek's disease virus. 40. The recombinant infectious laryngotracheitis virus of claim 38, wherein the antigenic polypeptide is derived from or derivable from a group consisting of avian encephalomyelitis virus, avian reovirus, avian paramyxovirus, avian influenza virus, avian adenovirus, fowl pox virus, avian coronavirus, avian rotavirus, chick anemia agent. Salmonella spp. , E. coli . , Pasteurella spp. , Bordetella spp. , Eimeria spp. , Histomonas spp. , Trichomonas spp. , Poultry nematodes, cestodes, trematodes, poultry mites/lice, poultry protozoa. 41. The recombinant infectious laryngotracheitis virus of claim 32, wherein the foreign gene is under control of an endogenous upstream infectious laryngotracheitis virus promoter. 42. The recombinant infectious laryngotracheitis virus of claim 32, wherein the foreign gene is under control of a heterologous upstream promoter. 43. The recombinant infectious laryngotracheitis virus of claim 42, wherein the promoter is selected from a group consisting of HCMV IE promoter, PRV gX promoter, and BHV-l.l VP8 promoter. 44. A vaccine for infectious laryngotracheitis virus comprising an effective immunizing amount of the recombinant infectious laryngotracheitis virus of claim 1 and a suitable carrier. 45. A vaccine for infectious laryngotracheitis virus comprising an effective immunizing amount of the recombinant infectious laryngotracheitis virus of claim 2 and a suitable carrier. 46. A vaccine for infectious laryngotracheitis virus comprising an effective immunizing amount of the recombinant infectious laryngotracheitis virus of claim 3 and a suitable carrier. 47. A vaccine for infectious laryngotracheitis virus comprising an effective immunizing amount of the recombinant infectious laryngotracheitis virus of claim 5 and a suitable carrier. 48. A vaccine for infectious laryngotracheitis virus ,. 5 comprising an effective immunizing amount of the recombinant infectious laryngotracheitis virus of claim 7 and a suitable carrier. » 49. A vaccine for infectious laryngotracheitis virus 10 comprising an effective immunizing amount of the recombinant infectious laryngotracheitis virus of claim 9 and a suitable carrier. 50. A vaccine for infectious laryngotracheitis virus 15 comprising an effective immunizing amount of the recombinant infectious laryngotracheitis virus claim 3, 4, 6, 8, 10, or 11 and a suitable carrier. 51. A vaccine for infectious laryngotracheitis virus 20 comprising an effective immunizing amount of the virus of claim 25 and a suitable carrier. 52. A vaccine for infectious laryngotracheitis virus comprising an effective immunizing amount of the 25 virus of claim 26 and a suitable carrier. 53. A vaccine for infectious laryngotracheitis virus comprising an effective immunizing amount of the virus of claim 27 and a suitable carrier. 30 54. A vaccine for infectious laryngotracheitis virus comprising an effective immunizing amount of the recombinant, infectious laryngotracheitis virus of claim 29, 30, or 31 and a suitable carrier. 35 55. A multivalent vaccine for infectious laryngotracheitis and for one or more of other avian -138- diseases comprising an effective immunizing amount of the recombinant virus of claim 19, 20, or 21 and a suitable carrier. 56. A method of immunizing chickens or other poultry against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of the vaccine of claim 44. 57. A method of immunizing chickens or other poultry against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of the vaccine of claim 45. 58. A method of immunizing chickens or other poultry against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of the vaccine of claim 46. 59. A method of immunizing chickens or other poultry against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of the vaccine of claim 47. 60. A method of immunizing chickens or other poultry against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of the vaccine of claim 48. 61. A method of immunizing chickens or other poultry against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of the vaccine of claim 49. 62. A method of immunizing chickens or other poultry , 5 against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of vaccine of claim 50. 63. A method of immunizing chickens or other poultry 10 against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of vaccine of claim 51. 64. A method of immunizing chickens or other poultry 15 against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of vaccine of claim 52. 65. A method of immunizing chickens or other poultry 20 against infectious laryngotracheitis which comprises administering to said chickens or other poultry an effective immunizing amount of vaccine of claim 53. 66. A method of immunizing chickens or other poultry 25 against infectious laryngotracheitis and one or more of other avian diseases which comprises administering to said chickens or other poultry an effective immunizing amount of vaccine of claim 55. 30 67. A method of distinguishing chickens or other poultry which are vaccinated with the vaccine of claim 26 <• from those which are infected with a naturally- occurring infectious laryngotracheitis virus which comprises analyzing samples of body fluids from 35 chickens or other poultry for the presence of glycoprotein gG and at least one other antigen normally expressed in chickens or other poultry infected by a naturally-occurring infectious laryngotracheitis virus, the presence of those antigens normally expressed in infected chickens but the absence of glycoprotein gG being indicative of vaccination with the vaccine of claim 25 and not infection with a naturally-occurring infectious laryngotracheitis virus. 68. A method of distinguishing chickens or other poultry which are vaccinated with the vaccine of claim 2, 3, 5, 7 or 9 from those which are infected with a naturally-occurring infectious laryngotracheitis virus which comprises analyzing samples of body fluids from chickens or other poultry for the presence of glycoprotein gG and at least one other antigen normally expressed in chickens or other poultry infected by a naturally-occurring infectious laryngotracheitis virus, the presence of those antigens normally expressed in infected chickens but the absence of glycoprotein gG being indicative of vaccination with the vaccine of claim 2, 3, 5, 7 or 9 and not infection with a naturally-occurring infectious laryngotracheitis virus. 69. A method of distinguishing chickens or other poultry which are vaccinated with the vaccine of claim 27 from those which are infected with a naturally- occurring infectious laryngotracheitis virus which comprises analyzing samples of body fluids from chickens or other poultry for the presence of glycoprotein gl, glycoprotein gG, and at least one other antigen normally expressed in chickens or other poultry infected by a naturally-occurring infectious laryngotracheitis virus, the presence of those antigens normally expressed in infected chickens but the absence of glycoprotein gG and glycoprotein gl being indicative vaccination with the vaccine of claim 27 and not infection with a naturally-occurring infectious laryngotracheitis virus. 70. A method of distinguishing chickens or other poultry which are vaccinated with the vaccine of claim 26 from those which are infected with a naturally- occurring infectious laryngotracheitis virus which comprises analyzing samples of body fluids from chickens or other poultry for the presence of glycoprotein gl and at least one other antigen normally expressed in chickens or other poultry infected by a naturally-occurring infectious laryngotracheitis virus, the presence of those antigens normally expressed in infected chickens but the absence of glycoprotein gl being indicative of vaccination with the vaccine of claim 26 and not infection with a naturally-occurring infectious laryngotracheitis virus. 71. A homology vector for producing a recombinant infectious laryngotracheitis virus by inserting a foreign DNA into the unique short region of the infectious laryngotracheitis genomic DNA, which comprises a double-stranded DNA molecule consisting essentially of a double-stranded foreign gene, which is flanked on either side by a double-stranded DNA homologous to the DNA located in the unique short region of the genomic DNA, provided, however, that the flanking sequences are not homologous to the glycoprotein gD gene, the glycoprotein gE gene, the protein kinase gene, and the ORF10 gene. 72. The homology vector of claim 71, wherein the foreign gene encodes a screenable marker. 73. The homology vector of claim 72, wherein the screenable marker is E. coli B-galactosidase or E. coli B-glucuronidase. 74. A homology vector for producing a recombinant infectious laryngotracheitis virus by deleting DNA which encodes a screenable marker, which has been inserted into the infectious laryngotracheitis virus genomic DNA, which comprises a double stranded DNA molecule consisting essentially of a double-stranded DNA to be deleted, which is flanked on each side by a double stranded DNA homologous to the infectious laryngotracheitis virus glycoprotein gG gene, glycoprotein gl gene, US2 gene, or UL-47 like gene. 75. The homology vector of claim 74, designated Homology Vector 544-55.12. 76. The homology vector of claim 74, designated Homology Vector 562-61.IF. 77. The homology vector of claim 74, designated Homology Vector 472-73.27. 78. The homology vector of claim 74, designated Homology Vector 560-52.Fl. 79. The homology vector of claim 74, designated Homology Vector 579-14.G2.

Inventors: COCHRAN MARK D, WILD MARTHA A, COCHRAN, MARK, D., WILD, MARTHA, A.
Applicants: SYNTRO CORP, SYNTRO CORPORATION
Application year: 1994
Main classification: C12N7
IPC codes: A61K31, A61K35, A61K38, A61K39, A61K48, A61P11, A61P31, C07H21, C07K14, C12N7, C12N15, C12R1